CN106188293A - 抗c-Met抗体和抗c-Met抗体-细胞毒性药物偶联物及其医药用途 - Google Patents
抗c-Met抗体和抗c-Met抗体-细胞毒性药物偶联物及其医药用途 Download PDFInfo
- Publication number
- CN106188293A CN106188293A CN201510300885.1A CN201510300885A CN106188293A CN 106188293 A CN106188293 A CN 106188293A CN 201510300885 A CN201510300885 A CN 201510300885A CN 106188293 A CN106188293 A CN 106188293A
- Authority
- CN
- China
- Prior art keywords
- antibody
- sequence
- seq
- met
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940127089 cytotoxic agent Drugs 0.000 title claims abstract description 17
- 239000002254 cytotoxic agent Substances 0.000 title claims abstract description 17
- 239000003814 drug Substances 0.000 claims abstract description 111
- 150000001875 compounds Chemical class 0.000 claims abstract description 96
- 229940079593 drug Drugs 0.000 claims abstract description 70
- 150000003839 salts Chemical class 0.000 claims abstract description 66
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 claims abstract description 50
- 206010070863 Toxicity to various agents Diseases 0.000 claims abstract description 50
- 201000010099 disease Diseases 0.000 claims abstract description 40
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 40
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 15
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 210000004027 cell Anatomy 0.000 claims description 144
- 230000000694 effects Effects 0.000 claims description 88
- 238000000034 method Methods 0.000 claims description 77
- 239000003053 toxin Substances 0.000 claims description 71
- 231100000765 toxin Toxicity 0.000 claims description 69
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 63
- -1 iodo-acetyl group Chemical group 0.000 claims description 60
- 206010028980 Neoplasm Diseases 0.000 claims description 53
- 125000000217 alkyl group Chemical group 0.000 claims description 41
- 239000000427 antigen Substances 0.000 claims description 41
- 108091007433 antigens Proteins 0.000 claims description 41
- 102000036639 antigens Human genes 0.000 claims description 41
- 238000005859 coupling reaction Methods 0.000 claims description 40
- 238000010168 coupling process Methods 0.000 claims description 38
- 239000012634 fragment Substances 0.000 claims description 38
- 230000008878 coupling Effects 0.000 claims description 37
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 34
- 230000009870 specific binding Effects 0.000 claims description 33
- 230000027455 binding Effects 0.000 claims description 30
- 235000001014 amino acid Nutrition 0.000 claims description 27
- 150000001413 amino acids Chemical class 0.000 claims description 26
- 229910052736 halogen Inorganic materials 0.000 claims description 24
- 150000002367 halogens Chemical class 0.000 claims description 24
- 210000004602 germ cell Anatomy 0.000 claims description 23
- 125000003545 alkoxy group Chemical group 0.000 claims description 22
- 125000003118 aryl group Chemical group 0.000 claims description 22
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 22
- 239000002773 nucleotide Substances 0.000 claims description 22
- 125000003729 nucleotide group Chemical group 0.000 claims description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 20
- 201000011510 cancer Diseases 0.000 claims description 19
- 206010017758 gastric cancer Diseases 0.000 claims description 18
- 125000001072 heteroaryl group Chemical group 0.000 claims description 18
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 15
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 13
- 201000011549 stomach cancer Diseases 0.000 claims description 13
- 230000008859 change Effects 0.000 claims description 12
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 claims description 11
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 11
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 11
- 230000035772 mutation Effects 0.000 claims description 11
- 125000002769 thiazolinyl group Chemical group 0.000 claims description 11
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 10
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 10
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 10
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 10
- 125000001424 substituent group Chemical group 0.000 claims description 10
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 10
- 206010038389 Renal cancer Diseases 0.000 claims description 9
- 201000010174 renal carcinoma Diseases 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 9
- AGGWFDNPHKLBBV-YUMQZZPRSA-N (2s)-2-[[(2s)-2-amino-3-methylbutanoyl]amino]-5-(carbamoylamino)pentanoic acid Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=O AGGWFDNPHKLBBV-YUMQZZPRSA-N 0.000 claims description 8
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 8
- 229940127093 camptothecin Drugs 0.000 claims description 8
- 239000013604 expression vector Substances 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 6
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims description 6
- 201000008275 breast carcinoma Diseases 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 6
- 201000002313 intestinal cancer Diseases 0.000 claims description 6
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 6
- 201000001441 melanoma Diseases 0.000 claims description 6
- 230000004048 modification Effects 0.000 claims description 6
- 238000012986 modification Methods 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 239000003960 organic solvent Substances 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
- 229940064734 aminobenzoate Drugs 0.000 claims description 3
- 229940088013 hycamtin Drugs 0.000 claims description 3
- 229960004768 irinotecan Drugs 0.000 claims description 3
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 3
- 101100230376 Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) celI gene Proteins 0.000 claims description 2
- 241000699802 Cricetulus griseus Species 0.000 claims description 2
- 108090000856 Lyases Proteins 0.000 claims description 2
- 102000004317 Lyases Human genes 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 210000001672 ovary Anatomy 0.000 claims description 2
- 101000945318 Homo sapiens Calponin-1 Proteins 0.000 claims 2
- 101000652736 Homo sapiens Transgelin Proteins 0.000 claims 2
- 102100031013 Transgelin Human genes 0.000 claims 2
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 claims 2
- NCQDNRMSPJIZKR-UHFFFAOYSA-N 4-[[1-(2,5-dioxopyrrolidin-1-yl)-2h-pyridin-2-yl]sulfanyl]pentanoic acid Chemical compound OC(=O)CCC(C)SC1C=CC=CN1N1C(=O)CCC1=O NCQDNRMSPJIZKR-UHFFFAOYSA-N 0.000 claims 1
- 238000007614 solvation Methods 0.000 claims 1
- 238000011275 oncology therapy Methods 0.000 abstract description 2
- 108700012359 toxins Proteins 0.000 description 68
- 239000000243 solution Substances 0.000 description 62
- 239000002585 base Substances 0.000 description 50
- 238000006243 chemical reaction Methods 0.000 description 48
- 239000000562 conjugate Substances 0.000 description 46
- 241000699666 Mus <mouse, genus> Species 0.000 description 35
- 239000000047 product Substances 0.000 description 34
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 32
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 27
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 27
- 108090000765 processed proteins & peptides Proteins 0.000 description 25
- 238000012360 testing method Methods 0.000 description 22
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 21
- 239000003153 chemical reaction reagent Substances 0.000 description 20
- 238000002474 experimental method Methods 0.000 description 20
- 239000001963 growth medium Substances 0.000 description 20
- 101710096655 Probable acetoacetate decarboxylase 1 Proteins 0.000 description 19
- 239000000499 gel Substances 0.000 description 19
- 125000000623 heterocyclic group Chemical group 0.000 description 19
- 239000012071 phase Substances 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 19
- 238000002965 ELISA Methods 0.000 description 18
- 229920005654 Sephadex Polymers 0.000 description 18
- 239000012507 Sephadex™ Substances 0.000 description 18
- 238000011033 desalting Methods 0.000 description 18
- 239000000376 reactant Substances 0.000 description 18
- 239000012980 RPMI-1640 medium Substances 0.000 description 17
- 230000002401 inhibitory effect Effects 0.000 description 17
- 125000005647 linker group Chemical group 0.000 description 17
- 239000007788 liquid Substances 0.000 description 17
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 17
- 238000001514 detection method Methods 0.000 description 16
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 16
- 229940049595 antibody-drug conjugate Drugs 0.000 description 15
- 239000000556 agonist Substances 0.000 description 14
- 239000000611 antibody drug conjugate Substances 0.000 description 14
- 239000000872 buffer Substances 0.000 description 14
- 230000012202 endocytosis Effects 0.000 description 14
- 150000002148 esters Chemical class 0.000 description 14
- 210000004881 tumor cell Anatomy 0.000 description 14
- 230000001472 cytotoxic effect Effects 0.000 description 13
- 230000003834 intracellular effect Effects 0.000 description 13
- 239000006228 supernatant Substances 0.000 description 13
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 12
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 description 12
- 229930188854 dolastatin Natural products 0.000 description 12
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 12
- 210000004408 hybridoma Anatomy 0.000 description 12
- 230000008569 process Effects 0.000 description 12
- 108020003175 receptors Proteins 0.000 description 12
- 102000005962 receptors Human genes 0.000 description 12
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 11
- 125000003275 alpha amino acid group Chemical group 0.000 description 11
- 230000000269 nucleophilic effect Effects 0.000 description 11
- 210000002381 plasma Anatomy 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- 230000001629 suppression Effects 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 125000004414 alkyl thio group Chemical group 0.000 description 10
- 125000002837 carbocyclic group Chemical group 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 10
- 230000000670 limiting effect Effects 0.000 description 10
- 230000026731 phosphorylation Effects 0.000 description 10
- 238000006366 phosphorylation reaction Methods 0.000 description 10
- 230000004663 cell proliferation Effects 0.000 description 9
- 229960002173 citrulline Drugs 0.000 description 9
- 231100000433 cytotoxic Toxicity 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 238000005406 washing Methods 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 230000013595 glycosylation Effects 0.000 description 8
- 238000006206 glycosylation reaction Methods 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 229940124597 therapeutic agent Drugs 0.000 description 8
- 0 CC(C(C(CC(*)(*)C1(*)S)N1C(CC([*-][*-])C(*)*C(C(*)NC(C(N)N(*)*)=N)=O)=O)OCI)C(N(C(C)C(*)*)*=I)=O Chemical compound CC(C(C(CC(*)(*)C1(*)S)N1C(CC([*-][*-])C(*)*C(C(*)NC(C(N)N(*)*)=N)=O)=O)OCI)C(N(C(C)C(*)*)*=I)=O 0.000 description 7
- 102000035195 Peptidases Human genes 0.000 description 7
- 108091005804 Peptidases Proteins 0.000 description 7
- 150000001299 aldehydes Chemical class 0.000 description 7
- 150000001412 amines Chemical class 0.000 description 7
- 125000004429 atom Chemical group 0.000 description 7
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 description 7
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 7
- 235000018417 cysteine Nutrition 0.000 description 7
- 230000000857 drug effect Effects 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 7
- 231100000331 toxic Toxicity 0.000 description 7
- 230000002588 toxic effect Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 241000282693 Cercopithecidae Species 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 241001597008 Nomeidae Species 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 229910052786 argon Inorganic materials 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000002255 enzymatic effect Effects 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 238000007689 inspection Methods 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- ORFNVPGICPYLJV-YTVPMEHESA-N (2s)-2-[[(2r,3r)-3-[(2s)-1-[(3r,4s,5s)-4-[[(2s)-2-[[(2s)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoyl-methylamino]-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-3-methoxy-2-methylpropanoyl]amino]-3-phenylpropan Chemical compound C([C@H](NC(=O)[C@H](C)[C@@H](OC)[C@@H]1CCCN1C(=O)C[C@H]([C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)CCCCCN1C(C=CC1=O)=O)C(C)C)OC)C(O)=O)C1=CC=CC=C1 ORFNVPGICPYLJV-YTVPMEHESA-N 0.000 description 5
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 5
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 5
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 5
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- NLMBVBUNULOTNS-HOKPPMCLSA-N [4-[[(2s)-5-(carbamoylamino)-2-[[(2s)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl n-[(2s)-1-[[(2s)-1-[[(3r,4s,5s)-1-[(2s)-2-[(1r,2r)-3-[[(1s,2r)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-o Chemical compound C1([C@H](O)[C@@H](C)NC(=O)[C@H](C)[C@@H](OC)[C@@H]2CCCN2C(=O)C[C@H]([C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCC=2C=CC(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN3C(C=CC3=O)=O)C(C)C)=CC=2)C(C)C)OC)=CC=CC=C1 NLMBVBUNULOTNS-HOKPPMCLSA-N 0.000 description 5
- 125000003282 alkyl amino group Chemical group 0.000 description 5
- 125000000304 alkynyl group Chemical group 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 150000001721 carbon Chemical group 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 238000005520 cutting process Methods 0.000 description 5
- 125000000000 cycloalkoxy group Chemical group 0.000 description 5
- 125000005366 cycloalkylthio group Chemical group 0.000 description 5
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 208000010749 gastric carcinoma Diseases 0.000 description 5
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 201000000498 stomach carcinoma Diseases 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- DJQYYYCQOZMCRC-UHFFFAOYSA-N 2-aminopropane-1,3-dithiol Chemical compound SCC(N)CS DJQYYYCQOZMCRC-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 4
- 108010016626 Dipeptides Proteins 0.000 description 4
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000007405 data analysis Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- KZNICNPSHKQLFF-UHFFFAOYSA-N dihydromaleimide Natural products O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 4
- 230000002121 endocytic effect Effects 0.000 description 4
- DUYAAUVXQSMXQP-UHFFFAOYSA-N ethanethioic S-acid Chemical compound CC(S)=O DUYAAUVXQSMXQP-UHFFFAOYSA-N 0.000 description 4
- 239000007850 fluorescent dye Substances 0.000 description 4
- 238000001215 fluorescent labelling Methods 0.000 description 4
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Chemical compound NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 229960002317 succinimide Drugs 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- QWPXBEHQFHACTK-KZVYIGENSA-N (10e,12e)-86-chloro-12,14,4-trihydroxy-85,14-dimethoxy-33,2,7,10-tetramethyl-15,16-dihydro-14h-7-aza-1(6,4)-oxazina-3(2,3)-oxirana-8(1,3)-benzenacyclotetradecaphane-10,12-dien-6-one Chemical compound CN1C(=O)CC(O)C2(C)OC2C(C)C(OC(=O)N2)CC2(O)C(OC)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 QWPXBEHQFHACTK-KZVYIGENSA-N 0.000 description 3
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 3
- NYCRCTMDYITATC-UHFFFAOYSA-N 2-fluorophenylalanine Chemical compound OC(=O)C(N)CC1=CC=CC=C1F NYCRCTMDYITATC-UHFFFAOYSA-N 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 229930126263 Maytansine Natural products 0.000 description 3
- QWPXBEHQFHACTK-UHFFFAOYSA-N Maytansinol Natural products CN1C(=O)CC(O)C2(C)OC2C(C)C(OC(=O)N2)CC2(O)C(OC)C=CC=C(C)CC2=CC(OC)=C(Cl)C1=C2 QWPXBEHQFHACTK-UHFFFAOYSA-N 0.000 description 3
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 102000052575 Proto-Oncogene Human genes 0.000 description 3
- 108700020978 Proto-Oncogene Proteins 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 125000002877 alkyl aryl group Chemical group 0.000 description 3
- 125000003368 amide group Chemical group 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000012292 cell migration Effects 0.000 description 3
- 238000003570 cell viability assay Methods 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 150000002923 oximes Chemical class 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 235000019419 proteases Nutrition 0.000 description 3
- 238000010188 recombinant method Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 229940070710 valerate Drugs 0.000 description 3
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- IADUWZMNTKHTIN-MLSWMBHTSA-N (2,5-dioxopyrrolidin-1-yl) 4-[[3-[3-[[(2S)-1-[[(1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl]oxy]-1-oxopropan-2-yl]-methylamino]-3-oxopropyl]sulfanyl-2,5-dioxopyrrolidin-1-yl]methyl]cyclohexane-1-carboxylate Chemical compound CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)[C@H](C)N(C)C(=O)CCSC2CC(=O)N(CC3CCC(CC3)C(=O)ON3C(=O)CCC3=O)C2=O)[C@]2(C)O[C@H]2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2 IADUWZMNTKHTIN-MLSWMBHTSA-N 0.000 description 2
- AZMIIVUEOLBHBL-LKTVYLICSA-N (3s,3as,8bs)-7-bromo-3,3a,6,8b-tetramethyl-2,3-dihydro-1h-cyclopenta[b][1]benzofuran Chemical compound BrC1=C(C)C=C2O[C@@]3(C)[C@@H](C)CC[C@@]3(C)C2=C1 AZMIIVUEOLBHBL-LKTVYLICSA-N 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 2
- MQLACMBJVPINKE-UHFFFAOYSA-N 10-[(3-hydroxy-4-methoxyphenyl)methylidene]anthracen-9-one Chemical compound C1=C(O)C(OC)=CC=C1C=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MQLACMBJVPINKE-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- OMNVYXHOSHNURL-WPRPVWTQSA-N Ala-Phe Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 OMNVYXHOSHNURL-WPRPVWTQSA-N 0.000 description 2
- AZMIIVUEOLBHBL-UHFFFAOYSA-N Aplysin Natural products BrC1=C(C)C=C2OC3(C)C(C)CCC3(C)C2=C1 AZMIIVUEOLBHBL-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 238000011729 BALB/c nude mouse Methods 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- DMUKOHYUYDBTIL-UHFFFAOYSA-N C(=O)=CCP Chemical class C(=O)=CCP DMUKOHYUYDBTIL-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 102000004225 Cathepsin B Human genes 0.000 description 2
- 108090000712 Cathepsin B Proteins 0.000 description 2
- 208000030808 Clear cell renal carcinoma Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 208000035126 Facies Diseases 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 101000878540 Homo sapiens Protein-tyrosine kinase 2-beta Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 2
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 101150024075 Mapk1 gene Proteins 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- FADYJNXDPBKVCA-STQMWFEESA-N Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 FADYJNXDPBKVCA-STQMWFEESA-N 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 102000008022 Proto-Oncogene Proteins c-met Human genes 0.000 description 2
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 description 2
- 102000004243 Tubulin Human genes 0.000 description 2
- 108090000704 Tubulin Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 102000035181 adaptor proteins Human genes 0.000 description 2
- 108091005764 adaptor proteins Proteins 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 108010011559 alanylphenylalanine Proteins 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 2
- 229930195731 calicheamicin Natural products 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
- 235000013477 citrulline Nutrition 0.000 description 2
- 206010073251 clear cell renal cell carcinoma Diseases 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 239000002619 cytotoxin Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 229940042396 direct acting antivirals thiosemicarbazones Drugs 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 2
- 150000007857 hydrazones Chemical class 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 239000002596 immunotoxin Substances 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 201000005296 lung carcinoma Diseases 0.000 description 2
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 2
- GTCAXTIRRLKXRU-UHFFFAOYSA-N methyl carbamate Chemical compound COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 238000007857 nested PCR Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 231100000956 nontoxicity Toxicity 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000007096 poisonous effect Effects 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000012146 running buffer Substances 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000007974 sodium acetate buffer Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000003396 thiol group Chemical class [H]S* 0.000 description 2
- 150000003584 thiosemicarbazones Chemical class 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- JKHVDAUOODACDU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCN1C(=O)C=CC1=O JKHVDAUOODACDU-UHFFFAOYSA-N 0.000 description 1
- PVGATNRYUYNBHO-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(2,5-dioxopyrrol-1-yl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCN1C(=O)C=CC1=O PVGATNRYUYNBHO-UHFFFAOYSA-N 0.000 description 1
- PMJWDPGOWBRILU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[4-(2,5-dioxopyrrol-1-yl)phenyl]butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCC(C=C1)=CC=C1N1C(=O)C=CC1=O PMJWDPGOWBRILU-UHFFFAOYSA-N 0.000 description 1
- VLARLSIGSPVYHX-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-(2,5-dioxopyrrol-1-yl)hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCN1C(=O)C=CC1=O VLARLSIGSPVYHX-UHFFFAOYSA-N 0.000 description 1
- WCMOHMXWOOBVMZ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-[3-(2,5-dioxopyrrol-1-yl)propanoylamino]hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCNC(=O)CCN1C(=O)C=CC1=O WCMOHMXWOOBVMZ-UHFFFAOYSA-N 0.000 description 1
- IHVODYOQUSEYJJ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-[[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]amino]hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCNC(=O)C(CC1)CCC1CN1C(=O)C=CC1=O IHVODYOQUSEYJJ-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- AXKGIPZJYUNAIW-UHFFFAOYSA-N (4-aminophenyl)methanol Chemical compound NC1=CC=C(CO)C=C1 AXKGIPZJYUNAIW-UHFFFAOYSA-N 0.000 description 1
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 description 1
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 description 1
- VILFTWLXLYIEMV-UHFFFAOYSA-N 1,5-difluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC([N+]([O-])=O)=C(F)C=C1F VILFTWLXLYIEMV-UHFFFAOYSA-N 0.000 description 1
- DIYPCWKHSODVAP-UHFFFAOYSA-N 1-[3-(2,5-dioxopyrrol-1-yl)benzoyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)C1=CC=CC(N2C(C=CC2=O)=O)=C1 DIYPCWKHSODVAP-UHFFFAOYSA-N 0.000 description 1
- CULQNACJHGHAER-UHFFFAOYSA-N 1-[4-[(2-iodoacetyl)amino]benzoyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)C1=CC=C(NC(=O)CI)C=C1 CULQNACJHGHAER-UHFFFAOYSA-N 0.000 description 1
- XETLOFNELZCXMX-UHFFFAOYSA-N 2-(diethylamino)ethyl 2-(4-hexoxyphenyl)-2-hydroxy-2-phenylacetate;hydrochloride Chemical compound Cl.C1=CC(OCCCCCC)=CC=C1C(O)(C(=O)OCCN(CC)CC)C1=CC=CC=C1 XETLOFNELZCXMX-UHFFFAOYSA-N 0.000 description 1
- FZDFGHZZPBUTGP-UHFFFAOYSA-N 2-[[2-[bis(carboxymethyl)amino]-3-(4-isothiocyanatophenyl)propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)C(C)CN(CC(O)=O)CC(N(CC(O)=O)CC(O)=O)CC1=CC=C(N=C=S)C=C1 FZDFGHZZPBUTGP-UHFFFAOYSA-N 0.000 description 1
- NYCRCTMDYITATC-QMMMGPOBSA-N 2-fluoro-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1F NYCRCTMDYITATC-QMMMGPOBSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- ZMRMMAOBSFSXLN-UHFFFAOYSA-N 4-[4-(2,5-dioxopyrrol-1-yl)phenyl]butanehydrazide Chemical compound C1=CC(CCCC(=O)NN)=CC=C1N1C(=O)C=CC1=O ZMRMMAOBSFSXLN-UHFFFAOYSA-N 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 1
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 101710186708 Agglutinin Proteins 0.000 description 1
- 102000014303 Amyloid beta-Protein Precursor Human genes 0.000 description 1
- 108010079054 Amyloid beta-Protein Precursor Proteins 0.000 description 1
- 101100028789 Arabidopsis thaliana PBS1 gene Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- UAKKTVBDTSQMAJ-UHFFFAOYSA-N CC(C)(C=C1)C#CCc2c1[nH]nc2 Chemical compound CC(C)(C=C1)C#CCc2c1[nH]nc2 UAKKTVBDTSQMAJ-UHFFFAOYSA-N 0.000 description 1
- XXQRKPKEVUDMDP-UHFFFAOYSA-N CC(C)(C=C1)C=CC2=C1NCO2 Chemical compound CC(C)(C=C1)C=CC2=C1NCO2 XXQRKPKEVUDMDP-UHFFFAOYSA-N 0.000 description 1
- NDGHQHBGYQTKKC-UHFFFAOYSA-N CC1(C)C=CC(OC=CC2)=C2C=C1 Chemical compound CC1(C)C=CC(OC=CC2)=C2C=C1 NDGHQHBGYQTKKC-UHFFFAOYSA-N 0.000 description 1
- CLUWGSZRWDSVME-UHFFFAOYSA-N CCCCCN[Ar] Chemical compound CCCCCN[Ar] CLUWGSZRWDSVME-UHFFFAOYSA-N 0.000 description 1
- BLWOYAGQQITVRF-UHFFFAOYSA-N CCCNC(C1NC1)O Chemical compound CCCNC(C1NC1)O BLWOYAGQQITVRF-UHFFFAOYSA-N 0.000 description 1
- DVRMFBPFJBFXSN-CTQCHYAJSA-N CC[C@H](C)C(/C(/CC(N)=O)=[O]/C)N(C)C([C@H](C(C)C)NC([C@H](C(C)C)NC)=O)=O Chemical compound CC[C@H](C)C(/C(/CC(N)=O)=[O]/C)N(C)C([C@H](C(C)C)NC([C@H](C(C)C)NC)=O)=O DVRMFBPFJBFXSN-CTQCHYAJSA-N 0.000 description 1
- AQRWKBMUSITGKH-DPZFAYFNSA-N CC[C@H](C)C([C@@H](CC(N(CCC1)[C@@H]1[C@@H]([C@@H](C)C(NC[C@H](C)C(c1ccccc1)O)=O)OC)=O)OC)N(C)C([C@H](C(C)C)NC(CC(C)(C)CNC)=O)=O Chemical compound CC[C@H](C)C([C@@H](CC(N(CCC1)[C@@H]1[C@@H]([C@@H](C)C(NC[C@H](C)C(c1ccccc1)O)=O)OC)=O)OC)N(C)C([C@H](C(C)C)NC(CC(C)(C)CNC)=O)=O AQRWKBMUSITGKH-DPZFAYFNSA-N 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 102000003902 Cathepsin C Human genes 0.000 description 1
- 108090000267 Cathepsin C Proteins 0.000 description 1
- 102000003908 Cathepsin D Human genes 0.000 description 1
- 108090000258 Cathepsin D Proteins 0.000 description 1
- 231100000023 Cell-mediated cytotoxicity Toxicity 0.000 description 1
- 206010057250 Cell-mediated cytotoxicity Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 1
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- OFDNQWIFNXBECV-UHFFFAOYSA-N Dolastatin 10 Natural products CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)CC)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 OFDNQWIFNXBECV-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical group C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 108091006020 Fc-tagged proteins Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 244000041633 Grewia tenax Species 0.000 description 1
- 235000005612 Grewia tenax Nutrition 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 101001106413 Homo sapiens Macrophage-stimulating protein receptor Proteins 0.000 description 1
- 101710146024 Horcolin Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 101710189395 Lectin Proteins 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 101710179758 Mannose-specific lectin Proteins 0.000 description 1
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 1
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 1
- 241001441512 Maytenus serrata Species 0.000 description 1
- 101000797092 Mesorhizobium japonicum (strain LMG 29417 / CECT 9101 / MAFF 303099) Probable acetoacetate decarboxylase 3 Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229940121849 Mitotic inhibitor Drugs 0.000 description 1
- 101100042271 Mus musculus Sema3b gene Proteins 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 101710096660 Probable acetoacetate decarboxylase 2 Proteins 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 241000220324 Pyrus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229910006069 SO3H Inorganic materials 0.000 description 1
- 101150098533 SOST gene Proteins 0.000 description 1
- 108060006706 SRC Proteins 0.000 description 1
- 102000001332 SRC Human genes 0.000 description 1
- 102000004495 STAT3 Transcription Factor Human genes 0.000 description 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 208000035199 Tetraploidy Diseases 0.000 description 1
- LJWZOKOFCBPNAG-UHFFFAOYSA-N Trichothecin Natural products CC=CC(=O)OC1CC2OC3C=C(C)C(=O)CC3(C)C1(C)C21CO1 LJWZOKOFCBPNAG-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000010811 Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry Methods 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- XBJFCYDKBDVADW-UHFFFAOYSA-N acetonitrile;formic acid Chemical compound CC#N.OC=O XBJFCYDKBDVADW-UHFFFAOYSA-N 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 239000000910 agglutinin Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003388 anti-hormonal effect Effects 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 150000001538 azepines Chemical class 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 238000005284 basis set Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 150000001639 boron compounds Chemical class 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- SNCZNSNPXMPCGN-UHFFFAOYSA-N butanediamide Chemical compound NC(=O)CCC(N)=O SNCZNSNPXMPCGN-UHFFFAOYSA-N 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 125000000609 carbazolyl group Chemical class C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000005890 cell-mediated cytotoxicity Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000006552 constitutive activation Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001352 cyclobutyloxy group Chemical group C1(CCC1)O* 0.000 description 1
- CHVJITGCYZJHLR-UHFFFAOYSA-N cyclohepta-1,3,5-triene Chemical compound C1C=CC=CC=C1 CHVJITGCYZJHLR-UHFFFAOYSA-N 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000002027 dichloromethane extract Substances 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- VFNGKCDDZUSWLR-UHFFFAOYSA-L disulfate(2-) Chemical compound [O-]S(=O)(=O)OS([O-])(=O)=O VFNGKCDDZUSWLR-UHFFFAOYSA-L 0.000 description 1
- OFDNQWIFNXBECV-VFSYNPLYSA-N dolastatin 10 Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 OFDNQWIFNXBECV-VFSYNPLYSA-N 0.000 description 1
- 108010045524 dolastatin 10 Proteins 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 229950007655 esilate Drugs 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- ALBYIUDWACNRRB-UHFFFAOYSA-N hexanamide Chemical compound CCCCCC(N)=O ALBYIUDWACNRRB-UHFFFAOYSA-N 0.000 description 1
- YWGHUJQYGPDNKT-UHFFFAOYSA-N hexanoyl chloride Chemical compound CCCCCC(Cl)=O YWGHUJQYGPDNKT-UHFFFAOYSA-N 0.000 description 1
- 210000003701 histiocyte Anatomy 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 102000057593 human F8 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- XVRPRIWMAWVUOR-UHFFFAOYSA-N hydrazinecarboxylic acid Chemical compound NNC(O)=O.NNC(O)=O XVRPRIWMAWVUOR-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000008880 microtubule cytoskeleton organization Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 230000001002 morphogenetic effect Effects 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- OWIUPIRUAQMTTK-UHFFFAOYSA-M n-aminocarbamate Chemical compound NNC([O-])=O OWIUPIRUAQMTTK-UHFFFAOYSA-M 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229940005654 nitrite ion Drugs 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 102000027450 oncoproteins Human genes 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 201000010279 papillary renal cell carcinoma Diseases 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 235000021017 pears Nutrition 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N pentadecanoic acid Chemical compound CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960003330 pentetic acid Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 210000004332 phalangeal cell Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000036314 physical performance Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 229940047431 recombinate Drugs 0.000 description 1
- 239000012557 regeneration buffer Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- MKNJJMHQBYVHRS-UHFFFAOYSA-M sodium;1-[11-(2,5-dioxopyrrol-1-yl)undecanoyloxy]-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCCCCCCCCCN1C(=O)C=CC1=O MKNJJMHQBYVHRS-UHFFFAOYSA-M 0.000 description 1
- ULARYIUTHAWJMU-UHFFFAOYSA-M sodium;1-[4-(2,5-dioxopyrrol-1-yl)butanoyloxy]-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCCN1C(=O)C=CC1=O ULARYIUTHAWJMU-UHFFFAOYSA-M 0.000 description 1
- VUFNRPJNRFOTGK-UHFFFAOYSA-M sodium;1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)C1CCC(CN2C(C=CC2=O)=O)CC1 VUFNRPJNRFOTGK-UHFFFAOYSA-M 0.000 description 1
- MIDXXTLMKGZDPV-UHFFFAOYSA-M sodium;1-[6-(2,5-dioxopyrrol-1-yl)hexanoyloxy]-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCCCCN1C(=O)C=CC1=O MIDXXTLMKGZDPV-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- WMOVHXAZOJBABW-UHFFFAOYSA-N tert-butyl acetate Chemical compound CC(=O)OC(C)(C)C WMOVHXAZOJBABW-UHFFFAOYSA-N 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- SRVJKTDHMYAMHA-WUXMJOGZSA-N thioacetazone Chemical compound CC(=O)NC1=CC=C(\C=N\NC(N)=S)C=C1 SRVJKTDHMYAMHA-WUXMJOGZSA-N 0.000 description 1
- CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- RUELTTOHQODFPA-UHFFFAOYSA-N toluene 2,6-diisocyanate Chemical compound CC1=C(N=C=O)C=CC=C1N=C=O RUELTTOHQODFPA-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229950004288 tosilate Drugs 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- LZAJKCZTKKKZNT-PMNGPLLRSA-N trichothecene Chemical compound C12([C@@]3(CC[C@H]2OC2C=C(CCC23C)C)C)CO1 LZAJKCZTKKKZNT-PMNGPLLRSA-N 0.000 description 1
- 229930013292 trichothecene Natural products 0.000 description 1
- LJWZOKOFCBPNAG-HULHSAFCSA-N trichothecin Chemical compound C([C@@]12[C@@]3(C)[C@@]4(C)CC(=O)C(C)=C[C@H]4O[C@@H]1C[C@H]3OC(=O)\C=C/C)O2 LJWZOKOFCBPNAG-HULHSAFCSA-N 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6819—Plant toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6859—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from liver or pancreas cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6861—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from kidney or bladder cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3023—Lung
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3038—Kidney, bladder
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明涉及抗c-Met抗体和抗c-Met抗体-细胞毒性药物偶联物及其医药用途。具体地,本发明涉及一种抗c-Met抗体,c-Met的抗原结合片段,包含所述抗c-Met抗体CDR区的嵌合抗体、人源化抗体,及其抗体-细胞毒性药物偶联物或其可药用盐或溶剂化合物,以及包含人源化抗c-Met抗体和抗原结合片段及其抗体-细胞毒性药物偶联物或其可药用盐或溶剂化合物的药物组合物,以及其作为抗癌药物的用途,尤其在制备用于治疗c-Met介导的疾病或病症的药物中的用途。
Description
技术领域
本发明公开了一种抗c-Met抗体或其抗原结合片段,包含所述抗c-Met抗体CDR区的嵌合抗体、人源化抗体,及抗c-Met抗体-细胞毒性药物偶联物或其可药用盐或溶剂化合物,以及包含人c-Met抗体或其抗原结合片段及其抗体-细胞毒性药物偶联物或其可药用盐或溶剂化合物的药物组合物,以及其作为抗癌药物的用途。尤其涉及一种人源化的抗c-Met抗体及抗c-Met抗体-细胞毒性药物偶联物或其可药用盐或溶剂化合物,在制备用于治疗c-Met介导的疾病或病症的药物中的用途。
背景技术
近年来分子生物学和肿瘤药理学研究表明,酪氨酸激酶(Protein Tyrosine Kinases,PTKs)相关的细胞信号转导通路在肿瘤的形成和发展中发挥了极其重要的作用,超过50%的原癌基因和癌基因产物都具有酪氨酸激酶活性。c-Met原癌基因属于PTKs家族中Ron亚族,其编码的c-Met蛋白是肝细胞生长因子/离散因子(Hepatocyte Growth Factor/Scatter Factor,HGF/SF)的高亲和性受体。HGF/c-Met信号通路与血管新生和肿瘤生长过程密切相关,其持续激活是组织细胞癌变或癌细胞增殖亢进的重要原因,抑制该通路已成为肿瘤靶向治疗的新手段。
c-Met原癌基因位于人类第7号染色体长臂(7q31),大小超过120kb,编码分子量约150kD的c-Met蛋白前体,经局部糖基化生成一个170kD的糖蛋白,该糖蛋白进一步剪切为亚基(50kDa)和亚基(140kDa),以二硫键相连,形成成熟的c-Met蛋白受体。该异二聚体包含两条链,链有胞外区、跨膜区(也称膜伸展片段)和胞内区(包含细胞内酪氨酸激酶结合位点)。链只有胞外部分,但它是高度糖基化,通过二硫键附着于链上。两个亚基的胞外区域是相应配体的识别部位,胞内区域具有酪氨酸激酶活性。
c-Met激活的机制分为三种:一是依赖HGF的激活机制,二是不依赖HGF激活机制,三是经过其他膜途径,例如通过透明质酸膜表面受体的CD44、粘附素以及RON信号传导途径等等。其中最常见的是依赖HGF的激活机制。HGF的N末端与c-Met结合,促进链上Tyr1234和Tyr1235二聚化和自磷酸化,C-末端附近的Tyr1349和Tyr1356磷酸化产生多个接头蛋白的结合位点,这些接头蛋白诱导了P13K/Akt、Ras/Mapk、c-Src和STAT3/5介导的下游信号的激活,引发不同细胞反应,如细胞生存和活动(与P13K/Akt通路密切相关),肿瘤转移 和细胞增殖(主要由Ras/Mapk介导)。此外,c-Met与其它膜受体存在交联(cross-talk),现已确知这种交联可促进肿瘤形成及转移,由于c-Met是导致肿瘤形成及转移的许多通路的交叉点,以c-Met为靶标可相对较容易地实现对许多通路的同时干扰,c-Met成为抗肿瘤生成和转移治疗的一个有希望的靶点。
抗体药物偶联物(antibody drug conjugate,ADC)把单克隆抗体或者抗体片段通过稳定的化学接头化合物与具有生物活性的细胞毒素相连,充分利用了抗体对肿瘤细胞特异或高表达抗原结合的特异性和细胞毒素的高效性,避免对正常细胞的毒副作用。这也就意味着,与以往传统的化疗药物相比,抗体药物偶联物能精准地结合肿瘤细胞并降低将对正常细胞的影响。
ADC药物由抗体(靶向),接头和毒素三部分组成。其中,好的靶点(抗体部分)决定了ADC药物的特异性,这不仅包括特异靶向结合,还包括有效的内吞。
目前针对c-Met激酶靶点抑制剂主要有三类:HGF和c-Met生物拮抗剂、HGF和c-Met抗体,以及小分子c-Met抑制剂。现有的临床结果表明,直接针对HGF,c-Met的抗体,或c-Met小分子抑制疗效不甚理想。针对c-Met的ADC药物可能是该靶点最有效的方法治疗肿瘤。目前,尚没有c-Met ADC药物临床研究。
本发明首创抗c-Met抗体ADC药物,不仅保留了本发明抗c-Met抗体的抗体依赖性的细胞增殖抑制作用,同时又增加了潜在的细胞毒素药物的效应。而且因为其毒素靶向在肿瘤细胞内释放,药物毒副作用并没有随着疗效的增加而同步增大。本发明提供特异性结合人c-Met的人源化抗体和嵌合抗体,并且该人源化抗体和嵌合抗体特征在于具有高亲和力,高药效,有内吞功效,稳定性好和无c-Met激动活性等特点。在这些优良性能基础上,本发明同时还提供特异性结合人c-Met的抗体-细胞毒性药物偶联物或其可药用盐或溶剂化合物,不仅保留了本发明抗c-Met抗体的抗体依赖性的细胞增殖抑制作用,同时又增加了潜在的细胞毒素药物的效应和治疗疾病的广谱性。而且因为其毒素靶向在肿瘤细胞内释放(本发明抗c-Met抗体的内吞作用),药物毒副作用并没有随着疗效的增加而同步增大。
发明内容
本发明提供一种特异性结合c-Met受体的抗体或其抗原结合片段,其包含至少1个选自以下CDR区的序列或其突变序列:
抗体重链可变区HCDR区序列:SEQ ID NO:6,SEQ ID NO:7或SEQ ID NO:8;和
抗体轻链可变区LCDR区序列:SEQ ID NO:9,SEQ ID NO:10或SEQ ID NO:11。
在本发明一个优选的实施方案中,提供一种如上所述的c-Met抗体或其抗原结合片段,其中所述的抗体重链可变区包含至少1个选自如下的HCDR区序列或其突变序列:SEQ ID NO:6,SEQ ID NO:7或SEQ ID NO:8。
在本发明一个优选的实施方案中,提供一种如上所述的c-Met抗体或其抗原结合片段,其中所述的抗体轻链可变区包含至少1个选自如下的LCDR区序列或其突变序列:SEQ ID NO:9,SEQ ID NO:10或SEQ ID NO:11。
在本发明一个优选的实施方案中,提供一种如上所述的c-Met抗体或其抗原结合片段,其中所述的抗体包含重链可变区序列SEQ ID NO:6(HCDR1),SEQ ID NO:7(HCDR2)和SEQ ID NO:8(HCDR3),或其突变序列,和轻链可变区序列SEQ ID NO:9(LCDR1),SEQ ID NO:10(LCDR2)和SEQ ID NO:11(LCDR3)或其突变序列。
在本发明一个优选的实施方案中,提供一种如上所述的c-Met抗体或其抗原结合片段,其中所述的CDR区突变序列为CDR区发生1-3个优化抗体活性的氨基酸突变,其中所述的HCDR2区突变序列优选为SEQ ID NO:12。
在本发明一个优选的实施方案中,提供一种如上所述的c-Met抗体或其抗原结合片段,其中所述的c-Met抗体或其抗原结合片段为鼠源抗体或其片段。
在本发明一个优选的实施方案中,提供一种如上所述的c-Met抗体或其抗原结合片段,其中所述的鼠源抗体重链可变区序列为:SEQ ID NO:4。
在本发明一个优选的实施方案中,提供一种如上所述的c-Met抗体或其抗原结合片段,其中所述的鼠源抗体轻链可变区序列为:SEQ ID NO:5。
在本发明一个优选的实施方案中,提供一种如上所述的c-Met抗体或其抗原结合片段,其中所述的鼠源抗体的-重链可变区为:SEQ ID NO:4,轻链可变区为:SEQ ID NO:5。
在本发明一个优选的实施方案中,提供一种如上所述的鼠源抗体或其片段,其抗体重链可变区进一步包含源自鼠源的IgG1、IgG2、IgG3或IgG4或其变体的重链FR区。
在本发明一个优选的实施方案中,提供一种如上所述的鼠源抗体或其片段,其进一步包含源自鼠源IgG1、IgG2、IgG3或IgG4、或其变体的重链恒定区。
在本发明一个优选的实施方案中,提供一种如上所述的鼠源抗体或其片段,其抗体轻链可变区进一步包含选自鼠源κ或λ链、或其变体的轻链FR区。
在本发明一个优选的实施方案中,提供一种如上所述的鼠源抗体或其片段,其进一步包含选自鼠源κ或λ链、或其变体的轻链恒定区。
在本发明一个优选的实施方案中,提供一种如上所述的c-Met抗体或其抗原结合片段,其为嵌合抗体或人源化抗体或其片段。
在本发明一个优选的实施方案中,提供一种如上所述的c-Met抗体或其抗原结合片段,其中所述人源化抗体重链可变区进一步包含人源IgG1、IgG2、IgG3、或IgG4或其变体的重链FR区。
在本发明一个优选的实施方案中,提供一种如上所述的c-Met抗体或其抗原结合片段,其中所述人源化抗体重链可变区上的重链FR区序列,来源于人种系重链序列,优选人种系重链IGHV 3-33*01;包含人种系重链IGHV 3-33*01的FR1,FR2,FR3区和FR4区的框架序列或其突变序列,优选所述突变序列为0-10个氨基酸的回复突变。
在本发明一个优选的实施方案中,提供一种如上所述的c-Met抗体或其抗原结合片段,其中所述的人源化抗体包含SEQ ID NO:13-15所示的重链可变区序列或其变体。
在本发明一个优选的实施方案中,提供一种如上所述的c-Met抗体或其抗原结合片段,其中所述人源化抗体轻链可变区上的轻链FR区序列,选自人种系轻链序列,优选人种系轻链IGKV085或IGKV 4-1*01,包含人种系轻链IGKV085和IGKV 4-1*01的FR1,FR2,FR3区和FR4区的框架序列或其突变序列,优选所述突变序列为0-10个氨基酸的回复突变。
在本发明一个优选的实施方案中,提供一种如上所述的c-Met抗体或其抗原结合片段,其中所述的人源化抗体包含选自SEQ ID NO:16-18所示的轻链可变区序列或其变体。
在本发明一个优选的实施方案中,提供一种如上所述的c-Met抗体或其抗原结合片段,所述的人源化抗体包含选自SEQ ID NO:13-15的重链可变区和选自SEQ ID NO:16-18的轻链可变区。
在本发明一个优选的实施方案中,提供一种如上所述的c-Met抗体或其抗原结合片段,其包含选自(a)至(c)任一的重链可变区序列和轻链可变区序列的组合:
(a)SEQ ID NO:13的重链可变区序列和SEQ ID NO:16的轻链可变区序列;
(b)SEQ ID NO:14的重链可变区序列和SEQ ID NO:17的轻链可变区序列;或
(c)SEQ ID NO:15的重链可变区序列和SEQ ID NO:18的轻链可变区序列。
在本发明一个优选的实施方案中,提供一种如上所述的c-Met抗体或其抗原结合片段,其中所述的人源化抗体的重链恒定区包含源自人源IgG1或其变体、人源IgG2或其变体、人源IgG3或其变体或人源IgG4或其变体的恒定区,优选包含人源IgG1或其变体或人源IgG2或其变体或人源IgG4或其变体的恒定区,更优选人源IgG2或其变体的恒定区。
在本发明一个优选的实施方案中,提供一种如上所述的c-Met抗体或其抗 原结合片段,其包含选自SEQ ID NO:23-25或与其具有至少90%同源性的全长重链序列。
在本发明一个优选的实施方案中,提供一种如上所述的c-Met抗体或其抗原结合片段,其中所述人源化抗体轻链可变区进一步包含任选自人源κ或λ链或其变体的轻链FR区。
在本发明一个优选的实施方案中,提供一种如上所述的c-Met抗体或其抗原结合片段,其所述的人源化抗体的轻链恒定区包含选自人源κ或λ链或其变体的恒定区。
在本发明一个优选的实施方案中,提供一种如上所述的c-Met抗体或其抗原结合片段,其包含选自SEQ ID NO:26-28或与其具有至少90%序列同源性的全长轻链序列。
在本发明一个优选的实施方案中,提供一种如上所述的c-Met抗体或其抗原结合片段,其中所述的人源化抗体包含选自SEQ ID NO:23-25的全长重链序列和SEQ ID NO:26-28的全长轻链序列。
在本发明一个优选的实施方案中,提供一种如上所述的c-Met抗体或其抗原结合片段,其中所述的人源化抗体选自(a)至(c)任一的全长轻链序列和全长重链序列的组合:
Ab-9:SEQ ID NO:23的重链序列和SEQ ID NO:26的轻链序列;
Ab-10:SEQ ID NO:24的重链序列和SEQ ID NO:27的轻链序列;或
Ab-11:SEQ ID NO:25的重链序列和SEQ ID NO:28的轻链序列。
在本发明一个优选的实施方案中,提供一种如上所述的c-Met抗体或其抗原结合片段,其中所述的抗原结合片段包含Fab、Fv、sFv或F(ab’)2。
本发明进一步提供一种编码如上所述的c-Met抗体或其抗原结合片段的表达前体产物的DNA分子。
本发明进一步提供一种含有如上所述的DNA分子的表达载体。
本发明进一步提供一种用如上所述的表达载体转化的宿主细胞。
在本发明一个优选的实施方案中,提供一种如上所述的宿主细胞,其中所述的宿主细胞优选为哺乳动物细胞,更优选为CHO细胞。
本发明进一步提供一种药物组合物,其包含含有如上所述的c-Met抗体或其抗原结合片段,和一种或多种可药用的赋形剂、稀释剂或载体。
本发明进一步提供一种如上所述的c-Met抗体或其抗原结合片段、或包含其的药物组合物,在制备用于治疗c-Met介导的疾病或病症的药物中的用途,其中所述的疾病或病症优选为癌症;更优选为表达c-Met的癌症;最优选为胃癌、胰腺癌、肝癌、乳腺癌、肺癌、肠癌、肾癌、黑素瘤、非小细胞肺癌;最优选为胃癌、非小细胞肺癌和肝癌。
本发明进一步提供一种治疗和预防c-Met介导的疾病或病症的方法,该方 法包括给予所需患者治疗有效量的如上所述的c-Met抗体或其抗原结合片段、或包含其的药物组合物;其中所述的疾病或病症优选为癌症;更优选为表达c-Met的癌症;最优选为胃癌、胰腺癌、肝癌、乳腺癌、肺癌、肠癌、肾癌、黑素瘤、非小细胞肺癌;最优选为胃癌、非小细胞肺癌和肝癌。
本发明进一步提供一种通式(I)所示的抗体-细胞毒性药物偶联物或其药学上可接受的盐或溶剂化合物:
Ab-[(L2)t-L1-D)]y (I)
其中:
D为药物模块;
L1,L2是接头单元;
t为0或1,优选1;
y为1-8,优选2-5;y可以为小数;
Ab为如上所述的特异性结合c-Met受体的抗体或其抗原结合片段。
在本发明一个优选的实施方案中,提供一种通式(I)所示的抗体-细胞毒性药物偶联物或其药学上可接受的盐或溶剂化合物,其中-L2-为以下通式(-L2-)所示的化合物:
其中
X1选自自氢原子、卤素、羟基、氰基、烷基、烷氧基和环烷基;
X2选自-烷基-、-环烷基-和-杂环基-;
m为0-5,优选1-3;S为硫原子。
在本发明一个优选的实施方案中,提供一种通式(I)所示的抗体-细胞毒性药物偶联物或其药学上可接受的盐或溶剂化合物,其中所述药物模块D为选自毒素、化疗剂、抗生素、放射性同位素和核溶酶的细胞毒剂。
在本发明一个优选的实施方案中,提供一种通式(I)所示的抗体-细胞毒性药物偶联物或其药学上可接受的盐或溶剂化合物,其中D为以下通式(D)所示的化合物:
或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中:
R1-R7选自氢原子、卤素、羟基、氰基、烷基、烷氧基和环烷基;
R8-R11任选自氢原子、卤素、烯基、烷基、烷氧基和环烷基;R8-R11优选至少其中一个选自卤素、烯基、烷基和环烷基,其余为氢原子;
或者R8-R11之中的任意两个形成环烷基,余下的两个基团任选自氢原子、烷基和环烷基;
R12-R13选自氢原子、烷基或卤素;
R14选自芳基或杂芳基,所述的芳基或杂芳基任选进一步被选自氢原子、卤素、羟基、烷基、烷氧基和环烷基的取代基所取代;
R15任选自卤素、烯基、烷基、环烷基和COO R17;
R16选自氢原子、卤素、羟基、氰基、烷基、烷氧基和环烷基;
R17选自氢原子、烷基和烷氧基。
在本发明一个优选的实施方案中,提供一种通式(I)所示的抗体-细胞毒性药物偶联物或其药学上可接受的盐或溶剂化合物,其中L2包含选自Val-Cit,MC,PAB和MC-PAB的接头,优选MC。
在本发明一个优选的实施方案中,提供一种通式(I)所示的抗体-细胞毒性药物偶联物或其药学上可接受的盐或溶剂化合物,其中D是美登木素生物碱;优选自DM1、DM3和DM4,更优选DM1。
在本发明一个优选的实施方案中,提供一种通式(I)所示的抗体-细胞毒性药物偶联物或其药学上可接受的盐或溶剂化合物,其中所述L2选自N-琥珀酰亚氨基4-(2-吡啶基硫代)戊酸酯(SPP)、N-琥珀酰亚氨基4-(N-马来酰亚胺基甲基)-环己烷-1-羧酸酯(SMCC)、和N-琥珀酰亚氨基(4-碘-乙酰基)氨基苯甲酸酯(SIAB);优选SPP或SMCC。
在本发明一个优选的实施方案中,提供一种通式(I)所示的抗体-细胞毒性药物偶联物或其药学上可接受的盐或溶剂化合物,其中D是喜树碱类生物碱;优 选自CPT、10-羟基-CPT、CPT-11(伊立替康)、SN-38和托泊替康,更优选SN-38。
在本发明一个优选的实施方案中,提供一种通式(I)所示的抗体-细胞毒性药物偶联物或其药学上可接受的盐或溶剂化合物,其中所述接头L2包含任选自Val-Cit,MC,PAB或MC-PAB的结构,优选MC或MC-vc-PAB。
在本发明一个优选的实施方案中,提供一种通式(I)所示的抗体-细胞毒性药物偶联物或其药学上可接受的盐或溶剂化合物,其包括通式(II)所示的偶联药物或其药学上可接受的盐或溶剂化合物:
其中:
R2-R16如通式(D)中所定义;
Ab,t,y,L1,L2如通式(I)中所定义。
在本发明一个优选的实施方案中,提供一种通式(I)所示的抗体-细胞毒性药物偶联物或其药学上可接受的盐或溶剂化合物,其包括通式(III)所示的偶联药物或其药学上可接受的盐或溶剂化合物:
其中:
R2-R16如通式(D)中所定义;
Ab,t,y,L1,L2如通式(I)中所定义;
n为3-6,优选5。
在本发明一个优选的实施方案中,提供一种通式(I)所示的抗体-细胞毒性药物偶联物或其药学上可接受的盐或溶剂化合物,其包括通式(IV)所示的偶联药物 或其药学上可接受的盐或溶剂化合物:
其中:
R2-R16如通式(D)中所定义;
Ab,y如通式(I)中所定义;
n如通式(III)中所定义;
X1,X2,m如通式L2中所定义。
在本发明一个优选的实施方案中,提供一种通式(I)所示的抗体-细胞毒性药物偶联物或其药学上可接受的盐或溶剂化合物,其包括通式(V)所示的偶联药物或其药学上可接受的盐或溶剂化合物:
其中:
Ab,D,y如通式(I)中所定义;
n如通式(III)中所定义;
X1,X2,m如通式L2中所定义。
本发明所述的抗体-细胞毒性药物偶联物或其可药用盐或溶剂化合物包括但不限于:
Ab-9,Ab-10,Ab-11为如上所述的c-Met抗体,y为1-8,优选2-5。
其中,y的范围为1-8;优选1-4。
本发明进一步提供一种制备通式(V)所示的抗体-细胞毒性药物偶联物的方法,该方法包括:
通式(Ab-L2)化合物与通式(L1-D)化合物在有机溶剂中反应,得到通式(V)化合物;所述的有机溶剂优选乙腈或乙醇;
其中:
Ab如前所述的特异性结合c-Met受体的抗体或其抗原结合片段;
X1选自自氢原子、卤素、羟基、氰基、烷基、烷氧基和环烷基;
X2选自烷基、环烷基和杂环基;
X为0-5,优选1-3;
m为0-5,优选1-3。
在本发明一个优选的实施方案中,提供一种如上所述的抗体-细胞毒性药物偶联物或其可药用盐或溶剂化合物,其具有体外或体内细胞杀伤活性。
本发明进一步提供一种药物组合物,其含有如上所述的c-Met抗体或其抗原结合片段、或抗体-细胞毒性药物偶联物或其可药用盐或溶剂化合物和可药用的赋形剂、稀释剂或载体。
本发明进一步提供一种如上所述的c-Met抗体或其抗原结合片段、或抗体-细胞毒性药物偶联物或其可药用盐或溶剂化合物、或包含其的药物组合物,在制备用于治疗c-Met介导的疾病或病症的药物中的用途,其中所述的疾病或病症优选为癌症;更优选为表达c-Met的癌症;最优选为胃癌、胰腺癌、肝癌、乳腺癌、肺癌、肠癌、肾癌、黑素瘤、非小细胞肺癌;最优选为胃癌、胰腺癌、非小细胞肺癌、肝癌和肾癌。
本发明进一步提供一种治疗和预防c-Met介导的疾病或病症的方法,该方法包括给予所需患者治疗有效量的如上所述的c-Met抗体或其抗原结合片段、或抗体-细胞毒性药物偶联物或其可药用盐或溶剂化合物、或包含其的药物组合物;其中所述的疾病或病症优选为癌症;更优选为表达c-Met的癌症;最优选为胃癌、胰腺癌、肝癌、乳腺癌、肺癌、肠癌、肾癌、黑素瘤、非小细胞肺癌;最优选为胃癌、胰腺癌、非小细胞肺癌、肝癌和肾癌。
附图说明
图1本发明抗c-Met抗体和ADC分子抑制肿瘤作用,结果表明ADC新分子通过带入的毒素能达到对肿瘤的完全抑制作用,而抗体单独无法达到。结果还表明,本发明ADC分子没有因为毒素的偶联而影响到T1/2,本发明ADC药物在小鼠体内未见毒性。
发明详述
一、术语
为了更容易理解本发明,以下具体定义了某些技术和科学术语。除显而易见在本文件中的它处另有明确定义,否则本文使用的所有其它技术和科学术语都具有本发明所属领域的一般技术人员通常理解的含义。
本发明所用氨基酸三字母代码和单字母代码如J.biol.chem,243,p3558(1968)中所述。
术语“c-Met”或“c-Met多肽”或“c-Met受体”是指结合肝细胞生长因子(HGF)的受体酪氨酸激酶。本发明中如非特指,比如鼠c-Met(m-c-Met)或猴c-Met(cyno-c-Met),均指人的c-Met(h-c-Met)。本发明中所用的人、鼠、食蟹猴c-Met均通过GenBank提供的核苷酸序列或多肽序列进行编码,例如GenBank 登录号NM_000245中提供的核苷酸序列编码的人多肽,或由GenBank登录号NP_000236中提供的多肽序列编码的人蛋白质或其细胞外结构域。原始的单链前体蛋白质在翻译后被剪切以产生α和β亚基,其通过二硫键连接以形成成熟受体。受体酪氨酸激酶c-Met参与细胞过程包括,例如伴随胚胎发生的组织再生的迁移、侵入和形态发生的过程。
术语“c-Met相关病症或状况”指任何源自c-Met的不利表达或缺乏表达,不利调控或缺乏调控,或有害活性或缺乏活性,或可以通过调节c-Met表达或活性来进行调节、治疗或治愈的疾病、病症或状况。例如在大部分癌症患者中,或在其疾病确实由与c-Met途径相关的变化驱动的患者中,可以预期HGF/c-Met途径的激活。例如上调归因于不同的机制,像HGF和/或c-Met的过表达,或通过c-Met突变的组成型激活。c-Met相关病症或状况包括但不限于,例如增生性疾病和紊乱和炎性疾病和紊乱。增生性疾病包括但不限于,例如癌症,其包括例如,胃癌、食道癌、乳腺癌、肾癌包括乳突状肾细胞癌、肺癌、神经胶质瘤、头颈癌、上皮癌、皮肤癌、白血病、淋巴癌,骨髓瘤、脑癌、胰腺癌,结直肠癌、胃肠癌、肠癌、生殖器癌症、泌尿器癌症、黑色素瘤、前列腺癌以及本领域技术人员已知的其它肿瘤。炎性疾病包括但不限于,例如细菌感染,包括李斯特菌属细菌引起的感染。
本发明所述的抗体指免疫球蛋白,是由两条相同的重链和两条相同的轻链通过链间二硫键连接而成的四肽链结构。免疫球蛋白重链恒定区的氨基酸组成和排列顺序不同,故其抗原性也不同。据此,可将免疫球蛋白分为五类,或称为免疫球蛋白的同种型,即IgM,IgD,IgG,IgA和IgE,其相应的重链分别为μ链,δ链,γ链,α链,ε链。同一类Ig根据其铰链区氨基酸组成和重链二硫键的数目和位置的差别,又可分为不同的亚类,如IgG可分为IgG1,IgG2,IgG3,IgG4。轻链通过恒定区的不同分为κ链或λ链。五类Ig中第每类Ig都可以有κ链或λ链。
抗体重链和轻链靠近N端的约110个氨基酸的序列变化很大,为可变区(V区);靠近C端的其余氨基酸序列相对稳定,为恒定区(C区)。可变区包括3个高变区(HVR)和4个序列相对保守的骨架区(FR)。3个高变区决定抗体的特异性,又称为互补性决定区(CDR)。每条轻链可变区(LCVR)和重链可变区(HCVR)由3个CDR区4个FR区组成,从氨基端到羧基端依次排列的顺序为:FR1,CDR1,FR2,CDR2,FR3,CDR3,FR4。轻链的3个CDR区指LCDR1,LCDR2,和LCDR3;重链的3个CDR区指HCDR1,HCDR2和HCDR3。发明所述的抗体或抗原结合片段的LCVR区和HCVR区的CDR氨基酸残基在数量和位置符合已知的Kabat编号规则(LCDR1-3,HCDE2-3),或者符合kabat和chothia的编号规则(HCDR1)。
术语“鼠源抗体”在本发明中为根据本领域知识和技能用小鼠制备的抗人c-Met的单克隆抗体。制备时用c-Met抗原注射试验对象,然后分离表达具有所需序列或功能特性的抗体的杂交瘤。在本发明一个优选的实施方案中,所述的鼠源c-Met抗体或其抗原结合片段,可进一步包含鼠源κ、λ链或其变体的轻链恒定区,或进一步包含鼠源IgG1,IgG2,IgG3或IgG4或其变体的重链恒定区。
术语“嵌合抗体(chimeric antibody)”,是将鼠源性抗体的可变区与人抗体的恒定区融合而成的抗体,可以减轻鼠源性抗体诱发的免疫应答反应。建立嵌合抗体,要先建立分泌鼠源性特异性单抗的杂交瘤,然后从小鼠杂交瘤细胞中克隆可变区基因,再克隆到人抗体的恒定区基因,进行重组表达。
术语“人源化抗体(humanized antibody)”,也称为CDR移植抗体(CDR-grafted antibody)人源化,是指将小鼠的CDR序列移植到人的抗体可变区框架,即不同类型的人种系抗体构架序列中产生的抗体。可以克服嵌合抗体由于携带大量小鼠蛋白成分,从而诱导的强烈的抗体可变抗体反应。此类构架序列可以从包括种系抗体基因序列的公共DNA数据库或公开的参考文献获得。如人重链和轻链可变区基因的种系DNA序列可以在“VBase”人种系序列数据库(在因特网www.mrccpe.com.ac.uk/vbase可获得),以及在Kabat,E.A.等人,1991Sequences of Proteins of Immunological Interest,第5版中找到。在本发明一个优选的实施方案中,所述的c-Met人源化抗体小鼠的CDR序列选自SEQ ID NO:6,7,8,9,10,11(please check the#s,in case just copy from sost draft)。人的抗体可变区框架经过设计选择,其中所述抗体轻链可变区上的轻链FR区序列,选自人种系轻链序列,优选人种系轻链IGKV085或IGKV 4-1*01,包含人种系轻链IGKV085和IGKV 4-1*01的FR1,FR2,FR3区和FR4区;其中所述抗体重链可变区上的重链FR区序列,来源于人种系重链序列,优选人种系重链IGHV 3-33*01;包含人种系重链IGHV 3-33*01的FR1,FR2,FR3区和FR4区。为避免免疫原性下降的同时,引起的活性下降,可对所述的人抗体可变区可进行最少反向突变,以保持活性。
本领域中有可获得的多种方法来产生人源化抗体。例如,可通过获得抗c-Met特异抗体(例如,鼠类抗体或由杂交瘤产生的抗体)HCVR和LCVR序列,将其移植到所选的人抗体框架编码序列上来产生人源化抗体。任选地,可通过随机诱变或在特定位置诱变来优化CDR区,以在将CDR区移植到框架区中之前用不同的氨基酸置换CDR中的一个或更多个氨基酸。或者,可使用本领域技术人员可获得的方法在将CDR区插入人框架区后对其进行优化。优选地,“人源化抗体”具有起源于或来自亲本抗体(即非人抗体,优选小鼠单克隆抗体)的CDR,而在其存在的程度上框架区和恒定区(或其主要部分或基本部分,即至少约90%、92%、94%、95%、96%、97%、98%或99%)序列同人类种系免疫球蛋白区(参见,例如the,International,ImMunoGeneTics,Database)或其重组或突变形式中,无论所 述抗体是否在人类细胞中产生。优选地,从人源化抗体来源的非人亲本抗体的CDR优化人源化抗体的至少2、3、4、5或6个CDR,以产生期望的性质,例如改善的特异性、亲和力或中和作用,其可以通过筛选测定,例如ELISA测定来进行鉴定。优选地,本发明抗体中优化的CDR当与亲本抗体中存在的CDR相比时,包含至少一个氨基酸置换。与亲本抗体的CDRs相比,本发明人源化抗体的CDR中某些氨基酸置换(参见本文的实施例6)降低了抗体不稳定性的可能性(例如除去CDR中Asn残基)或当对人受试者施用时降低了抗体的免疫原性(例如,由IMMUNOFILTERTM,Technology预测的)。
在CDR编码序列移植到所选人框架编码序列上之后,然后表达编码人源化可变重链和可变轻链序列的所得DNA序列,以产生结合c-Met的人源化抗体。可将人源化HCVR和LCVR表达为整个抗硬骨素抗体分子的部分,即表达为与人恒定域序列的融合蛋白。然而,HCVR和LCVR序列也可在不存在恒定序列的情况下进行表达,以产生人源化抗c-Met scFv。
进一步描述参与人源化可使用小鼠抗体的方法的文献包括,例如Queen等,Proc.,Natl.Acad.Sci.USA,88,2869,1991和Winter及其同事的方法[Jones等,Nature,321,522(1986),Riechmann,等,Nature,332,323-327(1988),Verhoeyen,等,Science,239,1534(1988)]。
本发明中所述的“抗原结合片段”,指具有抗原结合活性的Fab片段,Fab’片段,F(ab’)2片段,以及与人c-Met结合的Fv片段scFv片段;包含本发明所述抗体的选自SEQ ID NO:3至SEQ ID NO:8中的一个或多个CDR区。Fv片段含有抗体重链可变区和轻链可变区,但没有恒定区,并具有全部抗原结合位点的最小抗体片段。一般地,Fv抗体还包含在VH和VL结构域之间的多肽接头,且能够形成抗原结合所需的结构。也可以用不同的连接物将两个抗体可变区连接成一条多肽链,称为单链抗体(single chain antibody)或单链Fv(scFv)。scFv还可以和其它抗体,例如抗EGFR抗体构建双特异抗体(bispecific antibody)本发明的术语“与c-Met结合”,指能与人c-Met相互作用。本发明的术语“抗原结合位点”指抗原上不连续的,由本发明抗体或抗原结合片段识别的三维空间位点。本发明中所述的“ADCC”,即antibody-dependent cell-mediated cytotoxicity,抗体依赖的细胞介导的细胞毒作用,是指表达Fc受体的细胞通过识别抗体的Fc段直接杀伤被抗体包被的靶细胞。可通过对IgG上Fc段的修饰,降低或消除抗体的ADCC效应功能。所述的修饰指在抗体的重链恒定区进行突变,如选自IgG1的N297A,L234A,L235A;IgG2/4chimera,IgG4的F235E,或L234A/E235A突变。
本发明中所述的融合蛋白是一种通过DNA重组,得到的两个基因共表达的蛋白产物。重组c-Met胞外区Fc融合蛋白通过DNA重组,把c-Met胞外区和人抗体Fc片段共表达的融合蛋白。所述的c-Met胞外区,是指c-Met蛋白表达在 细胞膜以外的部分。
本发明工程化的抗体或抗原结合片段可用常规方法制备和纯化。比如,编码重链(SEQ ID NO:4)和轻链(SEQ ID NO:5)的cDNA序列,可以克隆并重组至表达载体pEE6.4((Lonza Biologics)。重组的免疫球蛋白表达载体可以稳定地转染CHO细胞。作为一种更推荐的现有技术,哺乳动物类表达系统会导致抗体的糖基化,特别是在FC区的高度保守N端。通过表达与人c-Met特异性结合的抗体得到稳定的克隆。阳性的克隆在生物反应器的无血清培养基中扩大培养以生产抗体。分泌了抗体的培养液可以用常规技术纯化。比如,用含调整过的缓冲液的A或G Sepharose FF柱进行过柱。洗去非特异性结合的组分。再用PH梯度法洗脱结合的抗体,用SDS-PAGE检测抗体片段,收集。抗体可用常规方法进行过滤浓缩。可溶的混合物和多聚体,也可以用常规方法去除,比如分子筛,离子交换。得到的产物需立即冷冻,如-70℃,或者冻干。
本发明的抗体指单克隆抗体。本发明所述的单克隆抗体或mAb,指由单一的克隆细胞株得到的抗体,所述的细胞株不限于真核的,原核的或噬菌体的克隆细胞株。单克隆抗体或抗原结合片段可以用如杂交瘤技术、重组技术、噬菌体展示技术,合成技术(如CDR-grafting),或其它现有技术进行重组得到。
“给予”和“处理”当应用于动物、人、实验受试者、细胞、组织、器官或生物流体时,是指外源性药物、治疗剂、诊断剂或组合物与动物、人、受试者、细胞、组织、器官或生物流体的接触。“给予”和“处理”可以指例如治疗、药物代谢动力学、诊断、研究和实验方法。细胞的处理包括试剂与细胞的接触,以及试剂与流体的接触,其中所述流体与细胞接触。
“治疗”意指给予患者内用或外用治疗剂,诸如包含本发明的任一种结合化合物的组合物,所述患者具有一种或多种疾病症状,而已知所述治疗剂对这些症状具有治疗作用。通常,在受治疗患者或群体中以有效缓解一种或多种疾病症状的量给予治疗剂,无论是通过诱导这类症状退化还是抑制这类症状发展到任何临床右测量的程度。有效缓解任何具体疾病症状的治疗剂的量(也称作“治疗有效量”)可根据多种因素变化,例如患者的疾病状态、年龄和体重,以及药物在患者产生需要疗效的能力。通过医生或其它专业卫生保健人士通常用于评价该症状的严重性或进展状况的任何临床检测方法,可评价疾病症状是否已被减轻。尽本发明的实施方案(例如治疗方法或制品)在缓解每个患都有的目标疾病症状方面可能无效,但是根据本领域已知的任何统计学检验方法如Student t检验、卡方检验、依据Mann和Whitney的U检验、Kruskal-Wallis检验(H检验)、Jonckheere-Terpstra检验和Wilcoxon检验确定,其在统计学显著数目的患者中应当减轻目标疾病症状。
“保守修饰”或“保守置换或取代”是指具有类似特征(例如电荷、侧链大 小、疏水性/亲水性、主链构象和刚性等)的其它氨基酸置换蛋白中的氨基酸,使得可频繁进行改变而不改变蛋白的生物学活性。本领域技术人员知晓,一般而言,多肽的非必需区域中的单个氨基酸置换基本上不改变生物学活性(参见例如Watson等(1987)Molecular Biology of the Gene,The Benjamin/Cummings Pub.Co.,第224页,(第4版))。另外,结构或功能类似的氨基酸的置换不大可能破环生物学活性。
整个说明书和权利要求书中使用的术语“基本上由……组成”或其变形表示包括所有所述元件或元件组,并且任选包括与所述元件类似或不同性质的其它元件,所述其它元件非显著改变指定给药方案、方法或组合物的基本性质或新性质。作为非限制性例子,基本上由所提及的氨基酸序列组成的结合化合物还可以包括一种或多种氨基酸,其不显著影响结合化合物的性质。
“有效量”包含足以改善或预防医字病症的症状或病症的量。有效量还意指足以允许或促进诊断的量。用于特定患者或兽医学受试者的有效量可依据以下因素而变化:如待治疗的病症、患者的总体健康情况、给药的方法途径和剂量以及副作用严重性。有效量可以是避免显著副作用或毒性作用的最大剂量或给药方案。
“外源性”指要据背景在生物、细胞或人体外产生的物质。“内源性”指根据背景在细胞、生物或人体内产生的物质。
“同源性”是指两个多核苷酸序列之间或两个多肽之间的序列相似性。当两个比较序列中的位置均被相同碱基或氨基酸单体亚基占据时,例如如果两个DNA分子的每一个位置都被腺嘌呤占据时,那么所述分子在该位置是同源的。两个序列之间的同源怀百分率是两个序列共有的匹配或同源位置数除以比较的位置数×100的函数。例如,在序列最佳比对时,如果两个序列中的10个位置有6个匹配或同源,那么两个序列为60%同源。一般而言,当比对两个序列而得到最大的同源性百分率时进行比较。
“任选”或“任选地”意味着随后所描述地事件或环境可以但不必发生,该说明包括该事件或环境发生或不发生地场合。例如,“任选包含1-3个抗体重链可变区”意味着特定序列的抗体重链可变区可以但不必须存在。
“药物组合物”表示含有一种或多种本文所述化合物或其生理学上/可药用的盐或前体药物与其他化学组分的混合物,以及其他组分例如生理学/可药用的载体和赋形剂。药物组合物的目的是促进对生物体的给药,利于活性成分的吸收进而发挥生物活性。
常规的药物组合物的制备见中国药典。
术语“载体”用于本发明的药物,是指能改变药物进入人体的方式和在体内的分布、控制药物的释放速度并将药物输送到靶向器官的体系。药物载体释放和 靶向系统能够减少药物降解及损失,降低副作用,提高生物利用度。如可作为载体的高分子表面活性剂由于其独特的两亲性结构,可以进行自组装,形成各种形式的聚集体,优选的实例如胶束、微乳液、凝胶、液晶、囊泡等。这些聚集体具有包载药物分子的能力,同时又对膜有良好的渗透性,可以作为优良的药物载体。术语“稀释剂”又称填充剂,其主要用途是增加片剂的重量和体积。稀释剂的加入不仅保证一定的体积大小,而且减少主要成分的剂量偏差,改善药物的压缩成型性等。当片剂的药物含有油性组分时,需加入吸收剂吸收油性物,使保持“干燥”状态,以利于制成片剂。如淀粉、乳糖、钙的无机盐、微晶纤维素等。
术语“可药用盐”是指本发明配体-细胞毒性药物偶联物的盐,这类盐用于哺乳动物体内时具有安全性和有效性,且具有应有的生物活性,本发明抗体-抗体药物偶联化合物至少含有一个氨基,因此可以与酸形成盐,可药用盐的非限制性实例包括:盐酸盐、氢溴酸盐、氢碘酸盐、硫酸盐、硫酸氢盐、柠檬酸盐、乙酸盐、琥珀酸盐、抗坏血酸盐、草酸盐、硝酸盐、梨酸盐、磷酸氢盐、磷酸二氢盐、水杨酸盐、柠檬酸氢盐、酒石酸盐、马来酸盐、富马酸盐、甲酸盐、苯甲酸盐、甲磺酸盐、乙磺酸盐、苯磺酸盐、对甲苯磺酸盐。
术语“溶剂化合物”指本发明的配体-药物偶联化合物与一种或多种溶剂分子形成可药用的溶剂化合物,溶剂分子的非限制性实例包括水、乙醇、乙腈、异丙醇、DMSO、乙酸乙酯。
术语“配体”是能识别和结合目标细胞相关的抗原或受体的大分子化合物。配体的作用是将药物呈递给与配体结合的目标细胞群,这些配体包括但不限于蛋白类激素、凝集素、生长因子、抗体或其他能与细胞结合的分子。
治疗剂是与结合部分如抗体或抗体片段、或其亚片段分别、同时或相继地给药的分子或原子,并且可用于疾病的治疗。治疗剂的实例包括但不限于抗体、抗体片段、共轭物、药物、细胞毒性剂、促细胞凋亡剂、毒素、核酸酶(包括DNA酶和RNA酶)、激素、免疫调节剂、螯合剂、硼化合物、光敏剂或染料、放射性同位素或放射性核素、寡核苷酸、干扰RNA、肽、抗血管发生剂、化疗剂、细胞因子、趋化因子、前药、酶、结合蛋白或肽、或其组合。
偶联物是与如上所述的治疗剂偶联的抗体组分或其他靶向部分。本文所用的术语“偶联物”和“免疫偶联物”可交换地使用。
术语“细胞毒剂”在用于本文时指抑制或防止细胞的功能和/或引起细胞死亡或破坏的物质。
“毒素”指能够对细胞的生长或增殖产生有害效果的任何物质。
“化疗剂”指可用于治疗癌症的化学化合物。该定义还包括起调节、降低、阻断或抑制可促进癌生长的激素效果作用的抗激素剂,且常常是系统或全身治疗的形式。它们自身可以是激素。
澳瑞他汀是全合成药物,化学结构式相对容易改造,以便优化其物理性质和成药特性。用于和抗体偶联的澳瑞他汀衍生物主要包括单甲基澳瑞他汀E(MMAE)和单甲基澳瑞他汀F(MMAF),前者是又天然微管蛋白聚合酶抑制剂尾海兔素-10(dolastatin-10)衍生出的合成五肽,在C-端加上一个2-氨基-1-苯基丙基-1-醇而合成。MMAE对多种人类肿瘤细胞株的抑制活性小于一纳摩尔。为了降低MMAE自身细胞毒活性,MMAF在尾海兔素-10的C-端加上一个苯丙氨酸,因为在结构上引入一个羧基,MMAF的细胞膜通过性较差,因此对细胞的生物活性显著降低,但是和抗体偶联后对细胞的抑制活性大幅度提高(US7750116)。
术语“微管蛋白抑制剂”是指通过抑制微管蛋白的聚合或促进微管蛋白的聚合而干扰细胞的有丝分裂过程,从而发挥抗肿瘤作用的一类化合物。其非限制性实例包括:美登素类、卡利奇霉素、紫杉烷类、长春新碱、秋水仙碱、尾海兔素/澳瑞他汀,优选自美登素类或尾海兔素/澳瑞他汀;更优选自通式D1或DM所示的化合物。
CPT是喜树碱的缩写,并且在本申请中CPT用于表示喜树碱本身或喜树碱的类似物或衍生物。具有所示的编号和用字母A-E标记的环的喜树碱和一些其类似物的结构在以下式提供。
CPT:R1=R2=R3=H
10-羟基-CPT:R1=OH;R2=R3=H
伊立替康(CPT-11):R2=乙基;R3=H
SN-38:R1=OH;R2=乙基;R3=H
托泊替康:R1=OH;R2=H;R3=CH-N(CH3)2
术语“胞内代谢物”指由细胞内对抗体-药物偶联物(ADC)的代谢过程或反应产生的化合物。所述代谢过程或反应可以是酶促过程,诸如ADC的肽接头的蛋白水解切割、或官能团诸如腙、酯或酰胺的水解。胞内代谢物包括但不限于在进 入、扩散、摄取或转运进入细胞后经历胞内切割的抗体和游离药物。
术语“胞内切割的”和“胞内切割”指细胞内对抗体-药物偶联物(ADC)的代谢过程或反应,由此药物模块(D)与抗体(Ab)之间的共价附着,即接头被打断,导致细胞内游离药物与抗体解离。ADC被切割的模块因而是胞内代谢物。
术语“生物利用度”指施用于患者的给定量的药物的系统利用度(即血液/血浆水平)。生物利用度是表明药物从所施用的剂量形式到达大循环的时间(速率)和总量(程度)二者度量的绝对项。
术语“细胞毒活性”指抗体-药物偶联物或抗体-药物偶联物的胞内代谢物的细胞杀伤、细胞抑制、或生长抑制效果。细胞毒活性可以表述为IC50值,即半数细胞存活时每单位体积的浓度(摩尔或质量)。
术语“烷基”指饱和脂肪族烃基团,其为包含1至20个碳原子的直链或支链基团,优选含有1至12个碳原子的烷基,更优选含有1至10个碳原子的烷基,最优选含有1至6个碳原子的烷基。非限制性实例包括甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、仲丁基、正戊基、1,1-二甲基丙基、1,2-二甲基丙基、2,2-二甲基丙基、1-乙基丙基、2-甲基丁基、3-甲基丁基、正己基、2,2-二乙基己基,及其各种支链异构体等。烷基可以是取代的或非取代的,当被取代时,取代基可以在任何可使用的连接点上被取代,所述取代基优选为一个或多个以下基团,其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、氧代基。
术语“环烷基”指饱和或部分不饱和单环或多环环状烃取代基,环烷基环包含3至20个碳原子,优选包含3至12个碳原子,更优选包含3至10个碳原子,最优选包含3至8个碳原子。单环环烷基的非限制性实例包括环丙基、环丁基、环戊基、环戊烯基、环己基、环己烯基、环己二烯基、环庚基、环庚三烯基、环辛基等;多环环烷基包括螺环、稠环和桥环的环烷基。
术语“杂环基”指饱和或部分不饱和单环或多环环状烃取代基,其包含3至20个环原子,其中一个或多个环原子为选自氮、氧或S(O)m(其中m是整数0至2)的杂原子,但不包括-O-O-、-O-S-或-S-S-的环部分,其余环原子为碳。优选包含3至12个环原子,其中1~4个是杂原子;更优选环烷基环包含3至10个环原子。单环杂环基的非限制性实例包括吡咯烷基、哌啶基、哌嗪基、吗啉基、硫代吗啉基、高哌嗪基等。多环杂环基包括螺环、稠环和桥环的杂环基。
所述杂环基环可以稠合于芳基、杂芳基或环烷基环上,其中与母体结构连接在一起的环为杂环基,其非限制性实例包括: 等。
杂环基可以是任选取代的或非取代的,当被取代时,取代基优选为一个或多个以下基团,其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、氧代基。
术语“芳基”指具有共轭的π电子体系的6至14元全碳单环或稠合多环(也就是共享毗邻碳原子对的环)基团,优选为6至10元,例如苯基和萘基,最优选苯基。所述芳基环可以稠合于杂芳基、杂环基或环烷基环上,其中与母体结构连接在一起的环为芳基环,其非限制性实例包括:
芳基可以是取代的或非取代的,当被取代时,取代基优选为一个或多个以下基团,其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基。
术语“杂芳基”指包含1至4个杂原子、5至14个环原子的杂芳族体系,其中杂原子选自氧、硫和氮。杂芳基优选为5至10元,更优选为5元或6元,例如呋喃基、噻吩基、吡啶基、吡咯基、N-烷基吡咯基、嘧啶基、吡嗪基、咪唑基、四唑基等。所述杂芳基环可以稠合于芳基、杂环基或环烷基环上,其中与母体结构连接在一起的环为杂芳基环,其非限制性实例包括:
杂芳基可以是任选取代的或非取代的,当被取代时,取代基优选为一个或多个以下基团,其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤 素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基。
术语“烷氧基”指-O-(烷基)和-O-(非取代的环烷基),其中烷基的定义如上所述。烷氧基的非限制性实例包括:甲氧基、乙氧基、丙氧基、丁氧基、环丙氧基、环丁氧基、环戊氧基、环己氧基。烷氧基可以是任选取代的或非取代的,当被取代时,取代基优选为一个或多个以下基团,其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环烷基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基。
术语“键”指用“—”表示的共价键。
术语“羟基”指-OH基团。
术语“卤素”指氟、氯、溴或碘。
术语“氨基”指-NH2。
术语“氰基”指-CN。
术语“硝基”指-NO2。
术语“氧代基”指=O。
“任选”或“任选地”意味着随后所描述的事件或环境可以但不必发生,该说明包括该事件或环境发生或不发生地场合。例如,“任选被烷基取代的杂环基团”意味着烷基可以但不必须存在,该说明包括杂环基团被烷基取代的情形和杂环基团不被烷基取代的情形。
“取代的”指基团中的一个或多个氢原子,优选为最多5个,更优选为1~3个氢原子彼此独立地被相应数目的取代基取代。不言而喻,取代基仅处在它们的可能的化学位置,本领域技术人员能够在不付出过多努力的情况下确定(通过实验或理论)可能或不可能的取代。例如,具有游离氢的氨基或羟基与具有不饱和(如烯属)键的碳原子结合时可能是不稳定的。
“接头”指包含使抗体共价附着于药物模块的共价键或原子链的化学模块。在各个实施方案中,接头包括:二价基,诸如亚烃基(alkyldiyl)、亚芳基、亚杂芳基,诸如-(CR2)nO(CR2)n-、烃氧基重复单元(例如聚亚乙基氧基(polyethyleneoxy)、PEG、聚亚甲基氧基(polymethyleneoxy)和烃氨基(例如聚乙烯氨基,JeffamineTM)等模块;及二酸酯和酰胺类,包括琥珀酸酯、琥珀酰胺、二乙醇酸酯、丙二酸酯和己酰胺。
缩写
接头组件
MC=6-马来酰亚氨基己酰基
Val-Cit或“vc”=缬氨酸-瓜氨酸(蛋白酶可切割接头中的例示二肽)
瓜氨酸=2-氨基-5-脲基戊酸
PAB=对氨基苄氧羰基(“自我牺牲”接头组件的例示)
Me-Val-Cit=N-甲基-缬氨酸-瓜氨酸(其中接头肽键已经修饰以防止其受到组织蛋白酶B的切割)
MC(PEG)6-OH=马来酰亚氨基己酰基-聚乙二醇(可附着于抗体半胱氨酸)
SPP=N-琥珀酰亚氨基4-(2-吡啶基硫代)戊酸酯
SPDP=N-琥珀酰亚氨基3-(2-吡啶基二硫代)丙酸酯
SMCC=琥珀酰亚氨基-4-(N-马来酰亚氨基甲基)环己烷-1-羧酸酯
IT=亚氨基硫烷
细胞毒性药物:
MMAE=单甲基澳瑞他汀E(MW 718)
MMAF=澳瑞他汀E(MMAE)的变体,其在药物的C-末端处有苯丙氨酸(MW731.5)
MMAF-DMAEA=有DMAEA(二甲基氨基乙胺)以酰胺连接至C-末端苯丙氨酸的MMAF(MW 801.5)
MMAF-TEG=有四乙二醇酯化至苯丙氨酸的MMAF
MMAF-NtBu=N-叔丁基作为酰胺附着于MMAF的C-末端
DM1=N(2’)-脱乙酰基-N(2′)-(3-巯基-1-氧丙基)-美登素
DM3=N(2’)-脱乙酰基-N2-(4-巯基-1-氧戊基)-美登素
DM4=N(2’)-脱乙酰基-N2-(4-巯基-4-甲基-1-氧戊基)-美登素
本发明还提供了包含偶联有一种或多种细胞毒剂的本发明任何抗c-Met抗体或其它具有内吞活性的c-Met抗体(如,LY-2875358)的抗体-细胞毒性药物偶联物或其可药用盐或溶剂化合物(可互换的称为“抗体-药物偶联物”或“ADC”),所述细胞毒剂诸如化疗剂、药物、生长抑制剂、毒素(例如细菌、真菌、植物或动物起源的酶活性毒素或其片段)或放射性同位素(即放射偶联物)。
在某些实施方案中,抗体-细胞毒性药物偶联物或其可药用盐或溶剂化合物包含抗c-Met抗体和化疗剂或其它毒素。本文中(上文))描述了可用于生成抗体-细胞毒性药物偶联物或其可药用盐或溶剂化合物的化疗剂。也可使用酶活性毒素及其片段,这些酶活性毒素及其片段已在说明书中描述。
在某些实施方案中,抗体-细胞毒性药物偶联物或其可药用盐或溶剂化合物包含抗c-Met抗体和一种或多种小分子毒素,包括但不限于小分子药物,诸如喜树碱衍生物、加利车霉素(calicheamicin)、美登木素生物碱(maytansinoids)、多拉司他汀(dolastatin)、澳瑞他汀、单端孢霉素(trichothecene)和CC1065及这些药物具有细胞毒活性的片段。
例示性的接头L2包括6-马来酰亚氨基己酰基(“MC”)、马来酰亚氨基丙酰基(“MP”)、缬氨酸-瓜氨酸(“val-cit”或“vc”)、丙氨酸-苯丙氨酸(“ala-phe”)、 对氨基苄氧羰基(“PAB”)、N-琥珀酰亚氨基4-(2-吡啶基硫代)戊酸酯(“SPP”)、N-琥珀酰亚氨基4-(N-马来酰亚氨基甲基)环己烷-1羧酸酯(“SMCC”)、和N-琥珀酰亚氨基(4-碘-乙酰基)氨基苯甲酸酯(“SIAB”)。本领域知道多种接头,下文也描述了一些。
接头可以是便于在细胞中释放药物的“可切割接头”。例如,可使用酸不稳定接头(例如腙)、蛋白酶敏感(例如肽酶敏感)接头、光不稳定接头、二甲基接头、或含二硫化物接头(Chari等,Cancer Research 52:127-131(1992);美国专利No.5,208,020)。
在有些实施方案中,接头构件可以是将抗体连接至另一接头构件或药物模块的“延伸物单元”(stretcher unit)。例示性的延伸物单元显示于下文(其中波形线指示共价附着至抗体的位点):
在有些实施方案中,接头单元可以是氨基酸单元。在一个这样的实施方案中,氨基酸单元容许蛋白酶切割接头,由此便于在暴露于胞内蛋白酶(诸如溶酶体酶)后从抗体-细胞毒性药物偶联物或其可药用盐或溶剂化合物释放药物。参见例如Doronina等(2003)Nat.Biotechnol.21:778-784。例示性的氨基酸单元包括但不限于二肽、三肽、四肽、和五肽。例示性的二肽包括:缬氨酸-瓜氨酸(vc或val-cit);丙氨酸-苯丙氨酸(af或ala-phe);苯丙氨酸-赖氨酸(fk或phe-lys);或N-甲基-缬氨酸-瓜氨酸(Me-val-cit)。例示性的三肽包括:甘氨酸-缬氨酸-瓜氨酸(gly-val-cit)和甘氨酸-甘氨酸-甘氨酸(gly-gly-gly)。氨基酸单元可以包含天然存在的氨基酸残基,以及次要氨基酸和非天然存在氨基酸类似物,诸如瓜氨酸。氨基酸单元可以在它们对特定酶(例如肿瘤相关蛋白酶,组织蛋白酶B、C和D,或血浆蛋白酶) 的酶促切割的选择性方面进行设计和优化。
在有些实施方案中,接头构件可以是将抗体连接(或是直接的或是通过延伸物单元和/或氨基酸单元)至药物模块的“间隔物”单元。间隔物单元可以是“自我牺牲的”(self-immolative)或“非自我牺牲的”。“非自我牺牲的”间隔物单元指间隔物单元的部分或整体在ADC的酶促(蛋白水解)切割后保持结合于药物模块的间隔物单元。非自我牺牲的间隔物单元的例子包括但不限于甘氨酸间隔物单元和甘氨酸-甘氨酸间隔物单元。还涵盖对序列特异性酶促切割易感的肽间隔物的其它组合。例如,肿瘤细胞相关蛋白酶对含甘氨酸-甘氨酸间隔物单元的ADC的酶促切割将导致甘氨酸-甘氨酸-药物模块从ADC的剩余部分释放。在一个这样的实施方案中,甘氨酸-甘氨酸-药物模块然后在肿瘤细胞中进行分开的水解步骤,如此从药物模块切割甘氨酸-甘氨酸间隔物单元。
“自我牺牲的”间隔物单元容许释放药物模块而没有分开的水解步骤。在某些实施方案中,接头的间隔物单元包含对氨基苄基单元。在一个这样的实施方案中,将对氨基苯甲醇经酰胺键附着至氨基酸单元,并且在苯甲醇与细胞毒剂之间生成氨基甲酸酯、甲基氨基甲酸酯、或碳酸酯。参见例如Hamann等(2005)Expert Opin.Ther.Patents(2005)15:1087-1103。在一个实施方案中,间隔物单元是对氨基苄氧羰基(PAB)。
本发明中的示例性接头如下:
接头,包括延伸物、间隔物、和氨基酸单元,可以通过本领域已知方法合成,诸如US2005-0238649A1中所记载的。
例示性的药物模块
美登素和美登木素生物碱
在有些实施方案中,抗体-细胞毒性药物偶联物或其可药用盐或溶剂化合物包含偶联有一个或多个美登木素生物碱分子的本发明抗体。美登木素生物碱是通过抑制微管蛋白多聚化来发挥作用的有丝分裂抑制剂。美登素最初从东非灌木齿叶美登木(Maytenus serrata)分离得到(美国专利No.3,896,111)。随后发现某些微生物也生成美登木素生物碱,诸如美登醇和C-3美登醇酯(美国专利No.4,151,042)。
美登木素生物碱药物模块在抗体-药物偶联物中是有吸引力的药物模块,因为它们:(i)相对易于通过发酵或发酵产物的化学修饰或衍生化来制备;(ii)易于用适于通过非二硫化物接头偶联至抗体的官能团衍生化;(iii)在血浆中稳定;且 (iv)有效针对多种肿瘤细胞系。
适于用作美登木素生物碱药物模块的美登素化合物是本领域公知的,而且可以依照已知方法从天然来源分离,或是使用遗传工程技术生产(参见Yu等(2002)PNAS 99:7968-7973)。美登醇和美登醇类似物也可以依照已知方法合成制备。
美登木素生物碱药物模块的例示性实施方案包括:DM1;DM3;和DM4,正如本文中所公开的。
澳瑞他汀和多拉司他汀
在有些实施方案中,抗体-细胞毒性药物偶联物或其可药用盐或溶剂化合物包含与多拉司他汀(dolastatin)或多拉司他汀肽类似物或衍生物(例如澳瑞他汀)(美国专利No.5,635,483;5,780,588)偶联的本发明抗体。多拉司他汀和澳瑞他汀已经显示出干扰微管动力学、GTP水解、及核和细胞分裂(Woyke等(2001)Antimicrob.Agents and Chemother.45(12):3580-3584)且具有抗癌(美国专利No.5663149)和抗真菌活性(Pettit等(1998)Antimicrob.Agents Chemother.42:2961-2965)。多拉司他汀或澳瑞他汀药物模块可经由肽药物模块的N(氨基)末端或C(羧基)末端附着于抗体(WO02/088172)。
例示性的澳瑞他汀实施方案包括N-末端连接的单甲基澳瑞他汀药物模块DE和DF,披露于Senter等,Proceedings of the American Association for CancerResearch,卷45,摘要号623,2004年3月28日,明确将其公开内容完整收入本文作为参考。肽药物模块可以选自下文通式DE和DF:
其中DE和DF的波形线指示抗体或抗体-接头的共价附着位点,且每个位置是独立的;
R2选自H和C1-C8烃基;
R3选自H、C1-C8烃基、C3-C8碳环、芳基、C1-C8烃基-芳基、C1-C8烃基-(C3-C8碳环)、C3-C8杂环和C1-C8烃基-(C3-C8杂环);
R4选自H、C1-C8烃基、C3-C8碳环、芳基、C1-C8烃基-芳基、C1-C8烃基-(C3-C8碳环)、C3-C8杂环和C1-C8烃基-(C3-C8杂环);
R5选自H和甲基;
或者R4与R5一起形成碳环且具有通式-(CRaRb)n-,其中Ra和Rb独立地选自H、C1-C8烃基和C3-C8碳环,而n选自2、3、4、5和6;
R6选自H和C1-C8烃基;
R7选自H、C1-C8烃基、C3-C8碳环、芳基、C1-C8烃基-芳基、C1-C8烃基-(C3-C8碳环)、C3-C8杂环和C1-C8烃基-(C3-C8杂环);
每个R8独立地选自H、OH、C1-C8烃基、C3-C8碳环和O-(C1-C8烃基);
R9选自H和C1-C8烃基;
R10选自芳基或C3-C8杂环;
Z为O、S、NH或NR12,其中R12为C1-C8烃基;
R11选自H、C1-C20烃基、芳基、C3-C8杂环、-(R13O)m-R14和-(R13O)m-CH(R15)2;
m是选自1-1000的整数;
R13为C2-C8烃基;
R14为H或C1-C8烃基;
R15每次出现独立为H、COOH、-(CH2)n-N(R16)2、-(CH2)n-SO3H或-(CH2)n-SO3-C1-C8烃基;
R16每次出现独立为H、C1-C8烃基或-(CH2)n-COOH;
R18选自-C(R8)2-C(R8)2-芳基、-C(R8)2-C(R8)2-(C3-C8杂环)和-C(R8)2-C(R8)2-(C3-C8碳环);且
n是为选自0到6的整数。
通式DE的一种例示性澳瑞他汀,实施方案是MMAE,其中波形线指示共价附着至抗体-药物偶联物的接头(L):
通式DF的一种例示性澳瑞他汀,实施方案是MMAF,其中波形线指示共价附着至抗体-药物偶联物的接头(L)(参见US2005/0238649及Doronina等(2006)Bioconjugate Chem.17:114-124):
其它药物模块包括选自以下的MMAF衍生物,其中波形线指示共价附着至抗体-药物偶联物的接头(L):
一方面,可以将亲水性基团在R11处附着于药物模块,所述亲水性基团包括但不限于三乙二醇酯(triethylene glycol ester,TEG),如上所述。不限于任何特定理论,所述亲水性基团有助于药物模块的内在化和不聚集(non-agglomeration)。包含澳瑞他汀/多拉司他汀或其衍生物的通式I ADC的例示性实施方案记载于US2005-0238649A1及Doronina等(2006)Bioconjugate Chem.17:114-124,明确收入本文作为参考。包含MMAE或MMAF及各种接头的通式I ADC的例示性实施方案具有如下结构和缩写(其中“Ab”是抗体;p是1到约8;“Val-Cit”是缬氨酸-瓜氨酸二肽;而“S”是硫原子):
典型的是,基于肽的药物模块可通过在两个或更多氨基酸和/或肽片段之间形成肽键来制备。此类肽键可依照例如肽化学领域众所周知的液相合成法来制备(参见E.Schroder和K.Lübke,“The Peptides”,卷1,pp 76-136,1965,Academic Press)。澳瑞他汀/多拉司他汀药物模块可依照以下文献中的方法来制备)US2005-0238649A1;美国专利No.5635483;美国专利No.5780588;Pettit等(1989)J.Am.Chem.Soc.111:5463-5465;Pettit等(1998)Anti-Cancer Drug Design 13:243-277;Pettit,G.R.等,Synthesis,1996,719-725;Pettit等(1996)J.Chem.Soc.Perkin Trans.15:859-863;及Doronina(2003)Nat.Biotechnol.21(7):778-784。
具体而言,通式DF的澳瑞他汀/多拉司他汀药物模块诸如MMAF及其衍生物可以使用US2005-0238649A1及Doronina等(2006)Bioconjugate Chem.17:114-124中记载的方法来制备。通式DE的澳瑞他汀/多拉司他汀药物模块诸如MMAE及其衍生物可以使用Doronina等(2003)Nat.Biotech.21:778-784中记载的方法来制备。可以通过常规方法方便地合成药物-接头模块MC-MMAF、MC-MMAE、MC-vc-PAB-MMAF和MC-vc-PAB-MMAE,例如Doronina等(2003)Nat.Biotech.21:778-784及美国专利申请公开号US2005/0238649A1中所记载的,然后将它们偶联至感兴趣的抗体。
药物载荷
药物载荷(loading)由y表示,即通式I的分子中每个抗体的平均药物模块数。药物载荷的范围可以为每个抗体1-20个药物模块(D)。通式I的ADC包括偶联 有一定范围(1-20个)药物模块的抗体的集合。来自偶联反应的ADC制备物中每个抗体的平均药物模块数可以通过常规手段来表征,诸如质谱、ELISA测定法、和HPLC。还可以测定ADC在y方面的定量分布。在有些情况中,将p为某数值的同质ADC从具有其它药物载荷的ADC中分离、纯化、和表征可以通过诸如反相HPLC或电泳的手段来实现。
对于有些抗体-药物偶联物,y可能受到抗体上附着位点数目的限制。例如,若附着是半胱氨酸硫醇,正如上文例示性实施方案中的那样,则抗体可能只有一个或数个半胱氨酸硫醇基,或者可能只有一个或数个有足够反应性的硫醇基,可附着接头。在某些实施方案中,较高的药物载荷,例如y>5,可引起某些抗体-药物偶联物的聚集、不溶性、毒性、或丧失细胞通透性。在某些实施方案中,本发明ADC的药物载荷的范围为1到约8;约2到约6;约3到约5;约3到约4;约3.1到约3.9;约3.2到约3.8;约3.2到约3.7;约3.2到约3.6;约3.3到约3.8;或约3.3到约3.7。事实上,对于某些ADC已经显示了每个抗体药物模块的最佳比率可以为小于8,可以为约2到约5。参见US2005-0238649A1(完整收入本文作为参考)。
在某些实施方案中,在偶联反应中将少于理论最大值的药物模块偶联至抗体。抗体可包含例如赖氨酸残基,其不与药物-接头中间物或接头试剂起反应,如下文所讨论的。只有最具反应性的赖氨酸基团可以与胺反应性接头试剂起反应。一般而言,抗体不包含许多游离的和反应性的半胱氨酸硫醇基,其可连接药物模块;事实上,抗体中的大多数半胱氨酸硫醇基以二硫桥形式存在。在某些实施方案中,可以在部分或完全还原性条件下用还原剂诸如二硫苏糖醇(DTT)或三羰基乙基膦(TCEP)还原抗体以产生反应性半胱氨酸硫醇基。在某些实施方案中,将抗体置于变性条件以暴露反应性亲核基团,诸如赖氨酸或半胱氨酸。
ADC的载荷(药物/抗体比率DAR)可以以不同方式来控制,例如通过:(i)限制药物-接头中间物或接头试剂相对于抗体的摩尔过量,(ii)限制偶联反应的时间或温度,(iii)半胱氨酸硫醇修饰的部分或限制还原性条件,(iv)通过重组技术对抗体的氨基酸序列进行工程改造,使得半胱氨酸残基的数目和位置为了控制接头-药物附着的数目和/或位置而进行改变(诸如如本文中和WO2006/034488(完整收入本文作为参考)中所述而制备的thioMab或thioFab)。
应当理解,若超过一个亲核基团与药物-接头中间物或者与接头试剂和接下来的药物模块试剂起反应,则所得产物是具有一个或多个药物模块附着于抗体之分布的ADC化合物混合物。可以通过对抗体特异性的和对药物特异性的双重ELISA抗体测定法自混合物计算每个抗体的平均药物数。混合物中的各种ADC分子可以通过质谱来鉴定,并通过HPLC来分离,例如疏水相互作用层析。在某些实施方案中,可以通过电泳或层析从偶联混合物中分离具有单一载荷值的同质 ADC。
制备抗体-细胞毒性药物偶联物或其可药用盐或溶剂化合物的某些方法
可以采用本领域技术人员知道的有机化学反应、条件和试剂通过数种路径来制备通式I的ADC,包括:(1)抗体的亲核基团经共价键与二价接头试剂反应形成Ab-L,接着与药物模块D反应;和(2)药物模块的亲核基团经共价键与二价接头试剂反应形成D-L,接着与抗体的亲核基团反应。经后一种路径制备通式I的ADC的例示性方法记载于US2005-0238649A1,明确收入本文作为参考。
抗体的亲核基团包括但不限于:(i)N末端胺基;(ii)侧链胺基,例如赖氨酸;(iii)侧链硫醇基,例如半胱氨酸;和(iv)糖基化抗体中糖的羟基或氨基。胺、硫醇、和羟基是亲核的,能够与接头模块上的亲电子基团反应而形成共价键,而接头试剂包括:(i)活性酯类,诸如NHS酯、HOBt酯、卤代甲酸酯、和酸性卤化物;(ii)烃基和苄基卤化物,诸如卤代乙酰胺;(iii)醛、酮、羧基和马来酰亚胺基团。某些抗体具有可还原的链间二硫化物,即半胱氨酸桥。可通过还原剂诸如DTT(二硫苏糖醇)或三羰基乙基膦(TCEP)处理使抗体完全或部分还原,从而具有与接头试剂偶联的反应性。每个半胱氨酸桥理论上将形成两个反应性硫醇亲核体。或者,可经由赖氨酸残基的修饰将硫氢基引入抗体,例如通过使赖氨酸残基与2-亚氨基硫烷(Traut氏试剂)起反应,导致胺转变为硫醇。
还可通过抗体上的亲电子基团(诸如醛或酮羰基)与接头试剂或药物上的亲核基团之间的反应来生成本发明的抗体-药物偶联物。接头试剂上的有用亲核基团包括但不限于酰肼(hydrazide)、肟(oxime)、氨基(amino)、肼(hydrazine)、缩氨基硫脲(thiosemicarbazone)、肼羧酸酯(hydrazine carboxylate)、和芳基酰肼(arylhydrazide)。在一个实施方案中,可以用例如高碘酸盐氧化剂氧化糖基化抗体的糖,从而形成可与接头试剂或药物模块的胺基团反应的醛或酮基团。所得亚胺Schiff碱基可形成稳定的连接,或者可以用例如硼氢化物试剂还原而形成稳定的胺连接。在一个实施方案中,糖基化抗体的碳水化合物部分与半乳糖氧化酶或偏高碘酸钠的反应可以在抗体中生成羰基(醛基和酮基),它可与药物上的适宜基团反应(Hermanson,Bioconjugate Techniques)。在另一个实施方案中,包含N-末端丝氨酸或苏氨酸残基的抗体可以与偏高碘酸钠反应,导致在第一个氨基酸处生成醛(Geoghegan和Stroh,(1992)Bioconjugate Chem.3:138-146;US5362852)。这样的醛可与药物模块或接头亲核体反应。
药物模块上的亲核基团包括但不限于:胺、硫醇、羟基、酰肼、肟、肼、缩氨基硫脲、肼羧酸酯、和芳基酰肼基团,它们能够与接头模块上的亲电子基团反应而形成共价键,而接头试剂包括:(i)活性酯类,诸如NHS酯、HOBt酯、卤代甲酸酯、和酸性卤化物;(ii)烃基和苄基卤化物,诸如卤代乙酰胺;(iii)醛、酮、羧基、和马来酰亚胺基团。
本发明的化合物明确涵盖但不限于用如下交联试剂制备的ADC:BMPS、EMCS、GMBS、HBVS、LC-SMCC、MBS、MPBH、SBAP、SIA、SIAB、SMCC、SMPB、SMPH、sulfo-EMCS、sulfo-GMBS、sulfo-KMUS、sulfo-MBS、sulfo-SIAB、sulfo-SMCC和sulfo-SMPB、及SVSB(琥珀酰亚氨基-(4-乙烯基砜)苯甲酸酯)它们可通过商业途径获得(例如Pierce Biotechnology,Inc.,Rockford,IL.,U.S.A参见2003-2004年度应用手册和产品目录(2003-2004Applications Handbook and Catalog)第467-498页)。
还可使用多种双功能蛋白质偶联剂来制备包含抗体和细胞毒剂的抗体-细胞毒性药物偶联物或其可药用盐或溶剂化合物,诸如N-琥珀酰亚氨基3-(2-吡啶基二硫代)丙酸酯(SPDP),琥珀酰亚氨基-4-(N-马来酰亚氨基甲基)环己烷-1-羧酸酯(SMCC),亚氨基硫烷(IT),亚氨酸酯(诸如盐酸己二酰亚氨酸二甲酯)、活性酯类(诸如辛二酸二琥珀酰亚氨基酯)、醛类(诸如戊二醛)、双叠氮化合物(诸如双(对-叠氮苯甲酰基)己二胺)、双重氮衍生物(诸如双(对-重氮苯甲酰基)-乙二胺)、二异硫氰酸酯(诸如甲苯2,6-二异氰酸酯)、和双活性氟化合物(诸如1,5-二氟-2,4-二硝基苯)的双功能衍生物。例如,可以如Vitetta等,Science 238:1098(1987)中所述制备蓖麻毒蛋白免疫毒素。碳-14标记的1-异硫氰酸苄基-3-甲基二亚乙基三胺五乙酸(MX-DTPA)是用于将放射性核苷酸与抗体偶联的例示性螯合剂。参见WO94/11026。
或者,可通过例如重组技术或肽合成来制备包含抗体和细胞毒剂的融合蛋白。重组DNA分子可以包含各自编码偶联物的抗体和细胞毒部分的区域,彼此或是毗邻或是由编码接头肽的区域分开,该接头肽不破坏偶联物的期望特性。
在又一个实施方案中,可以将抗体与“受体”(诸如链霉亲合素)偶联从而用于肿瘤预先靶向,其中对患者施用抗体-受体偶联物,接着使用清除剂由循环中清除未结合的偶联物,然后施用与细胞毒剂(例如放射性核苷酸)偶联的“配体”(例如亲合素)。提供以下实施例仅为说明性目的,并不旨在限制本发明的范围。
具体实施方式
以下结合实施例用于进一步描述本发明,但这些实施例并非限制本发明的范围。
本发明实施例或测试例中未注明具体条件的实验方法,通常按照常规条件,或按照原料或商品制造厂商所建议的条件。参见Sambrook等,分子克隆,实验室手册,冷泉港实验室;当代分子生物学方法,Ausubel等著,Greene出版协会,Wiley Interscience,NY。未注明具体来源的试剂,为市场购买的常规试剂。
实施例
实施例1.抗原抗体克隆表达
本发明所用抗体(轻、重链),抗原用领域周知的重叠延伸PCR方法构建,将重叠延伸PCR得到的DNA片段用HindIII/BstBI这两个酶切位点插入到表达载体pEE6.4((Lonza Biologics),在293F细胞(Invitrogen,Cat#R790-07)中表达得到。所得重组蛋白用于免疫或筛选。c-Met基因模板来源于origene公司(货号RC217003)。所克隆表达的DNA序列如下。
人c-Met细胞外区域(ECD)和鼠Fc区域融合蛋白(human c-Met ECD-mFc)DNA序列:
atgaaggcccccgctgtgcttgcacctggcatcctcgtgctcctgtttaccttggtgcagaggagcaatggggagtgtaaagaggcactagcaaagtccgagatgaatgtgaatatgaagtatcagcttcccaacttcaccgcggaaacacccatccagaatgtcattctacatgagcatcacattttccttggtgccactaactacatttatgttttaaatgaggaagaccttcagaaggttgctgagtacaagactgggcctgtgctggaacacccagattgtttcccatgtcaggactgcagcagcaaagccaatttatcaggaggtgtttggaaagataacatcaacatggctctagttgtcgacacctactatgatgatcaactcattagctgtggcagcgtcaacagagggacctgccagcgacatgtctttccccacaatcatactgctgacatacagtcggaggttcactgcatattctccccacagatagaagagcccagccagtgtcctgactgtgtggtgagcgccctgggagccaaagtcctttcatctgtaaaggaccggttcatcaacttctttgtaggcaataccataaattcttcttatttcccagatcatccattgcattcgatatcagtgagaaggctaaaggaaacgaaagatggttttatgtttttgacggaccagtcctacattgatgttttacctgagttcagagattcttaccccattaagtatgtccatgcctttgaaagcaacaattttatttacttcttgacggtccaaagggaaactctagatgctcagacttttcacacaagaataatcaggttctgttccataaactctggattgcattcctacatggaaatgcctctggagtgtattctcacagaaaagagaaaaaagagatccacaaagaaggaagtgtttaatatacttcaggctgcgtatgtcagcaagcctggggcccagcttgctagacaaataggagccagcctgaatgatgacattcttttcggggtgttcgcacaaagcaagccagattctgccgaaccaatggatcgatctgccatgtgtgcattccctatcaaatatgtcaacgacttcttcaacaagatcgtcaacaaaaacaatgtgagatgtctccagcatttttacggacccaatcatgagcactgctttaataggacacttctgagaaattcatcaggctgtgaagcgcgccgtgatgaatatcgaacagagtttaccacagctttgcagcgcgttgacttattcatgggtcaattcagcgaagtcctcttaacatctatatccaccttcattaaaggagacctcaccatagctaatcttgggacatcagagggtcgcttcatgcaggttgtggtttctcgatcaggaccatcaacccctcatgtgaattttctcctggactcccatccagtgtctccagaagtgattgtggagcatacattaaaccaaaatggctacacactggttatcactgggaagaagatcacgaagatcccattgaatggcttgggctgcagacatttccagtcctgcagtcaatgcctctctgccccaccctttgttcagtgtggctggtgccacgacaaatgtgtgcgatcggaggaatgcctgagcgggacatggactcaacagatctgtctgcctgcaatctacaaggttttcccaaatagtgcaccccttgaaggagggacaaggctgaccatatgtggctgggactttggatttcggaggaataataaatttgatttaaagaaaactagagttctccttggaaatgagagctgcaccttgactttaagtgagagcacgatgaatacattgaaatgcacagttggtcctgccatgaataagcatttcaatatgtccataattatttcaaatggccacgggacaacacaatacagtacattctcctatgtggatcctgtaataacaagtatttcgccgaaatacggtcctatggctggtggcactttacttactttaactggaaattacctaaacagtgggaattctagacacatttcaattggtggaaaaacatgtactttaaaaagtgtgtcaaacagtattcttgaatgttataccccagcccaaaccatttcaactgagtttgctgttaaattgaa
aattgacttagccaaccgagagacaagcatcttcagttaccgtgaagatcccattgtctatgaaattcatccaaccaaatcttttattagtggtgggagcacaataacaggtgttgggaaaaacctgaattcagttagtgtcccgagaatggtcataaatgtgcatgaagcaggaaggaactttacagtggcatgtcaacatcgctctaattcagagataatctgttgtaccactccttccctgcaacagctgaatctgcaactccccctgaaaaccaaagcctttttcatgttagatgggatcctttccaaatactttgatctcatttatgtacataatcctgtgtttaagccttttgaaaagccagtgatgatctcaatgggcaatgaaaatgtactggaaattaagggaaatgatattgaccctgaagcagttaaaggtgaagtgttaaaagttggaaataagagctgtgagaatatacacttacattctgaagccgttttatgcacggtccccaatgacctgctgaaattgaacagcgagctaaatatagagtggaagcaagcaatttcttcaaccgtccttggaaaagtaatagttcaaccagatcagaatttcaca(SEQ ID NO:1)
人c-Met细胞外Sema区域和Flag-His标签(Human c-Met Sema-Flis)DNA序列:
atgaaggcccccgctgtgcttgcacctggcatcctcgtgctcctgtttaccttggtgcagaggagcaatggggagtgtaaagaggcactagcaaagtccgagatgaatgtgaatatgaagtatcagcttcccaacttcaccgcggaaacacccatccagaatgtcattctacatgagcatcacattttccttggtgccactaactacatttatgttttaaatgaggaagaccttcagaaggttgctgagtacaagactgggcctgtgctggaacacccagattgtttcccatgtcaggactgcagcagcaaagccaatttatcaggaggtgtttggaaagataacatcaacatggctctagttgtcgacacctactatgatgatcaactcattagctgtggcagcgtcaacagagggacctgccagcgacatgtctttccccacaatcatactgctgacatacagtcggaggttcactgcatattctccccacagatagaagagcccagccagtgtcctgactgtgtggtgagcgccctgggagccaaagtcctttcatctgtaaaggaccggttcatcaacttctttgtaggcaataccataaattcttcttatttcccagatcatccattgcattcgatatcagtgagaaggctaaaggaaacgaaagatggttttatgtttttgacggaccagtcctacattgatgttttacctgagttcagagattcttaccccattaagtatgtccatgcctttgaaagcaacaattttatttacttcttgacggtccaaagggaaactctagatgctcagacttttcacacaagaataatcaggttctgttccataaactctggattgcattcctacatggaaatgcctctggagtgtattctcacagaaaagagaaaaaagagatccacaaagaaggaagtgtttaatatacttcaggctgcgtatgtcagcaagcctggggcccagcttgctagacaaataggagccagcctgaatgatgacattcttttcggggtgttcgcacaaagcaagccagattctgccgaaccaatggatcgatctgccatgtgtgcattccctatcaaatatgtcaacgacttcttcaacaagatcgtcaacaaaaacaatgtgagatgtctccagcatttttacggacccaatcatgagcactgctttaataggacacttctgagaaattcatcaggctgtgaagcgcgccgtgatgaatatcgaacagagtttaccacagctttgcagcgcgttgacttattcatgggtcaattcagcgaagtcctcttaacatctatatccaccttcattaaaggagacctcaccatagctaatcttgggacatcagagggtcgcttcatgcaggttgtggtttctcgatcaggaccatcaacccctcatgtgaattttctcctggactcccatccagtgtctccagaagtgattgtggagcatacattaaaccaaaatggctacacactggttatcactgggaagaagatcacgaagatcccattgaatggcttgggctgcagacatttccagtcctgcagtcaatgcctctctgccccaccctttgttcagtgtggctggtgccacgacaaatgtgtgcgatcggaggaatgcctgagcgggacatggactcaacagatctgtctgcctgcaatctacaaggactacaaggacgacgacgacaagcatgtccaccatcatcaccatcactgattcgaa(SEQ ID NO:2)
人c-Met ECD his标签(Human c-Met ECD-His)重组蛋白DNA序列:
atgaaggcccccgctgtgcttgcacctggcatcctcgtgctcctgtttaccttggtgcagaggagcaatggggagtgtaaagaggcactagcaaagtccgagatgaatgtgaatatgaagtatcagcttcccaacttcaccgcggaaacacccatccagaatgtcattctacatgagcatcacattttccttggtgccactaactacatttatgttttaaatgaggaagaccttcagaaggttgctgagtacaagactgggcctgtgctggaacacccagattgtttcccatgtcaggactgcagcagcaaagccaatttatcaggaggtgtttggaaagataacatcaacatggctctagttgtcgacacctactatgatgatcaactcattagctgtggcagcgtcaacagagggacctgccagcgacatgtctttccccacaatcatactgctgacatacagtcggaggttcactgcatattctccccacagatagaagagcccagccagtgtcctgactgtgtggtgagcgccctgggagccaaagtcctttcatctgtaaaggaccggttcatcaacttctttgtaggcaataccataaattcttcttatttcccagatcatccattgcattcgatatcagtgagaaggctaaaggaaacgaaagatggttttatgtttttgacggaccagtcctacattgatgttttacctgagttcagagattcttaccccattaagtatgtccatgcctttgaaagcaacaattttatttacttcttgacggtccaaagggaaactctagatgctcagacttttcacacaagaataatcaggttctgttccataaactctggattgcattcctacatggaaatgcctctggagtgtattctcacagaaaagagaaaaaagagatccacaaagaaggaagtgtttaatatacttcaggctgcgtatgtcagcaagcctggggcccagcttgctagacaaataggagccagcctgaatgatgacattcttttcggggtgttcgcacaaagcaagccagattctgccgaaccaatggatcgatctgccatgtgtgcattccctatcaaatatgtcaacgacttcttcaacaagatcgtcaacaaaaacaatgtgagatgtctccagcatttttacggacccaatcatgagcactgctttaataggacacttctgagaaattcatcaggctgtgaagcgcgccgtgatgaatatcgaacagagtttaccacagctttgcagcgcgttgacttattcatgggtcaattcagcgaagtcctcttaacatctatatccaccttcattaaaggagacctcaccatagctaatcttgggacatcagagggtcgcttcatgcaggttgtggtttctcgatcaggaccatcaacccctcatgtgaattttctcctggactcccatccagtgtctccagaagtgattgtggagcatacattaaaccaaaatggctacacactggttatcactgggaagaagatcacgaagatcccattgaatggcttgggctgcagacatttccagtcctgcagtcaatgcctctctgccccaccctttgttcagtgtggctggtgccacgacaaatgtgtgcgatcggaggaatgcctgagcgggacatggactcaacagatctgtctgcctgcaatctacaaggttttcccaaatagtgcaccccttgaaggagggacaaggctgaccatatgtggctgggactttggatttcggaggaataataaatttgatttaaagaaaactagagttctccttggaaatgagagctgcaccttgactttaagtgagagcacgatgaatacattgaaatgcacagttggtcctgccatgaataagcatttcaatatgtccataattatttcaaatggccacgggacaacacaatacagtacattctcctatgtggatcctgtaataacaagtatttcgccgaaatacggtcctatggctggtggcactttacttactttaactggaaattacctaaacagtgggaattctagacacatttcaattggtggaaaaacatgtactttaaaaagtgtgtcaaacagtattcttgaatgttataccccagcccaaaccatttcaactgagtttgctgttaaattgaaaattgacttagccaaccgagagacaagcatcttcagttaccgtgaagatcccattgtctatgaaattcatccaaccaaatcttttattagtggtgggagcacaataacaggtgttgggaaaaacctgaattcagttagtgtcccgagaatggtcataaatgtgcatgaagcaggaaggaactttacagtggcatgtcaacatcgctctaattcagagataatctgttgtaccactccttccctgcaacagctgaatctgcaactccccctgaaaaccaaagcctttttcatgttagatgggatcctttccaaatactttgatctcatttatgtacataatcctgtgtttaagccttttgaaaagccagtgatgatctcaatgggcaatgaaaatgtactggaaattaagggaaatgatattgaccctgaagcagttaaaggtgaagtgttaaaagttggaaataagagctgtgagaatatacacttacattctgaagccgttttatgcacggtccccaatgacctgctgaaattgaacagcgagctaaatatagagtggaagcaagcaatttcttcaaccgtccttggaaaagtaatagttcaaccagatcagaatttcacacaccatcatcaccatcactgattcgaa(SEQ ID NO:3)
实施例2.抗原抗体结合实验(ELISA)
本实验是利用酶联免疫吸附的方法检验抗c-Met抗体(包括杂交瘤上清或重组表达的单克隆抗体等)在体外对c-Met抗原的亲和力。
实验步骤为:用包被液(PBS)(Hyclone,Cat No.:SH30256.01B)稀释抗原(human c-Met-His,实施例1)至2μg/ml,加入100μl/孔于96孔酶标板(Costar 9018,Cat No.:03113024),4℃孵育过夜。次日将包被有抗原的96孔酶标板恢复至室温,洗涤液(PBS+0.05%Tween 20(Sigma,Cat No.:P1379)洗涤三次。随后加入200μl/孔封闭液(PBS+1%BSA(Roche,Cat No.:738328),37℃孵育1小时。洗涤液洗涤三次。加入待测抗c-Met抗体于96孔酶标板,室温孵育1小时。洗涤液洗涤三次。加入封闭液10000倍稀释二抗(Goat anti-Mouse IgG(H+L)(HRP)(Thermo,货号:31432)100μl/孔至96孔酶标板,室温孵育1小时。洗涤液洗涤三次。加入100μl/孔显色液TMB(eBioscience REF:00-4201-56)至96孔酶标板。加入100μl/孔终止液(2N H2SO4)至96孔酶标板。使用读板仪450nm读板。
实施例3.抗人c-Met的小鼠单克隆抗体细胞株产生
本发明通过免疫小鼠,脾细胞融合、杂交瘤筛选方法得到小鼠来源抗人c-Met单克隆细胞株。该方法为本领域熟知。即将重组表达抗原(human c-Met ECD-mFc,human c-Met Sema-flis,见实施例1)用PBS(Hyclone,Cat No.:SH30256.01B)稀释至1mg/ml,与弗氏佐剂(首次免疫用完全弗氏佐剂,加强免疫用不完全弗氏佐剂)乳化后,皮下注射接种Balb/C小鼠(每组5只),每只小鼠接种100ug抗原,间隔两周加强免疫。从第一次加强免疫开始,每次加强免疫后的7至10天内采集小鼠血清用ELISA测定(方法见实施例2)效价。
选择免疫后血清效价高于1:105的小鼠进行细胞融合。分别无菌制备小鼠B细胞和骨髓瘤细胞(SP2/0,ATCC number:CRL-1581TM)并计数,将两种细胞按照B细胞:SP2/0=1:4的比例进行混合后离心(1500r/min,7min),弃上清加入1ml 50%聚乙二醇(Supplier:SIGMA,Catalogue#RNBB306),之后用1ml无血清RPMI1640(Supplier:GIBCO,Catalogue#C22400)终止,离心10min,弃上清,用含杂交瘤细胞生长因子(Supplier:Roche,Catalogue#1363735001),血清(Supplier:GIBCO,Catalogue#C20270)和HAT(Supplier:Invitrogen,Catalogue#21060-017)的RPMI1640重悬沉淀,按照每孔105个B细胞的标准铺板,每孔100ul,置37℃细胞培养箱中培养,3天后加入每孔100ul含杂交瘤细胞生长因子,血清和HT(Supplier:Invitrogen,Catalogue#11067-030)的RPMI1640,2至4天后全换液每孔加入150ul含杂交瘤细胞生长因子,血清和HT的RPMI1640,次日ELISA(方法见实施例2)检测阳性克隆。结果见表1.
表1.人c-Met免疫小鼠杂交瘤融合检测
克隆号 | 检测结果(OD450) |
阴性对照 | 0.07 |
Ab-1 | 1.48 |
Ab-2 | 1.38 |
Ab-3 | 1.29 |
Ab-4 | 1.6 |
Ab-5 | 1.64 |
Ab-6 | 1.75 |
Ab-7 | 1.58 |
Ab-8 | 1.24 |
实施例4抗人c-Met单克隆抗体对胃癌细胞MKN45增值的抑制作用
选择上述克隆,进一步培养得到单克隆,ELISA验证了结合活性后,挑选单克隆培养上清进行细胞活性检测。该实验原理是利用本发明抗人c-Met抗体能抑制人胃癌细胞(MKN45)表面c-Met发生磷酸化,而抑制MNK45细胞的增殖。
人胃癌细胞(MKN45,JCRB,JCRB0254,P11)1x105个细胞/mL,50ul/孔加至96孔细胞培养板(costar,#3799),培养基为RPMI 1640medium:(GIBCO,cat#11835)+10%胎牛血清(FBS)(GIBCO-10099141)。随后加入50ul/孔抗人c-Met待测抗体,37度培养箱(厂商:SANYO设备编号TINC035)中培养5天。使用细胞增殖检测试剂盒(Luminescent Cell Viability Assay)(Promega,G7573),按试剂盒说明书方法检测细胞增殖情况。读板仪(PerkinElmer,TREA001-RDA-IBA100)读板。使用如下公式计算细胞的增值百分率:细胞增殖率%=(1-实验组细胞读数/不作处理组细胞读数)*100%。结果见表2。
表2抗人c-Met单克隆抗体细胞活性
克隆号 | MKN45抑制率(%) |
空白对照 | 0.01 |
Ab-1 | 59.2 |
Ab-2 | 58.4 |
Ab-3 | 59.6 |
Ab-4 | 54.9 |
Ab-5 | 77.4 |
Ab-6 | 70.8 |
Ab-7 | 56.4 |
Ab-8 | 53.8 |
实施例5.抗c-Met抗体序列克隆
将实施例4中得到的活性好的单细胞株Ab-5进行cDNA序列克隆,然后重组表达出单克隆抗体并进行各项活性检测。本发明用逆转录PCR扩增抗体基因的重链和轻链可变区,连接到载体测序得到单克隆抗体轻重链序列。首先采用RNA纯化试剂盒(Qiagen公司,货号74134,步骤见此说明书)提取实施例4中活性好的单细胞株的细胞总RNA。然后使用Invitrogen公司的货号为18080-051cDNA合成试剂盒制备cDNA单链,即Oligo-dT primers cDNA反转录。以此为模版,采用PCR方法合成抗体轻重链可变区序列,PCR产物克隆到TA载体pMD-18T,然后送去测序。将得到的抗体轻重链序列分别克隆到表达载体(见实施例1),表达重组单克隆抗体,验证活性(见实施例2,4)后,进行人源化工作。
本发明小鼠杂交瘤细胞单克隆抗体Ab-5的序列:
重链可变区:
QVQLKQSGPGLVQPSQSLSITCTVSGFSLPNYGVHWVRQSPGKGLEWLGVIWSGGSTNYAAAFVSRLRISKDNSKSQVFFEMNSLQADDTAVYYCARNHDNPYNYAMDYWGQGTTVTVSS(SEQ ID NO:4)
轻链可变区:
DIVLTQSPGSLAVYLGQRATISCRANKSVSTSTYNYLHWYQQKPGQPPKLLIYLASNLASGVPARFSGSGSGTDFTLNIHPLEEEDAATYYCQHSRDLPPTFGAGTKLELKR(SEQ ID NO:5)
抗人c-Met抗体的VH/VL CDR的氨基酸残基由Kabat编号系统确定并注释。
本发明中鼠源的CDR序列如表3所述:
表3鼠源抗硬骨素抗体的CDR序列
抗体 | Ab-5 |
重链CDR1 | NYGVH(SEQ ID NO:6) |
重链CDR2 | VIWSGGSTNYAAAFVS(SEQ ID NO:7) |
重链CDR3 | NHDNPYNYAMDY(SEQ ID NO:8) |
轻链CDR1 | RANKSVSTSTYNYLH(SEQ ID NO:9) |
轻链CDR2 | LASNLA(SEQ ID NO:10) |
轻链CDR3 | QHSRDLPPT(SEQ ID NO:11) |
实施例6.抗c-Met抗体人源化
将实施例5得到鼠源抗c-Met单克隆抗体轻重链序列在抗体数据库里进行同源性比较后,建立人源化抗体模型,根据模型选择回复突变筛选最优的人源化抗 c-Met单克隆抗体为本发明优选分子。该方法从已经发表的小鼠Fab晶体结构模型数据库(比如PDB数据库)中查找与所得鼠源候选分子同源性相似的晶体结构开始,挑取高分辨率(比如)的Fab晶体结构,建立小鼠Fab模型。将本发明鼠源抗体轻重链序列和模型中的序列比对,保留和模型中和鼠源抗体序列一致的序列,得到本发明鼠抗体的结构模型,其中不一致氨基酸为可能的回复突变位点。用Swiss-pdb viewer软件运行鼠抗体结构模型,优化能量(最小化)。将模型中除CDR外的不同氨基酸位点进行回复突变,将所得的突变抗体(人源化)和人源化之前抗体对比进行活性检测。保留活性好的人源化抗体。之后,对CDR区域优化,包括避免糖基化,脱酰胺化,氧化位点等。优化后的人源化抗c-Met抗体的CDR区如表4所示:
表4.优化的抗c-Met抗体的CDR序列
抗体 | 优化的人源化抗体 |
重链CDR1 | NYGVH(SEQ ID NO:6) |
重链CDR2 | VIWSGGSTNYAAAFVS(SEQ ID NO:7) |
重链CDR3 | NHDNPYNYAMDY(SEQ ID NO:8) |
轻链CDR1 | RADKSVSTSTYNYLH(SEQ ID NO:12) |
轻链CDR2 | LASNLA(SEQ ID NO:10) |
轻链CDR3 | QHSRDLPPT(SEQ ID NO:11) |
人源化以后的轻重链可变区如以下所示:
1、重链可变区:
Ab-9
QVTLKESGPVLVKPTETLTLTCTVSGFSLPNYGVHWVRQPPGKALEWLAVIWSGGSTNYAAAFVSRLRISKDTSKSQVVFTMNNMDPVDTATYYCARNHDNPYNYAMDYWGQGTTVTVSS(SEQ ID NO:13)
Ab-10
QVQLVESGGGVVQPGRSLRLSCAASGFSLSNYGVHWVRQAPGKGLEWLAVIWSGGSTNYAAAFVSRLTISKDNSKNTVYLQMNSLRAEDTAVYYCARNHDNPYNYAMDYWGQGTTVTVSS(SEQ ID NO:14)
Ab-11
QVQLVESGGGVVQPGRSLRLSCAASGFTLPNYGVHWVRQAPGKGLEWLAVIWSGGSTNYAAAFVSRLTISKDNSKNTVYLQMNSLRAEDTAVYYCARNHDNPYNYAMDYWGQGTTVTVSS(SEQ ID NO:15)
2、轻链可变区:
Ab-9
DIVLTQSPASLAVSPGQRATITCRANKSVSTSTYNYLHWYQQKPGQPPKLLIYLASNLASGVPARFSGSGSGTDFTLTINPVEANDTANYYCQHSRDLPPTFGQGTKLEIKR(SEQ ID NO:16)
Ab-10
DIVLTQSPDSLAVSLGERATINCRADKSVSTSTYNYLHWYQQKPGQPPKLLIYLASNLASGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQHSRDLPPTFGQGTKLEIKR(SEQ ID NO:17)
Ab-11
DIVLTQSPDSLAVSLGERATINCRANKSVSTSTYNYLHWYQQKPGQPPKLLIYLASNLASGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQHSRDLPPTFGQGTKLEIKR(SEQ ID NO:18)
人源化以后的轻重链和IgG Fc区段重组,得到本发明人源化抗c-Met单克隆抗体。所用的Fc序列任选自以下序列:
重链恒定区:
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK(SEQ ID NO:19)
ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK(SEQ ID NO:20)
ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWES
NGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK(SEQ ID NO:21)
轻链恒定区:
TVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC(SEQ ID NO:22)
用基因克隆、重组表达的方法分别克隆、表达、纯化上述抗体,经ELISA(实施例2)和体外结合活性检测(实施例7),最终选出活性保持最好的人源化抗体Ab-9,Ab-10,Ab-11,序列如下:
Ab-9人源化抗体:
重链:
QVTLKESGPVLVKPTETLTLTCTVSGFSLPNYGVHWVRQPPGKALEWLAVIWSGGSTNYAAAFVSRLRISKDTSKSQVVFTMNNMDPVDTATYYCARNHDNPYNYAMDYWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK(SEQ ID NO:23)
轻链:
DIVLTQSPASLAVSPGQRATITCRANKSVSTSTYNYLHWYQQKPGQPPKLLIYLASNLASGVPARFSGSGSGTDFTLTINPVEANDTANYYCQHSRDLPPTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC(SEQ ID NO:26)
Ab-10人源化抗体:
重链:
QVQLVESGGGVVQPGRSLRLSCAASGFSLSNYGVHWVRQAPGKGLEWLAVIWSGGSTNYAAAFVSRLTISKDNSKNTVYLQMNSLRAEDTAVYYCARNHDNPYNYAMDYWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVV
HQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK(SEQ ID NO:24)
轻链:
DIVLTQSPDSLAVSLGERATINCRADKSVSTSTYNYLHWYQQKPGQPPKLLIYLASNLASGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQHSRDLPPTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC(SEQ ID NO:27)
Ab-11人源化抗体:
重链:
QVQLVESGGGVVQPGRSLRLSCAASGFTLPNYGVHWVRQAPGKGLEWLAVIWSGGSTNYAAAFVSRLTISKDNSKNTVYLQMNSLRAEDTAVYYCARNHDNPYNYAMDYWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK(SEQ ID NO:25)
轻链:
DIVLTQSPDSLAVSLGERATINCRANKSVSTSTYNYLHWYQQKPGQPPKLLIYLASNLASGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQHSRDLPPTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC(SEQ ID NO:28)
实施例7.抗c-Met人源化抗体体结合外活性检测
本发明人源化抗体体外活性除了用ELISA(实施例2)检测之外,还检测了其与c-Met高表达细胞株MKN45的结合,及其与c-Met抗原的亲和力(BIACore测定)。结果见表5和表6。
用FACS方法检测本发明抗c-Met人源化体同c-Met高表达细胞株MKN45的结合活性。
在具有10%(v/v)胎牛血清(FBS)(GIBCO,Cat No.:10099-141)和青霉素/链霉素(GIBCO,Cat No.:15070-063)的RPMI 1640培养基(GIBCO,Cat No.: 11835-030)中重悬浮MKN45细胞(JCRB,Cat No.:JCRB0254)至10000,000细胞/mL。将2mL重悬的MKN45细胞以150,000细胞/孔加入96孔微滴定板(Corning,Cat No.:3799)中,加入8个浓度(20ug/ml起5倍浓度梯度稀释)的c-Met抗体至对应的孔中,最终体积为100ul,在4度孵育1小时。加入FACS缓冲液(具有2.5%(v/v)胎牛血清(FBS)的磷酸盐缓冲液(PBS)(Hyclone,Cat:SH30256.01B),4度,1300rpm,4分钟,离心弃上清,重复三次。每孔加入100ul二抗溶液(荧光标记羊抗鼠二抗:1:200稀释,Biolegend,Cat#405307;荧光标记抗人二抗:1:30稀释,Biolegend,Cat#409304),在4度孵育1小时。加入FACS缓冲液,4度,1300rpm,4分钟,离心弃上清,重复三次。加入200ul FACS缓冲液,重悬细胞,准备好样品,使用流式细胞仪(BD FACS Array)检测。
本发明采用表面等离子共振技术(surface plasmon resonance,SPR)检测c-Met抗体与c-Met抗原Sema-His之间的亲和力。
Anti-mouse IgG(GE Life Sciences catalog#BR-1008-38)或anti-human IgG(GE Life Sciences catalog#BR-1008-39)抗体用pH5.0乙酸钠溶液(GE Healthcare,Cat#BR-1003-51)分别稀释至30ug/ml和50ug/ml,用氨基偶联试剂盒(GE Life Sciences,Cat#BR100050)固定化至CM5芯片(GE Life Sciences catalog#BR-1000-12)的试验及对比通道,偶联水平设定在15000RU。运行缓冲液PBS(Hyclone,Cat#SH30256.01B)+0.05%P20(GE Life Sciences,Cat#BR-1000-54))稀释c-Met抗体至1.5ug/ml,运行缓冲液稀释抗原sema-his至200nM,之后用同样缓冲液1:2倍稀释直至0.78nM。将稀释好的抗体在30ul/min的流速下流过实验通道一分钟,抗原在同样的流速下流经实验通道和对比通道3分钟,解离10分钟后将流速调至10ul/min,在实验通道和对比通道流过再生缓冲液3分钟。数据经双重扣减后用BiaEvaluation 4.1拟合,拟合模型用1:1(Langmuir)模型。
表5.人源化抗c-Met抗体的结合活性
人源化抗体 | Ab-9 | Ab-10 | Ab-11 |
ELISA检测(EC50,nM) | 0.13 | 0.39 | 0.2 |
表6.人源化抗c-Met抗体的MKN45结合活性及抗原亲和力
人源化抗体 | MKN45/FCAS结合活性(nM) | 和抗原亲和力Biacore(nM) |
Ab-9 | 1.6 | 4 |
Ab-10 | 1.23 | 8 |
上述结果表明,本发明人源化抗体和抗原的结合活性在0.13-8nM,因检测方法的不同,检测结果有所不同。结果表明了人源化后的抗c-Met抗体保留了人源化之前抗体的结合活性。
实施例8.抗c-Met人源化抗体体外功能,细胞活性评价
为了检测本发明抗体的功能,用阻断c-Met ligand(肝细胞生长因子HGF)和c-Met的结合实验,以及抑制细胞增值实验(实施例4)对实施例7中的抗体进行了评估。
HGF与c-Met的结合造成c-Met分子的酪氨酸磷酸化以及c-Met信号通路的活化。本实验通过ELISA方法检测本发明抗c-Met抗体阻断HGF结合在受体c-Met蛋白上的活力,即IC50。
c-Met ECD-mFc(实施例子1)稀释在PBS(Hyclone,Cat#SH30256.01B)中,终浓度为2ug/ml,包被在96孔ELISA板(Costar,cat#2592)常温过夜。使用洗板机(Suppler:BioTex;Model:ELX405;S/N:251504)用PBST(PBS+0.05%Tween20(Simga,Cat#P1379))洗涤3次,300ul封闭液PBS+1%BSA(Roche,Cat#738328)加入到96孔板37℃孵育60分钟。用PBST洗涤3次后,封闭液稀释好的抗体50ul加入到96孔中,37℃孵育90分钟。添加封闭液稀释好的终浓度为20ng/ml的人HGF(Sino Biological,#10463-HNAS)50ul到含有c-Met抗体的96孔板中,在室温孵育120分钟。用PBST洗涤三次后,添加100ul封闭液稀释好的终浓度为100ng/ml生物素标记的抗HGF抗体(R&D,Cat#BAF294)到96孔板中孵育90分钟。PBST洗涤后,添加100ul封闭液稀释好的辣根过氧化物酶(ebioscience,#18-4100-51)到96孔板中孵育30分钟。PBST洗涤后,加入100ul底物(ebioscience,cat#00-4201-56)室温孵育10分钟,加入100ul终止液(2N H2SO4),用450nM酶标仪(Supplier:Moleculer Devices;Model:MNR0643;Equip ID:TMRP001)读数。使用SoftMax Pro v5进行数据分析。结果见表7。
表7.本发明人源化抗c-Met抗体的体外功能,细胞活性
上述结果表明,本发明人源化抗体不仅保留了和抗原的结合活性,而且能够阻止抗原和配体(ligand)的结合,同时显示了抑制肿瘤细胞的生长活性。
实施例9本发明抗c-Met人源化抗体的激动剂(agonist)活性评估
抗c-Met抗体阻止HGF/c-Met结合,也有可能激活c-Met信号,即具有激动剂活性。抗c-Met激动剂活性不是本发明所需要的。为了检测本发明抗体是否有激动剂活性,用c-Met磷酸化,人肾透明细胞癌皮肤转移细胞(caki-1)增值,人肺癌H441细胞迁移等三项实验进行检测评估。
HGF与c-Met的结合激活c-Met分子的酪氨酸磷酸化以及活化c-Met信号通路。因此,HGF激活c-Met用于激动剂实验的正对照,用人肺癌细胞株A459来评估诱导c-Met酪氨酸残基1349处磷酸化的作用强弱。
将A549cells悬浮在Ham’s F12K+2mM谷氨酰胺(Invitrogen,#21127-022)+10%(v/v)胎牛血清(FBS)(GIBCO,#10099141),取0.2mL细胞悬液加入到96孔板(Corning,#3599),细胞浓度是60,000细胞/孔。37℃,5%CO2条件下孵育24小时。24小时后弃96孔的培养基,加入100uL的低血清培养基(Ham’s F12K+2mM谷氨酰胺+0.5%FBS)37℃,5%CO2条件下饥饿6小时。抗体用上面的低血清培养基进行稀释(终浓度为20ug/ml)。阳性对照HGF的浓度是200ng/ml。37℃孵育15分钟。弃掉培养基后,加入50ul细胞裂解液(10mM Tris,150mM NaCl,2mM EDTA),50mM NaF,1%(v/v)TRITON-X 100,蛋白酶抑制剂(Roche cat#05892791001),磷酸酶抑制剂cocktail II(Sigma#P5726)及磷酸酶抑制剂cocktail III(Sigma#P0044)。细胞裂解后用ELISA方法检测c-Met酪氨酸磷酸化。c-Met capture antibody(CST,cat#3148s)用PBS1:1000稀释后加入到96孔ELISA板(costar,cat#9018),每个孔100ul,在4度孵育过夜。用TBS-T洗涤3次后加入300ul封闭液(TBS-T plus 2%(w/v)BSA)孵育1小时。用TBS-T洗涤3次后加入75uL细胞封闭液,加入25ul细胞裂解物,4度孵育过夜。用TBS-T洗涤3次,用封闭液1:1000稀释pY1349c-Met抗体(cell signal,#3133),每个孔100ul。室温孵育2小时后TBST洗涤4次,用封闭液1:12000稀释HRP标记的羊抗兔多抗(cell signaling,cat#7074),每个孔100ul室温孵育1小时。TBS-T洗涤5次,加入100uL of TMB(ebioscience#TMB,004201)到每个孔,再加入100ul终止液(2N H2SO4),用450nM酶标仪(Supplier:Moleculer Devices;Model:MNR0643;Equip ID:TMRP001)读数。使用SoftMax Pro v5进行数据分析。结果见表8。
人肾透明细胞癌皮肤(Caki-1)细胞表达肝细胞生长因子受体(c-Met),HGF能结合c-Met刺激Caki-1细胞增殖。因此,本发明的人源化抗c-Met抗体和HGF平行出来Caki-1细胞,可评价抗c-Met抗体的激动剂活性。
Caki-1(上海中科院,TCHu135,P12)细胞1000个/孔加至96孔细胞培养板(costar,#3799),培养基为McCoy’s 5A(invitrogen,#16600)+10%胎牛血清(FBS)(GIBCO-10099141),37℃,24小时。随后细胞饥饿24小时(细胞饥饿培养基为McCoy’s 5A+0.5%胎牛血清)。饥饿后,细胞用梯度稀释的抗c-Met抗体(最高浓度为20ug/ml)及阳性对照处理5天后,用细胞增殖检测试剂盒(Luminescent Cell Viability Assay(Promega,G7573)检测细胞增殖情况。读板仪(厂商:PerkinElmer设备编号:TREA001-RDA-IBA100)读板。计算细胞的增值百分率:细胞增殖%=实验组细胞读数/不作处理组细胞读数* 100%。结果表明,本发明抗体均对Caki-1细胞没有增值作用。见表8。
抗c-Met抗体如果有激动剂活性,能影响细胞的迁移能力。本发明用表达c-Met的H441细胞株来评估本发明c-Met抗体影响细胞迁移能力。
在具有10%(v/v)胎牛血清(FBS)(GIBCO,Cat No.:10099-141)和青霉素/链霉素(GIBCO,Cat No.:15070-063)的RPMI 1640培养基(GIBCO,Cat No.:11835-030)中重悬浮H441细胞(ATCC,Cat No.:HTB-174)至500,000细胞/ml。将重悬的H441细胞以1ml/孔加入12孔培养板(Costar,Cat No.:3513)中,在37℃,5%CO2下培养3天,用磷酸盐缓冲液(PBS)洗两遍细胞,加入含低浓度胎牛血清(0.5%FBS)的RPMI 1640培养基,37℃,5%CO2下培养16小时。用5ml枪头在每个孔的底部划痕,并用含低浓度胎牛血清培养基清洗一遍,加入1ml低浓度血清培养基RPMI 1640,在4倍倒置显微镜下随机选取划痕区域照相保存并在培养板做好标记,此时的记为时间零点,细胞用10ug/ml的c-Met抗体或HGF对照(200ng/ml)处理(37℃,5%CO2)16小时后,在4倍倒置显微镜下将已标记的划痕区域照相保存,此时的记为迁移后时间。影响细胞迁移百分比为相对于零点时的迁移距离除以培养基组相对于零点时的迁移距离乘以100。结果见表8。
表8.本发明人源化抗c-Met抗体的激动剂活性评价
人源化抗体 | 激活c-Met磷酸化(%)* | 刺激Caki-1增值所用 | H441迁移率(%)# |
Ab-9 | 29.9 | 无 | 53 |
Ab-10 | 33.7 | 无 | 34 |
*:抗体浓度为20ug/ml,对照HGF(200ng/ml)激活c-Met磷酸化设为100%.#:抗体浓度为20ug/ml,HGF(200ng/ml)影响H441迁移率设为100%。
上述结果表明,本发明人源化抗体激动剂活性比较弱(c-Met磷酸化,H441迁移实验结果)或没有(20ug/ml抗体未能看到刺激Caki-1增值)。
实施例10抗c-Met抗体体内药效评价
为了评价本发明抗体的抗肿瘤活性,用BALB/c裸小鼠皮下移植人源胃癌MKN45细胞模型进行检测。
MKN45细胞用RPMI-1640培养基(10%胎牛血清)单层培养,培养条件为37℃,5%CO2。在对数生长期计数并且收集细胞。将细胞用PBS重悬至合适浓度,在小鼠(BALB/c Nude小鼠,雌性,10周,体重22-28g。购自上海斯莱克实验动物有限公司,动物合格证编号:2007000548777。饲养环境:SPF级。)右翼皮下接种0.1ml 3×106细胞。肿瘤平均体积达到114mm3时,称量体重,测量肿瘤体积,分组,开始给药。对照组给PBS,抗体治疗组给本发明抗体5mg/kg,每周一次,给药两次。每周2次,测量肿瘤体积和体重,第25天终止 试验。肿瘤大小计算公式:肿瘤体积(mm3)=0.5×(肿瘤长径×肿瘤短径2)。抑瘤率计算公式:抑瘤率=(V0-VT)/V0*100%,其中V0、VT分别为实验开始时及实验结束时的肿瘤体积。
结果表明本发明抗体Ab-9,Ab-10,的肿瘤抑制率分别为56%,和64%。小鼠体重在试验过程中无明显变化(22-24g)。该结果表明,本发明人源化抗c-Met抗体在体内有抑制肿瘤生长的活性。
实施例11抗c-Met抗体的内吞作用
本发明抗体结合人c-Met,具有非常好的体外活性,体内抑制肿瘤活性。此外,该抗体没有或有很弱的激动剂活性。为了检测本发明抗体结合人c-Met后,是否能够和人c-Met一起内吞到细胞内,用表达c-Met的人胃癌细胞MKN45(JCRB,Cat No.:JCRB0254)进行了评估。
在具有10%(v/v)胎牛血清(FBS)(GIBCO,Cat No.:10099-141)和青霉素/链霉素(GIBCO,Cat No.:15070-063)的RPMI 1640培养基(GIBCO,Cat No.:11835-030)中重悬浮MKN45细胞至10000,000细胞/mL。将2mL重悬的MKN45细胞以250,000细胞/孔加入96孔微滴定板中,加入10ug/ml的c-Met抗体至对应的孔中,最终体积为100ul,在4度孵育1小时。加入FACS缓冲液(具有2.5%胎牛血清的磷酸盐缓冲液(Hyclone,Cat:SH30256.01B),4℃,1300rpm,4分钟,离心弃上清,重复三次。每孔加入100ul二抗溶液(荧光标记羊抗鼠二抗:1:200稀释,Biolegend,Cat#405307;荧光标记抗人二抗:1:30稀释,Biolegend,Cat#409304),在4℃孵育1小时。加入FACS缓冲液,4℃,1300rpm,4分钟,离心弃上清,重复三次。加入细胞完全培养基(具有10%胎牛血清的RPMI 1640培养基),在37℃,5%CO2下孵育0小时,0.5小时,1小时,2小时,4小时。每孔加入5ul 7-AAD(Biolegend,Cat:420403)至100ul FACS缓冲液中,在4℃孵育30分钟,加入FACS缓冲液,4℃,1300rpm,4分钟,离心弃上清,重复三次。加入200ul Stripping buffer(0.05M甘氨酸,pH 3.0;0.1M氯化钠,按照1:1(v/v)混匀)至每孔细胞中,重悬细胞,室温孵育7分钟。室温,1300rpm,4分钟,离心弃上清。加入200ul中和洗液(0.15M三羟甲基氨基甲烷,pH 7.4)至每孔细胞中,重悬细胞,室温,1300rpm,4分钟,离心弃上清。加入200ul FACS缓冲液,重悬细胞,准备好样品,使用流式细胞仪(BD FACS Calibur)检测。结果见表9。
c-Met抗体内吞百分比=(各个时间点荧光强度值-零点时的平均荧光强度值)/零点时的平均荧光强度值。
表9.本发明人源化抗c-Met抗体的细胞内吞性能评价(内吞百分比%)
人源化抗体 | 0h | 0.5h | 1h | 2h | 4h |
hIgG(对照)* | 0 | -0.9 | -4.4 | -4.9 | 3.6 |
Ab-9 | 0 | 26 | 32 | 32 | 31 |
Ab-10 | 0 | 24 | 38 | 53 | 59 |
*:对照组-4.9%-3.6%均为实验误差(背景值)。均视为没有内吞作用
表9结果表明,本发明抗体除了没有激动剂活性外,还有很好的内吞作用。结合靶细胞后,抗体和受体一起迅速内吞到靶细胞内,2-4小时内吞达到最大值。
实施例12抗c-Met抗体生物物理稳定性特性分析
为了评估本发明抗体的生物物理稳定性,比如糖基化,脱氨基化位点是否存在,以及其稳定性等,用质谱(LC-MS)分析方法对本发明抗c-Met抗体进行了综合评价。
样品直接LC-MS检测轻重链分子量分析糖基化。在4℃长时间(3个月以上),或40℃,21天加速条件下,LC-MS分析脱氨基化。不同条件处理样品后,取出样品,用pH7.2Tris-HCl稀释样品至2mg/ml,加入终浓度为10mM TCEP和6M尿素(AMRESCO,Cat#0378)37℃孵育20min.加入终浓度为20mM IAA(Sigma-Aldrich,Cat#I1149)室温避光孵育15min保护巯基,用pH 7.2Tris-HCl稀释样品以调节pH,按照蛋白:酶=10:1(重量比)的比例添加蛋白酶(Sigma-Aldrich,Cat#T6567),37℃孵育25min后添加终浓度为0.1%的甲酸(Fluca,Cat#94318)终止反应,离心上LC-MS分析。
用BiopharmaLynx来分析有无脱酰胺基作用。所得到的质谱数据通过找到包含脱酰胺化位点的原生肽(native peptide)和修饰产物,提取母离子得到EIC(Extracted Ion Chromatogram)图,积分得到峰面积并计算脱酰胺化和氧化产物所占比例。结果见表10。
表10.本发明人源化抗c-Met抗体的物理稳定性能评价
*:重链均有糖基化,分子量均和预期一致。#:脱氨基分子比例(%)。0.66-1.0%在检测背景范围内
上述结果表明,本发明的抗体稳定,物理性能好。
实施例13、抗c-Met抗体Ab-10偶联毒素MC-MMAF
本发明抗c-Met抗体具有受体结合阻止活性、无激动剂活性、具有靶细胞内吞活性和物理稳定性等特性,这些特性使得本发明抗体特别适合和毒素偶联成 ADC药物用于c-Met表达癌症治疗。偶联过程见下式:
第一步将硫代乙酸S-(3-羰基丙基)酯(0.7mg,5.3mol)溶解于0.9mL乙腈溶液,备用。向Ab-10单抗pH=4.3的乙酸/乙酸钠缓冲液(10.35mg/ml,9.0mL,0.97mmol)加入上述预制的硫代乙酸S-(3-羰基丙基)酯的乙腈溶液,然后滴加1.0mL的氰基硼氢化钠(14.1mg,224mol)的水溶液,于25℃下振荡反应2小时。反应结束后,用Sephadex G25凝胶柱脱盐纯化(洗脱相:pH为6.5的0.05M的PBS溶液)后,得产物1b溶液,浓缩到约10mg/ml后直接进行下一步反应。
第二步,向1b溶液(11.0mL)中加入0.35mL的2.0M盐酸羟胺溶液,于25℃下振荡反应30分钟后,将反应液用Sephadex G25凝胶柱脱盐纯化(洗脱相:pH为6.5的0.05M的PBS溶液)后,得标题产物Ab-10单抗-丙硫醇1c溶液(浓度6.17mg/ml,14.7mL)。
第三步,将化合物MC-MMAF(1.1mg,1.2mol,采用PCT专利WO2005081711公开的方法制备而得)溶解于0.3mL乙腈中,加入Ab-10单抗-丙硫醇溶液1c(6.17mg/mL,3.0mL)中,于25℃下振荡反应4小时后,将反应液用Sephadex G25凝胶柱脱盐纯化(洗脱相:pH为6.5的含0.05M的PBS溶液),在无菌条件下通过0.2m滤器过滤后得标题产物ADC-1的PBS缓冲液(3.7mg/mL,4.7mL),于4℃冷冻储存。
Q-TOF LC/MS:特征峰:148119.2(MAb+0D)、149278.1(MAb+1D)、 150308.1(MAb+2D)、151314.1(MAb+3D)。分析得每个抗体分子连接毒素量(DAR)平均值:y=1.7。
实施例14、抗c-Met抗体Ab-10偶联毒素MC-VC-PAB-MMAE
将化合物MC-VC-PAB-MMAE(1.6mg,1.2μmol,采用PCT专利WO2004010957公开的方法制备而得)溶解于0.3mL乙腈中,加入Ab-10单抗-丙硫醇溶液1c(6.17mg/mL,3.0mL)中,于25℃下振荡反应4小时后,将反应液用Sephadex G25凝胶柱脱盐纯化(洗脱相:pH为6.5的含0.05M的PBS溶液),在无菌条件下通过0.2m滤器过滤后得标题产物ADC-2的PBS缓冲液(3.6mg/mL,4.8mL),于4℃冷冻储存。
Q-TOF LC/MS:特征峰:148118.4(MAb+0D)、149509.2(MAb+1D)、150903.1(MAb+2D)、152290.4(MAb+3D)、153680.7(MAb+4D)。分析得每个抗体分子连接毒素量(DAR)平均值:y=1.8。
实施例15、抗c-Met抗体Ab-10偶联毒素MC-VC-PAB-MMAF
将化合物MC-VC-PAB-MMAF(1.6mg,1.2μmol,采用PCT专利WO2005081711公开的方法制备而得)溶解于0.3mL乙腈中,加入Ab-10单抗-丙硫醇溶液1c(6.17mg/mL,3.0mL)中,于25℃下振荡反应4小时后,将反应液用Sephadex G25凝胶柱脱盐纯化(洗脱相:pH为6.5的含0.05M的PBS溶液),在无菌条件下通过0.2m滤器过滤后得标题产物ADC-3的PBS缓冲液(3.5mg/mL,4.9mL),于4℃冷冻储存。
Q-TOF LC/MS:特征峰:148119.1(MAb+0D)、149525.3(MAb+1D)、150930.7(MAb+2D)、152335.2(MAb+3D)、153739.8(MAb+4D)。分析得每个抗体分子连接毒素量(DAR)平均值:y=1.6。
实施例16、抗c-Met抗体Ab-10偶联毒素MC-MMAE
化合物MC-MMAE(1.2mg,1.2μmol,采用专利申请”US7/750/116B1”公开的方法制备而得)溶解于0.3mL乙腈中,加入Ab-10单抗-丙硫醇溶液1c(6.17mg/mL,3.0mL)中,于25℃下振荡反应4小时后,将反应液用Sephadex G25凝胶柱脱盐纯化(洗脱相:pH为6.5的含0.05M的PBS溶液),在无菌条件下通过0.2m滤器过滤后得标题产物ADC-4的PBS缓冲液(3.4mg/mL,5.0mL),于4℃冷冻储存。
Q-TOF LC/MS:特征峰:148118.6(MAb+0D)、149104.3(MAb+1D)、150090.1(MAb+2D)、151075.8(MAb+3D)。分析得每个抗体分子连接毒素量(DAR)平均值:y=1.6。
实施例17、抗c-Met抗体Ab-9偶联毒素MC-MMAE
第一步,将硫代乙酸S-(3-羰基丙基)酯(0.7mg,5.3mol),溶解于0.9mL乙腈溶液,备用;向Ab-9单抗pH=4.3的乙酸/乙酸钠缓冲液(10.85mg/ml,9.0mL,0.976mmol)加入上述预制的硫代乙酸S-(3-羰基丙基)酯的乙腈溶液,然后滴加1.0mL的氰基硼氢化钠(14.1mg,224mol)的水溶液,于25℃下振荡反应2小时。反应结束后,用Sephadex G25凝胶柱脱盐纯化(洗脱相:pH为6.5的0.05M的PBS溶液)后,得标题产物5b溶液,浓缩到约10mg/ml后直接进行下一步反应。
第二步,向5b溶液(11.0mL)中加入0.35mL的2.0M盐酸羟胺溶液,于25℃下振荡反应30分钟后,将反应液用Sephadex G25凝胶柱脱盐纯化(洗脱相:pH为6.5的0.05M的PBS溶液)后,得标题产物Ab-9单抗-丙硫醇5c溶液(浓度6.2mg/ml,15.0mL)。
第三步,将化合物MC-MMAE(1.1mg,1.2mol)溶解于0.3mL乙腈中,加入Ab-9单抗-丙硫醇溶液5c(6.2mg/mL,3.0mL)中,于25℃下振荡反应4小时后,将反应液用Sephadex G25凝胶柱脱盐纯化(洗脱相:pH为6.5的含0.05M的PBS溶液),在无菌条件下通过0.2m滤器过滤后得标题产物ADC-5的PBS缓冲液(3.8mg/mL,4.6mL),于4℃冷冻储存。
Q-TOF LC/MS:特征峰:150530.9(MAb+0D)、151915.7(MAb+1D)、153333.6(MAb+2D)、154763.4(MAb+3D)、156271.9(MAb+4D)。分析得每个抗体分子连接毒素量(DAR)平均值:y=1.5。
实施例18、抗c-Met抗体Ab-9偶联毒素MC-MMAF
将化合物MC-MMAF(1.1mg,1.2mol)溶解于0.3mL乙腈中,加入Ab-9单抗-丙硫醇溶液5c(6.2mg/mL,3.0mL)中,于25℃下振荡反应4小时后,将反应液用Sephadex G25凝胶柱脱盐纯化(洗脱相:pH为6.5的含0.05M的PBS溶液),在无菌条件下通过0.2m滤器过滤后得标题产物ADC-6的PBS缓冲液(3.8mg/mL,4.6mL),于4℃冷冻储存。
Q-TOF LC/MS:特征峰:150537.8(MAb+0D)、152087.9(MAb+1D)、153486.5(MAb+2D)、154911.7(MAb+3D)、156499.9(MAb+4D)。分析得每个抗体分子连接毒素量(DAR)平均值:y=1.7。
实施例19、抗c-Met抗体Ab-9偶联毒素MC-VC-PAB-MMAF
将化合物MC-VC-PAB-MMAF(1.6mg,1.2mol)溶解于0.3mL乙腈中,加入Ab-9单抗-丙硫醇溶液5c(6.2mg/mL,3.0mL)中,于25℃下振荡反应4小时 后,将反应液用Sephadex G25凝胶柱脱盐纯化(洗脱相:pH为6.5的含0.05M的PBS溶液),在无菌条件下通过0.2m滤器过滤后得标题产物ADC-7的PBS缓冲液(3.8mg/mL,4.6mL),于4℃冷冻储存。
Q-TOF LC/MS:特征峰:150537.8(MAb+0D)、152087.9(MAb+1D)、153486.5(MAb+2D)、154911.7(MAb+3D)、156499.9(MAb+4D)。分析得每个抗体分子连接毒素量(DAR)平均值:y=1.8。
实施例20、抗c-Met抗体Ab-9偶联毒素MC-VC-PAB-MMAE
将化合物MC-VC-PAB-MMAE(1.6mg,1.2mol)溶解于0.3mL乙腈中,加入Ab-9单抗-丙硫醇溶液5c(6.2mg/mL,3.0mL)中,于25℃下振荡反应4小时后,将反应液用Sephadex G25凝胶柱脱盐纯化(洗脱相:pH为6.5的含0.05M的PBS溶液),在无菌条件下通过0.2m滤器过滤后,得标题产物ADC-8的PBS缓冲液(3.8mg/mL,4.6mL),于4℃冷冻储存。
Q-TOF LC/MS:特征峰:150508.6(MAb+0D)、151903.6(MAb+1D)、153314.5(MAb+2D)、154747.8(MAb+3D)、156039.5MAb+4D)。分析得每个抗体分子连接毒素量(DAR)平均值:y=1.6。
实施例21、抗c-Met抗体Ab-10偶联毒素SMCC-DM1
第一步
将SMCC(4-(N-马来酰亚胺基甲基)环己烷-1-羧酸琥珀酰亚胺酯(1.65mg,4.94mol,购自上海瀚鸿化工科技有限公司,批号BH-4857-111203),溶解于0.9mL乙腈溶液,备用;向Ab-10单抗pH=6.5的PBS缓冲液(10.15mg/ml,9.0mL,0.62mol)加入上述预制的4-(N-马来酰亚胺基甲基)环己烷-1-羧酸琥珀酰亚胺酯的乙腈溶液,于25℃下振荡反应2小时。反应结束后用Sephadex G25凝胶柱脱盐纯化(洗脱相:pH为6.5的0.05M的PBS溶液)后得标题产物9b溶液,浓缩到约10mg/ml(8.3mg/ml,11ml)后直接进行下一步反应。
第二步
向9b溶液(11.0mL)中加入3.0mg的L-DM1(采用公知的方法文献“Journal of Medicinal Chemistry.2006,49,4392-4408”制备而得)乙醇溶液(3.0mgL-DM1/1.1ml乙醇),于25℃下振荡反应约4.0小时后,将反应液用Sephadex G25凝胶柱脱盐纯化(洗脱相:pH为6.5的0.05M的PBS溶液)后,得标题产物ADC-9溶液(浓度6.3mg/ml,14mL),于4℃冷冻储存。
Q-TOF LC/MS:特征峰:148119.6(MAb+0D)、149078.1(MAb+1D)、149836.4(MAb+2D)、150593.7(MAb+3D)、151552.5(MAb+4D)。
平均值:y=2.3。
实施例22、抗c-Met抗体Ab-9偶联毒素SMCC-DM1
第一步
将SMCC(4-(N-马来酰亚胺基甲基)环己烷-1-羧酸琥珀酰亚胺酯(1.65mg,4.94mol),溶解于0.9mL乙腈溶液,备用;向Ab-9单抗pH=6.5的PBS缓冲液(10.15mg/ml,9.0mL,0.62umol)加入上述预制的4-(N-马来酰亚胺基甲基)环己烷-1-羧酸琥珀酰亚胺酯的乙腈溶液,于25℃下振荡反应2小时。反应结束后用Sephadex G25凝胶柱脱盐纯化(洗脱相:pH为6.5的0.05M的PBS溶液)后,得标题产物10b溶液,浓缩到约10mg/ml(8.3mg/ml,11ml)后直接进行下一步反应。
第二步
向9b溶液(11.0mL)中加入3.0mg的L-DM1(3.0mgL-DM1/1.1ml乙醇)乙醇溶液,于25℃下振荡反应约4.0小时后,将反应液用Sephadex G25凝胶柱脱盐纯化(洗脱相:pH为6.5的0.05M的PBS溶液)后得标题产物ADC-10溶液(浓度6.3mg/ml,14mL),于4℃冷冻储存。
Q-TOF LC/MS:特征峰:150534.2(MAb+0D)、151492.6(MAb+1D)、152451.7(MAb+2D)、153409.7(MAb+3D)、154368.1(MAb+4D)。
平均值:y=2.2。
实施例23、抗c-Met抗体Ab-9偶联毒素-SN-38
将化合物MC-VC-PAB-SN-38(1.3mg,1.2mol)溶解于0.3mL乙腈中,加入Ab-9单抗-丙硫醇溶液5c(6.2mg/mL,3.0mL)中,于25℃下振荡反应4小时后,将反应液用Sephadex G25凝胶柱脱盐纯化(洗脱相:pH为6.5的含0.05M的PBS溶液),在无菌条件下通过0.2m滤器过滤后,得标题产物ADC-11的PBS缓冲液(3.7mg/mL,4.5mL),于4℃冷冻储存。
Q-TOF LC/MS:特征峰:150537.1(MAb+0D)、151786.6(MAb+1D)、152948.6(MAb+2D)、154161.7(MAb+3D)、155365.9(MAb+4D)、156477.8(MAb+5D)。
平均值:y=2.6。
实施例24、抗c-Met抗体Ab-10偶联毒素
1、毒素的制备
(S)-2-((2R,3R)-3-((1S,3S,5S)-2-((3R,4S,5S)-4-((S)-N,3-二甲基-2-((S)-3-甲基-2-(甲基氨基)丁酰胺)丁酰胺)-3-甲氧基-5-甲基庚酰基)-2-氮杂双环[3.1.0]己烷-3-基)-3-甲氧基-2-甲基丙酰胺)-3-(2-氟苯基)丙酸
第一步
(S)-叔丁酯2-氨基-3-(2-氟苯基)丙酸
将原料((S)-2-氨基-3-(2-氟苯基)丙酸12a(400mg,2.18mmol,采用公知的方法“Advanced Synthesis&Catalysis,2012,354(17),3327-3332”制备而得)溶于10Ml乙酸叔丁酯,加入高氯酸(300mg(70%),3.3mmol),于室温下搅拌16小时。反应完毕后加入6Ml水,分液,有机相用饱和碳酸氢钠溶液(5Ml)洗涤。水相用饱和碳酸氢钠溶液调节至Ph=8,二氯甲烷(5Ml×3)萃取,合并有机相,依次用水(3Ml),饱和氯化钠溶液(5Ml)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩得粗品标题产物(S)-叔丁酯2-氨基-3-(2-氟苯基)丙酸12b(390mg,黄色油状物),产品不经纯化直接进行下一步反应。
第二步
(1S,3S,5S)-叔丁酯3-((1R,2R)-3-(((S)-1-(叔丁氧基)-3-(2-氟苯基)-1-羰基丙基-2-基)氨基)-1-甲氧基-2-甲基-3-羰基丙基)-2-氮杂双环[3.1.0]己烷-2-羧酸
将原料(2R,3R)-3-((1S,3S,5S)-2-(叔丁氧羰基)-2-氮杂双环[3.1.0]己烷-3-基)-3-甲氧基-2-甲基丙酸12e(100mg,0.334mmol)溶于6Ml二氯甲烷和二甲基甲酰胺(V/V=5:1)混合溶剂中,加入反应物粗品(S)-叔丁酯2-氨基-3-(2-氟苯基)丙酸12b(80mg,0.334mmol)。再加入N,N-二异丙基乙基胺(0.29Ml,1.67mmol)和2-(7- 偶氮苯并三氮唑)-N,N,N’,N’-四甲基脲六氟磷酸酯(152.3mg,0.40mmol)。反应体系在氩气氛下,于室温搅拌1小时。反应结束后,加10Ml水搅拌,分层,二氯甲烷层用饱和氯化钠溶液(10Ml)洗涤,无水硫酸钠干燥,过滤,滤液减压浓缩。用硅胶柱色谱法以洗脱剂体系B纯化所得残余物,得到标题产物(1S,3S,5S)-叔丁酯3-((1R,2R)-3-(((S)-1-(叔丁氧基)-3-(2-氟苯基)-1-羰基丙基-2-基)氨基)-1-甲氧基-2-甲基-3-羰基丙基)-2-氮杂双环[3.1.0]己烷-2-羧酸12c(173mg,无色液体),收率99.5%。
MS m/z(ESI):521.2[M+1]
第三步
(S)-叔丁酯2-((2R,3R)-3-((1S,3S,5S)-2-氮杂双环[3.1.0]己烷-3-基)-3-甲氧基-2-甲基丙酰胺)-3-(2-氟苯基)丙酸
将原料(1S,3S,5S)-叔丁酯3-((1R,2R)-3-(((S)-1-(叔丁氧基)-3-(2-氟苯基)-1-羰基丙基-2-基)氨基)-1-甲氧基-2-甲基-3-羰基丙基)-2-氮杂双环[3.1.0]己烷-2-羧酸12c(173mg,0.33mmol)溶于2Ml二氧六环中,加入5.6M的氯化氢二氧六环溶液(0.21Ml,1.16mmol),氩气氛下,于室温搅拌1小时,置于0℃冰箱内12小时。反应结束后,将反应液减压浓缩,加入5Ml二氯甲烷稀释,加入10Ml饱和碳酸氢钠溶液,搅拌10分钟。体系分层,水层用二氯甲烷萃取(5Ml×3)。合并二氯甲烷层,用饱和氯化钠溶液(10Ml)洗涤,无水硫酸钠干燥。过滤,滤液减压浓缩,得到粗品标题产品(S)-叔丁酯2-((2R,3R)-3-((1S,3S,5S)-2-氮杂双环[3.1.0]己烷-3-基)-3-甲氧基-2-甲基丙酰胺)-3-(2-氟苯基)丙酸12d(77mg,黄色液体),产品不经纯化直接进行下一步反应。
MS m/z(ESI):421.2[M+1]
第四步
(S)-叔丁酯2-((2R,3R)-3-((1S,3S,5S)-2-((5S,8S,11S,12R)-11-((S)-仲丁基)-1-(9H-芴-9-基)-5,8-二异丙基-12-甲氧基-4,10-二甲基-3,6,9-三羰基-2-氧-4,7,10-三氮杂十四烷基-14-酰基)-2-氮杂双环[3.1.0]己烷-3-基)-3-甲氧基-2-甲基丙酰胺)-3-(2-氟苯基)丙酸
将粗品(S)-叔丁酯2-((2R,3R)-3-((1S,3S,5S)-2-氮杂双环[3.1.0]己烷-3-基)-3-甲氧基-2-甲基丙酰胺)-3-(2-氟苯基)丙酸12d(77mg,0.183mmol),(5S,8S,11S,12R)-11-((S)-仲丁基)-1-(9H-芴-9-基)-5,8-二异丙基-12-甲氧基-4,10-二甲基-3,6,9-三羰基-2-氧杂-4,7,10-三氮杂十四烷-14-羧酸12i(116.8mg,0.183mmol,采用专利申请“WO 2013072813”公开的方法制备而得)溶于6Ml二氯甲烷和二甲基甲酰胺(V/V=5:1)混合溶剂中,加入N,N-二异丙基乙基胺(0.16Ml,0.915mmol)和2-(7-偶氮苯并三氮唑)-N,N,N’,N’-四甲基脲六氟磷酸酯(84mg,0.22mmol)。反应体系在氩气氛下,于室温下搅拌1小时。反应结束后,加入10Ml水搅拌,分层。二氯甲烷层用饱和氯化钠溶液(10Ml)洗涤,无水硫酸钠干燥。过滤,滤液减压浓缩。 用硅胶柱色谱法以洗脱剂体系B纯化残留物,得到标题产品(S)-叔丁酯2-((2R,3R)-3-((1S,3S,5S)-2-((5S,8S,11S,12R)-11-((S)-仲丁基)-1-(9H-芴-9-基)-5,8-二异丙基-12-甲氧基-4,10-二甲基-3,6,9-三羰基-2-氧杂-4,7,10-三氮杂十四烷基-14-酰基)-2-氮杂双环[3.1.0]己烷-3-基)-3-甲氧基-2-甲基丙酰胺)-3-(2-氟苯基)丙酸12e(190.5mg,黄色粘稠物),收率100%。
MS m/z(ESI):1040.6[M+1]
第五步
(S)-叔丁酯2-((2R,3R)-3-((1S,3S,5S)-2-((3R,4S,5S)-4-((S)-N,3-二甲基-2-((S)-3-甲基-2-(甲基氨基)丁酰胺)丁酰胺)-3-甲氧基-5-甲基庚酰基)-2-氮杂双环[3.1.0]己烷-3-基)-3-甲氧基-2-甲基丙酰胺)-3-(2-氟苯基)丙酸
将原料(S)-叔丁酯2-((2R,3R)-3-((1S,3S,5S)-2-((5S,8S,11S,12R)-11-((S)-仲丁基)-1-(9H-芴-9-基)-5,8-二异丙基-12-甲氧基-4,10-二甲基-3,6,9-三羰基-2-氧杂-4,7,10-三氮杂十四烷基-14-酰基)-2-氮杂双环[3.1.0]己烷-3-基)-3-甲氧基-2-甲基丙酰胺)-3-(2-氟苯基)丙酸12e(190.5mg,0.183mmol)溶于1.5Ml二氯甲烷中,加入2Ml二乙胺。反应体系在氩气氛下,于室温搅拌3小时。反应结束后,将反应液减压浓缩,得到粗品标题产品(S)-叔丁酯2-((2R,3R)-3-((1S,3S,5S)-2-((3R,4S,5S)-4-((S)-N,3-二甲基-2-((S)-3-甲基-2-(甲基氨基)丁酰胺)丁酰胺)-3-甲氧基-5-甲基庚酰基)-2-氮杂双环[3.1.0]己烷-3-基)-3-甲氧基-2-甲基丙酰胺)-3-(2-氟苯基)丙酸12f(150mg,黄色粘稠物),产品不经纯化直接进行下一步反应。
MS m/z(ESI):818.5[M+1]
第六步
(S)-2-((2R,3R)-3-((1S,3S,5S)-2-((3R,4S,5S)-4-((S)-N,3-二甲基-2-((S)-3-甲基-2-(甲基氨基)丁酰胺)丁酰胺)-3-甲氧基-5-甲基庚酰基)-2-氮杂双环[3.1.0]己烷-3-基)-3-甲氧基-2-甲基丙酰胺)-3-(2-氟苯基)丙酸
将粗品(S)-叔丁酯2-((2R,3R)-3-((1S,3S,5S)-2-((3R,4S,5S)-4-((S)-N,3-二甲基-2-((S)-3-甲基-2-(甲基氨基)丁酰胺)丁酰胺)-3-甲氧基-5-甲基庚酰基)-2-氮杂双环[3.1.0]己烷-3-基)-3-甲氧基-2-甲基丙酰胺)-3-(2-氟苯基)丙酸12f(150mg,0.183mmol)溶于1Ml二氧六环中,加入5.6M的氯化氢二氧六环溶液3Ml,氩气氛下,于室温搅拌12小时。反应结束后,将反应液减压浓缩,用乙醚带旋溶剂。所得残余物用高效液相色谱法纯化得标题产品(S)-2-((2R,3R)-3-((1S,3S,5S)-2-((3R,4S,5S)-4-((S)-N,3-二甲基-2-((S)-3-甲基-2-(甲基氨基)丁酰胺)丁酰胺)-3-甲氧基-5-甲基庚酰基)-2-氮杂双环[3.1.0]己烷-3-基)-3-甲氧基-2-甲基丙酰胺)-3-(2-氟苯基)丙酸12g(28mg,白色粉末固体),收率20%。
MS m/z(ESI):762.7[M+1]
1H NMR(400MHz,CD3OD):δ7.38-7.18(m,2H),7.13-7.01(m,2H),4.80-4.67(m,2H),4.30-4.15(m,1H),4.13-4.01(m,1H),3.96-3.83(m,2H),3.75-3.60(m,2H),
3.42-3.11(m,9H),3.06-2.95(m,1H),2.70-2.58(m,4H),2.28-2.01(m,4H),1.88-1.70(m,3H),1.57-1.25(m,4H),1.22-0.95(m,18H),0.92-0.80(m,4H),0.78-0.65(m,1H).
2、毒素中间体的制备
(S)-2-((2R,3R)-3-((1S,3S,5S)-2-((3R,4S,5S)-4-((S)-2-((S)-2-(6-(2,5-二羰基-2,5-二氢-1H-吡咯-1-基)-N-甲基己酰胺)-3-甲基丁酰胺)-N,3-二甲基丁酰胺)-3-甲氧基-5-甲基庚酰基)-2-氮杂双环[3.1.0]己烷-3-基)-3-甲氧基-2-甲基丙酰胺)-3-(2-氟苯基)丙酸
将原料(S)-2-((2R,3R)-3-((1S,3S,5S)-2-((3R,4S,5S)-4-((S)-N,3-二甲基-2-((S)-3-甲基-2-(甲基氨基)丁酰胺)丁酰胺)-3-甲氧基-5-甲基庚酰基)-2-氮杂双环[3.1.0]己烷-3-基)-3-甲氧基-2-甲基丙酰胺)-3-(2-氟苯基)丙酸12g(25mg,0.033mmol)溶于3mL二氯甲烷中,加入N,N-二异丙基乙基胺(0.029mL,0.164mmol),反应体系在氩气氛下,冰浴下滴加预制的6-(2,5-二羰基-2,5-二氢-1H-吡咯-1-基)己酰氯4b(11.3mg,0.049mmol)的二氯甲烷溶液,于室温反应3小时。反应结束后,加入5mL水,搅拌20分钟,分液,有机层用无水硫酸钠干燥,过滤,滤液减压浓缩,残留物用高效液相色谱法纯化得标题产物(S)-2-((2R,3R)-3-((1S,3S,5S)-2-((3R,4S,5S)-4-((S)-2-((S)-2-(6-(2,5-二羰基-2,5-二氢-1H-吡咯-1-基)-N-甲基己酰胺)-3-甲基丁酰胺)-N,3-二甲基丁酰胺)-3-甲氧基-5-甲基庚酰基)-2-氮杂双环[3.1.0]己烷-3-基)-3-甲氧基-2-甲基丙酰胺)-3-(2-氟苯基)丙酸12h(7mg,黄色粘稠物),收率22.4%。
MS m/z(ESI):955.4[M+1]
1H NMR(400MHz,CD3OD):δ7.36-7.30(m,1H),7.29-7.21(m,1H),7.17-7.02(m,2H),6.83-6.79(m,2H),4.81-4.71(m,2H),4.69-4.55(m,2H),4.25-4.15(m,1H),4.13-4.04(m,1H),3.96-3.85(m,2H),3.70-3.61(m,1H),3.55-3.46(m,3H),3.40-3.21(m,4H),3.18-3.10(m,2H),3.07-2.96(m,4H),2.67-2.56(m,2H),2.54-2.34(m,3H),2.29-2.17(m,2H),2.10-1.99(m,1H),1.89-1.57(m,7H),1.52-1.28(m,6H),1.21-1.11(m,4H),1.07-0.96(m,6H),0.95-0.81(m,12H),0.80-0.69(m,1H).
3、抗体毒素偶联物的制备
将化合物12h(1.2mg,1.2μmol)溶解于0.3mL乙腈中,加入Ab-10单抗-丙硫醇1c溶液(6.17mg/mL,3.0mL)中,于25℃下振荡反应4小时后将反应液用Sephadex G25凝胶柱脱盐纯化(洗脱相:pH为6.5的含0.05M的PBS溶液),在无菌条件下通过0.2μm滤器过滤后得标题产物ADC-12的PBS缓冲液(3.3mg/mL,5.0mL),于4℃冷冻储存。
Q-TOF LC/MS:特征峰:148119.6(MAb+0D)、149150.5(MAb+1D)、150221.1(MAb+2D)、151265.1(MAb+3D)、152314.3(MAb+4D)。
平均值:y=1.6。
参照实施例13-24,制备实施例25-27的ADC化合物。
抗c-Met抗体毒素偶联(ADC)分子测试例
测试例1抗c-Met抗体毒素偶联(ADC)分子稳定性评价
本发明ADC分子或其它具有内吞作用的c-Met抗体-毒素偶联物(如,LY-2875358-ADC)的毒素中间体和毒素,在PBS、人和猴血浆中进行了游离毒素的稳定性评价。
将实施例化合物ADC-1和ADC-12的毒素中间体和毒素用PBS、人或猴血浆(苏州西山中科药物研究开发有限公司,动物生产许可证号:SCXK(苏)2012-0009)稀释至500μg/mL,37℃孵育7天,于0、3、7天取样测定样品中游离毒素和毒素中间体的浓度。50μL含药人、猴血浆或PBS样品,加入20uL内对照(喜树碱,上海融禾医药科技发展有限公司,批号090107,100ng/ml),加入150μL乙腈,涡旋混匀3min,15000rpm,离心10min,取上清液80μL与80μL 0.2%甲酸混匀后,10μL进样。标准曲线分析方法为50μL空白人、猴血浆或PBS样品,加入50μL系列工作溶液,加入20μL内对照(喜树碱,100ng/ml),加入100μL乙腈,涡旋混匀3min,15000rpm,离心10min,取上清液80μL与80μL 0.2%甲酸混匀后,10μL进样。
使用Shimadzu LC-30AD超高效液相色谱系统(日本岛津公司),UPLC-MS/MS质谱仪为API4000三重四极杆串联质谱仪(美国AB SCIEX公司),设定色谱条件(色谱柱:Waters XBridgeTM BEH300C18(100mm*4.6mm i.d.,3.5mm),流动相为0.2%甲酸-乙腈(梯度洗脱)。结果见表11a,表11b,。
表11a.本发明ADC-1的毒素中间体和毒素药物血浆稳定性评价
*:检测值以样品中含游离毒素的百分比。0.01-0.19%均在检测背景值范围内;ND:Not detectable,未能检测到。
表11b.本发明ADC-12的毒素中间体和毒素药物血浆稳定性评价
ND:Not detectable,未能检测到。
上述结果表明,b本发明ADC-1,ADC-12的毒素中间体和毒素在各种溶剂(PBS,人血浆,猴血浆等)中稳定。37℃孵育0、3和7天均未检测到降解产物游离毒素和毒素中间体(毒素-linker)。
测试例2抗c-Met抗体毒素偶联(ADC)分子体外活性评价
本发明ADC-1,ADC-12的体外活性用FACS(检测和c-Met阳性细胞的结合力)和内吞作用(方法见实施例11)评价。结果见表12。
表12.本发明ADC分子体外活性
*:数据为1小时内吞比例
上述结果表明,本发明抗体和毒素偶联后,保留了抗体的结合活性和内吞活性。
测试例3抗c-Met抗体毒素偶联(ADC)分子细胞毒性实验
为了评估本发明ADC分子对细胞的毒性作用,用细胞ATP毒性实验进行了评估。ATP是活细胞新陈代谢的一个指标,检测ATP可以反应分子对细胞的毒性大小。
HepG2细胞(中科院细胞库,Cat#TCHu 72)培养在含10%FBS的EMEM完全培养基中,MKN45细胞培养在含10%FBS的RPMI1640完全培养基中,实验时加入2-3ml胰蛋白酶消化2-3min,待细胞消化完全,加入10-15ml完全培养基将经过消化的细胞洗脱下来,1000rpm离心3min,弃上清,接着加入10-20ml完全培养基将细胞重悬,制成单细胞悬液,调整细胞密度为4*104cells/ml。在96孔细胞培养板各孔中加0.1ml上述细胞悬液,37℃5%CO2的培养箱中培养,24小时后去掉培养基,每孔加入90ul含2%FBS的EMEM培养基或含2%FBS的RPMI1640培养基,将待测样品(实施例13化合物和毒素)用PBS稀释成不同浓度梯度,每孔加入10ul,37℃5%CO2的培养箱中孵育72小时。用 Luminescent Cell Viability Assay试剂盒(Promega,Cat#G7571)按说明书检测。用酶标仪(VICTOR 3,PerkinElmer公司)检测化学发光,GraphPad Prism(version 5.0)软件进行数据分析。结果将表13。
表13本发明ADC分子和相应的游离细胞毒素的细胞毒性作用
ND:没有检测到活性;NA:不适用
上述结果表明,本发明ADC-1,ADC-12对c-Met阳性细胞MKN45的细胞毒性作用相同(IC50分别为0.51nM,和0.59nM)。但是各自的毒素部分对c-Met阳性细胞MKN45的细胞毒性作用不同,两者相差93倍(79.4/0.85)。
本发明ADC-1,ADC-12对c-Met阴性性细胞HepG2均没有细胞毒性作用,表明ADC化合物具有特异靶向作用。但是各自的毒素部分对c-Met阴性细胞HepG2的细胞毒性作用不同,两者相差82倍(400.8/4.88)。
这些结果表明,本发明ADC-1,ADC-12具有特异靶向作用,能抑制c-Met阳性细胞增值,但对非特异(正常细胞)没有毒性作用。ADC-1,ADC-12不同之处在于,各自的游离毒素对靶向细胞和非靶向细胞的毒性不同。ADC-12的毒 素部分对c-Met阳性细胞和阴性细胞HepG2的细胞毒性要比ADC-1的毒素部分弱93,82倍。因此,该分子到达靶细胞过程中,如果有游离的毒素被释放,其非特异的毒性作用要比ADC-1弱。因而,毒副作用要小,安全性好。
测试例4抗c-Met抗体毒素偶联(ADC)分子对肿瘤细胞的增值抑制作用
上述结果表明,ADC-1(实施例13)能够特异杀死c-Met表达的肿瘤靶细胞。为了检测该毒性作用对肿瘤细胞的增值抑制所用。用本发明分子检测了多种肿瘤细胞,采用CCK法测试样品对细胞增殖的抑制作用,根据IC50大小评价本发明ADC分子体外细胞活性。
所用细胞及相应的培养基见下表14-1,用Cell Counting Kit(东仁化学科技有限公司,Cat#CK04)检测细胞增值(按说明书进行操作)。
实验时加入2-3ml胰蛋白酶消化2-3min,待细胞消化完全,加入10-15ml完全培养基将经过消化的细胞洗脱下来,1000rpm离心3min,弃上清,接着加入10-20ml培养基将细胞重悬,制成单细胞悬液,调整细胞密度为4*104cells/ml。在96孔细胞培养板各孔中加0.1ml上述细胞悬液,37℃5%CO2的培养箱中培养,24小时后去掉培养基,每孔加入90μl含2%FBS的培养基,将待测样品用PBS稀释成不同浓度梯度,每孔加入10μl,37℃5%CO2的培养箱中孵育72小时。每孔加入10ul CCK8,培养箱中继续孵育2小时,酶标仪(VICTOR 3,PerkinElmer公司)检测OD450,采用GraphPad Prism(version 5.0)软件进行数据分析。结果见表14-2。
表14-1本实施例所用细胞的培养基
细胞系 | 培养基 | 厂家货号 |
MKN45 | RPMI1640+10%FBS | JCRB,JCRB0254 |
SNU5 | IMDM+10%FBS | ATCC,Cat#CRL-5973TM |
BxPC3 | RPMI1640+10%FBS | 中科院细胞库(Cat#TCHu 12) |
Caki-1 | McCOY's 5A+10%FBS | 中科院细胞库,Cat#TCHu135 |
HepG2 | EMEM+10%FBS | 中科院细胞库,Cat#TCHu 72 |
Hep3B | EMEM+10%FBS | 中科院细胞库,Cat#TCHu106 |
SK-HEP-1 | EMEM+10%FBS | 中科院细胞库,Cat#TCHu109 |
NCI-H1993 | RPMI1640+10%FBS | ATCC,Cat#CRL-5909TM |
HCCLM3 | DMEM+10%FBS | 江苏豪森药业有限公司 |
QGY-7701 | DMEM+10%FBS | 上海拜力生物科技有限公司 |
SMMC-7721 | DMEM+10%FBS | 上海拜力生物科技有限公司 |
Bel-7402 | DMEM+10%FBS | 上海拜力生物科技有限公司 |
PC9 | DMEM+10%FBS | 上海拜力生物科技有限公司 |
NCI-H596 | DMEM+10%FBS | 上海拜力生物科技有限公司 |
表14-2本发明分子对不同癌细胞增殖抑制作用
表14-2结果表明本发明抗c-Met抗体在胃癌细胞系MKN45,SUN上有比较好的活性,而在其它c-Met表达低或不表达的肿瘤细胞,例如肝癌,肺癌细胞上活性很弱,或者没有。而本发明的ADC-1因为带有额外的毒素,对c-Met表达的肿瘤细胞,包括胃癌细胞系MKN45,SUN,特别抗c-Met抗体没有作用或作用非常微弱的是肝癌,肺癌、胰腺癌和肾细胞癌细胞上显示出很好的活性。
测试例5抗c-Met抗体毒素偶联(ADC)分子体内药效评价
为了更好评价本发明抗c-Met抗体和ADC分子的抗肿瘤药效活性,用实施例方法对抗体和ADC进行了平行比较实验。和实施例11不同的是,本实施例子是单次给药,观察到肿瘤抑制作用直到有回复后趋势停止试验。结果见图1。
图1结果表明,本发明抗体单独在5mg/kg剂量时候,抑制率为43%。进一步加大剂量到30mg/kg时候,抑制肿瘤的效果没有进一步加大(抑瘤率为42%),即5mg/kg抗体已经达到药效饱和。而ADC-1在2.5mg/kg的时候,肿 瘤几乎停止增大。加大剂量到5mg/kg时候,肿瘤已经不再增长,显示剂量效应。即ADC新分子通过带入的毒素能达到对肿瘤的完全抑制作用,而抗体单独无法达到。此外,本实验是单次给药。肿瘤的抑制作用在18天后开始有回复,说明ADC和抗体半衰期(T1/2)接近。不仅如此,10mpk ADC药效维持到28天,其剂量依赖药效更加明显。这表明本发明ADC分子没有因为毒素的偶联而影响到T1/2 。此外,体实验过程中无小鼠出现死亡,体重也无明显下降,表明所本发明抗体和ADC均未见毒性。
为了评价本发明ADC-12的体内药效,用上述同样的试验方法,平行比较了ADC-1和ADC-12。同样剂量3mg/kg,单次给药后,结果见表15。
表15.ADC-1和ADC-12对肿瘤的抑制作用
抑制率(%) | 11天 | 15天 | 18天 | 21天 |
ADC‐1 | 42.8 | 44.7 | 35.4 | 27.1 |
ADC‐12 | 44.6 | 54.5 | 50.5 | 50.4 15 |
上述结果表明ADC-1和12在11天抑瘤率相近,但是从15天之后,ADC-1的药效减弱(21天为27.1%),而ADC-12的抑瘤作用仍然维持在第11天的水平(50.4%)。
Claims (42)
1.特异性结合c-Met受体的抗体或其抗原结合片段,其包含至少1个选自以下的CDR区序列或其突变序列:
抗体重链可变区HCDR区序列:SEQ ID NO:6,SEQ ID NO:7或SEQ IDNO:8;和
抗体轻链可变区LCDR区序列:SEQ ID NO:9,SEQ ID NO:10或SEQ IDNO:11。
2.根据权利要求1所述的特异性结合c-Met受体的抗体或其抗原结合片段,其中所述的抗体重链可变区包含至少1个选自如下的HCDR区序列或其突变序列:SEQ ID NO:6,SEQ ID NO:7或SEQ ID NO:8。
3.根据权利要求1所述的特异性结合c-Met受体的抗体或其抗原结合片段,其中所述的抗体轻链可变区包含至少1个选自如下的LCDR区序列或其突变序列:SEQ ID NO:9,SEQ ID NO:10或SEQ ID NO:11。
4.根据权利要求1-3任一项所述的特异性结合c-Met受体的抗体或其抗原结合片段,其中所述的抗体包含重链可变区序列SEQ ID NO:6,SEQ ID NO:7和SEQ ID NO:8,或其突变序列,和轻链可变区序列SEQ ID NO:9,SEQ IDNO:10和SEQ ID NO:11或其突变序列。
5.根据权利要求1-4任一项所述的特异性结合c-Met受体的抗体或其抗原结合片段,其中所述的突变序列为CDR区发生1-3个优化抗体活性的氨基酸突变,其中HCDR2区突变序列优选为SEQ ID NO:12。
6.根据权利要求1-5任一项所述的特异性结合c-Met受体的抗体或其抗原结合片段,其中所述的特异性结合c-Met受体的抗体或其抗原结合片段为鼠源抗体或其片段。
7.根据权利要求6所述的特异性结合c-Met受体的抗体或其抗原结合片段,其中所述的鼠源抗体重链可变区序列为:SEQ ID NO:4。
8.根据权利要求6所述的特异性结合c-Met受体的抗体或其抗原结合片段,其中所述的鼠源抗体轻链可变区序列为:SEQ ID NO:5。
9.根据权利要求6-8任一项所述的特异性结合c-Met受体的抗体或其抗原结合片段,其中所述的鼠源抗体的重链可变区为:SEQ ID NO:4,轻链可变区为:SEQ ID NO:5。
10.根据权利要求1-5任一项所述的特异性结合c-Met受体的抗体或其抗原结合片段,其为嵌合抗体或人源化抗体或其片段。
11.根据权利要求10所述的特异性结合c-Met受体的抗体或其抗原结合片段,其中所述人源化抗体重链可变区上的重链FR区序列,来源于人种系重链序列,优选人种系重链IGHV 3-33*01;其中所述重链FR区序列包含人种系重链IGHV 3-33*01的FR1,FR2,FR3区和FR4区的框架序列或其突变序列,优选所述突变序列为0-10个氨基酸的回复突变。
12.根据权利要求11所述的特异性结合c-Met受体的抗体或其抗原结合片段,其中所述的人源化抗体包含选自SEQ ID NO:13-15所示的重链可变区序列或其变体。
13.根据权利要求10所述的特异性结合c-Met受体的抗体或其抗原结合片段,其中所述人源化抗体轻链可变区上的轻链FR区序列,选自人种系轻链序列,优选人种系轻链IGKV085或IGKV 4-1*01,其中所述轻链FR区序列包含人种系轻链IGKV085和IGKV 4-1*01的FR1,FR2,FR3区和FR4区的框架序列或其突变序列,优选所述突变序列为0-10个氨基酸的回复突变。
14.根据权利要求13所述的特异性结合c-Met受体的抗体或其抗原结合片段,其中所述的人源化抗体包含选自SEQ ID NO:16-18所示的轻链可变区序列或其变体。
15.根据权利要求10-14任一项的特异性结合c-Met受体的抗体或其抗原结合片段,所述的人源化抗体包含选自SEQ ID NO:13-15的重链可变区序列和选自SEQ ID NO:16-18的轻链可变区序列。
16.根据权利要求1-5和10-15任一项所述的特异性结合c-Met受体的抗体或其抗原结合片段,其包含选自a)至c)任一的重链可变区序列和轻链可变区序列的组合:
a)SEQ ID NO:13的重链可变区序列和SEQ ID NO:16的轻链可变区序列;
b)SEQ ID NO:14的重链可变区序列和SEQ ID NO:17的轻链可变区序列;或
c)SEQ ID NO:15的重链可变区序列和SEQ ID NO:18的轻链可变区序列。
17.根据权利要求10-16任一项所述的特异性结合c-Met受体的抗体或其抗原结合片段,其中所述的人源化抗体的重链恒定区包含源自人源IgG1或其变体、人源IgG2或其变体、人源IgG3或其变体或人源IgG4或其变体的恒定区,优选包含人源IgG1或其变体或人源IgG2或其变体或人源IgG4或其变体的恒定区,更优选人源IgG2或其变体的恒定区。
18.根据权利要求17所述的特异性结合c-Met受体的抗体或其抗原结合片段,其包含选自SEQ ID NO:23-25或与其具有至少90%同源性的全长重链序列。
19.根据权利要求10-16任一项所述的特异性结合c-Met受体的抗体或其抗原结合片段,其所述的人源化抗体的轻链恒定区包含选自人源κ或λ链或其变体的恒定区。
20.根据权利要求19所述的特异性结合c-Met受体的抗体或其抗原结合片段,其包含选自SEQ ID NO:26-28或与其具有至少90%序列同源性的全长轻链序列。
21.根据权利要求10-20任一项所述的特异性结合c-Met受体的抗体或其抗原结合片段,其中所述的人源化抗体包含选自以下全长轻链序列和全长重链序列的组合:
Ab-9:SEQ ID NO:23的重链序列和SEQ ID NO:26的轻链序列;
Ab-10:SEQ ID NO:24的重链序列和SEQ ID NO:27的轻链序列;或
Ab-11:SEQ ID NO:25的重链序列和SEQ ID NO:28的轻链序列。
22.一种DNA分子,其编码根据权利要求1-21任一项所述的特异性结合c-Met受体的抗体或其抗原结合片段。
23.一种表达载体,其含有根据权利要求22所述的DNA分子。
24.一种用根据权利要求23所述的表达载体转化的宿主细胞,其中所述的宿主细胞优选为哺乳动物细胞,更优选为CHO细胞。
25.一种药物组合物,其包含权利要求1-21任一项所述的特异性结合c-Met受体的抗体或其抗原结合片段,和一种或多种可药用的赋形剂、稀释剂或载体。
26.一种通式(I)所示的抗体-细胞毒性药物偶联物或其药学上可接受的盐或溶剂化合物:
Ab-[(L2)t-L1-D)]y (I)
其中:
D为药物模块;
L1,L2是接头单元;
t为0或1,优选1;
y为1-8,优选2-5;
Ab如权利要求1-21任一项所述的特异性结合c-Met受体的抗体或其抗原结合片段。
27.如权利要求26所述的通式(I)所示的抗体-细胞毒性药物偶联物或其药学上可接受的盐或溶剂化合物,其中-L2-为以下通式(-L2-)所示的化合物:
其中
X1选自自氢原子、卤素、羟基、氰基、烷基、烷氧基和环烷基;
X2选自-烷基-、-环烷基-和-杂环基-;
m为0-5,优选1-3;S为硫原子。
28.根据权利要求26所述的通式(I)所示的抗体-细胞毒性药物偶联物或其可药用盐或溶剂化合物,其中所述药物模块D为选自毒素、化疗剂、抗生素、放射性同位素和核溶酶的细胞毒剂。
29.如权利要求26所述的通式(I)所示的抗体-细胞毒性药物偶联物或其药学上可接受的盐或溶剂化合物,其中D为以下通式(D)所示的化合物:
或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中:
R1-R7选自氢原子、卤素、羟基、氰基、烷基、烷氧基和环烷基;
R8-R11任选自氢原子、卤素、烯基、烷基、烷氧基和环烷基;R8-R11优选至少其中一个选自卤素、烯基、烷基和环烷基,其余为氢原子;
或者R8-R11之中的任意两个形成环烷基,余下的两个基团任选自氢原子、烷基和环烷基;
R12-R13选自氢原子、烷基或卤素;
R14选自芳基或杂芳基,所述的芳基或杂芳基任选进一步被选自氢原子、卤素、羟基、烷基、烷氧基和环烷基的取代基所取代;
R15任选自卤素、烯基、烷基、环烷基和COO R17;
R16选自氢原子、卤素、羟基、氰基、烷基、烷氧基和环烷基;
R17选自氢原子、烷基和烷氧基。
30.根据权利要求29所述的通式(I)所示的抗体-细胞毒性药物偶联物或其可药用盐或溶剂化合物,其中L2包含选自Val-Cit,MC,PAB和MC-PAB的接头,优选MC。
31.根据权利要求26所述的通式(I)所示的抗体-细胞毒性药物偶联物或其可药用盐或溶剂化合物,其中D是美登木素生物碱;优选DM1、DM3和DM4,更优选DM1。
32.根据权利要求31所述的通式(I)所示的抗体-细胞毒性药物偶联物或其可药用盐或溶剂化合物,其中所述L2选自N-琥珀酰亚氨基4-(2-吡啶基硫代)戊酸酯(SPP)、N-琥珀酰亚氨基4-(N-马来酰亚胺基甲基)-环己烷-1-羧酸酯(SMCC)、和N-琥珀酰亚氨基(4-碘-乙酰基)氨基苯甲酸酯(SIAB);优选SPP或SMCC。
33.根据权利要求26所述的通式(I)所示的抗体-细胞毒性药物偶联物或其可药用盐或溶剂化合物,其中D是喜树碱类生物碱;优选自CPT、10-羟基-CPT、CPT-11(伊立替康)、SN-38和托泊替康,更优选SN-38。
34.根据权利要求33所述的通式(I)所示的抗体-细胞毒性药物偶联物或其可药用盐或溶剂化合物,其中所述接头L2包含任选自Val-Cit,MC,PAB或MC-PAB的结构,优选MC或MC-vc-PAB。
35.如权利要求26所述的通式(I)所示的抗体-细胞毒性药物偶联物或其药学上可接受的盐或溶剂化合物,其为通式(II)所示的偶联药物或其药学上可接受的盐或溶剂化合物:
其中:
R2-R16如权利要求27中所定义;
Ab,t,y,L1,L2如权利要求24中所定义。
36.如权利要求26所述的通式(I)所示的抗体-细胞毒性药物偶联物或其药学上可接受的盐或溶剂化合物,其为通式(III)所示的偶联药物或其药学上可接受的盐或溶剂化合物:
其中:
R2-R16如权利要求27中所定义;
Ab,t,y,L1,L2如权利要求24中所定义;
n为3-6,优选5。
37.如权利要求26所述的通式(I)所示的抗体-细胞毒性药物偶联物或其药学上可接受的盐或溶剂化合物,其为通式(IV)所示的偶联药物或其药学上可接受的盐或溶剂化合物:
其中:
R2-R16如权利要求27中所定义;
Ab,y如权利要求24中所定义;
n如权利要求34中所定义;
X1,X2,m如权利要求25中所定义。
38.如权利要求26所述的通式(I)所示的抗体-细胞毒性药物偶联物或其药学上可接受的盐或溶剂化合物,其为通式(V)所示的偶联药物或其药学上可接受的盐或溶剂化合物:
其中:
Ab,D,y如权利要求24中所定义;
n如权利要求34中所定义;
X1,X2,m如权利要求25中所定义。
39.根据权利要求26-38任一项所述的抗体-细胞毒性药物偶联物或其可药用盐或溶剂化合物,其中所述抗体-细胞毒性药物偶联物或其可药用盐或溶剂化合物选自:
Ab-9,Ab-10,Ab-11如权利要求21中所定义,其中,y的范围为1-8;优选2-5。
40.一种制备根据权利要求38所述的通式(V)所示的抗体-细胞毒性药物偶联物的方法,该方法包括:
通式(Ab-L2)化合物与通式(L1-D)化合物在有机溶剂中反应,得到通式(V)化合物;所述的有机溶剂优选乙腈或乙醇;
其中:
Ab如权利要求1-21任一项所述的特异性结合c-Met受体的抗体或其抗原结合片段;
X1选自自氢原子、卤素、羟基、氰基、烷基、烷氧基和环烷基;
X2选自烷基、环烷基和杂环基;
X为0-5,优选1-3;
m为0-5,优选1-3。
41.一种药物组合物,其含有根据权利要求26-39任一项所述的c-Met抗体或其抗原结合片段和抗体-细胞毒性药物偶联物或其可药用盐或溶剂化合物和可药用的赋形剂、稀释剂或载体。
42.根据权利要求1-21任一项所述的特异性结合c-Met受体的抗体或其抗原结合片段、或根据权利要求25所述的药物组合物、或根据权利要求26-39任一项所述的抗体-细胞毒性药物偶联物或其可药用盐或溶剂化合物、或根据权利要求41所述的药物组合物,在制备用于治疗c-Met介导的疾病或病症的药物中的用途,其中所述的疾病或病症优选为癌症;更优选为表达c-Met的癌症;最优选为胃癌、胰腺癌、肝癌、乳腺癌、肺癌、肠癌、肾癌、黑素瘤、非小细胞肺癌;最优选为胃癌、胰腺癌、非小细胞肺癌、肝癌和肾癌。
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2017135257A RU2017135257A (ru) | 2015-04-17 | 2016-04-07 | Антитело к с-мет и конъюгат антитело к с-мет-цитотоксическое лекарственное средство, и их фармацевтическое применение |
BR112017021245-5A BR112017021245A2 (zh) | 2015-04-17 | 2016-04-07 | Anti-c-Met antibody and anti-c-Met antibody - cytotoxic drug conjugates and pharmaceutical use |
PCT/CN2016/078699 WO2016165580A1 (zh) | 2015-04-17 | 2016-04-07 | 抗c-Met抗体和抗c-Met抗体-细胞毒性药物偶联物及其医药用途 |
CN201910217709.XA CN111196853A (zh) | 2015-04-17 | 2016-04-07 | 抗c-Met抗体和抗c-Met抗体-细胞毒性药物偶联物及其医药用途 |
CN201680001857.2A CN106687480B (zh) | 2015-04-17 | 2016-04-07 | 抗c-Met抗体和抗c-Met抗体-细胞毒性药物偶联物及其医药用途 |
JP2017553320A JP2018516539A (ja) | 2015-04-17 | 2016-04-07 | 抗c−Met抗体および抗c−Met抗体−細胞毒性薬物複合体ならびにそれらの医薬用途 |
KR1020177031260A KR20170138451A (ko) | 2015-04-17 | 2016-04-07 | 항-c-met 항체 및 항-c-met 항체-세포독성 약물 컨쥬게이트 및 이의 약학적 용도 |
MX2017012965A MX2017012965A (es) | 2015-04-17 | 2016-04-07 | Anticuerpo anti-c-met y conjugado de farmaco citotoxico de anticuerpo anti-c-met y uso farmaceutico del mismo. |
AU2016248357A AU2016248357A1 (en) | 2015-04-17 | 2016-04-07 | Anti-c-Met antibody and anti-c-Met antibody-cytotoxic drug conjugate and pharmaceutical use thereof |
CA2982777A CA2982777A1 (en) | 2015-04-17 | 2016-04-07 | Anti-c-met antibody and anti-c-met antibody-cytotoxic drug conjugate and pharmaceutical use thereof |
US15/565,928 US10543284B2 (en) | 2015-04-17 | 2016-04-07 | Anti-c-Met antibody and anti-c-Met antibody-cytotoxic drug conjugate and pharmaceutical use thereof |
EP16779555.8A EP3284751A4 (en) | 2015-04-17 | 2016-04-07 | Anti-c-met antibody and anti-c-met antibody-cytotoxic drug conjugate and pharmaceutical use thereof |
TW105111792A TWI731856B (zh) | 2015-04-17 | 2016-04-15 | 抗c-Met抗體和抗c-Met抗體-細胞毒性藥物偶聯物及其醫藥用途 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2015101856023 | 2015-04-17 | ||
CN201510185602 | 2015-04-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106188293A true CN106188293A (zh) | 2016-12-07 |
Family
ID=57459461
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510300885.1A Pending CN106188293A (zh) | 2015-04-17 | 2015-06-04 | 抗c-Met抗体和抗c-Met抗体-细胞毒性药物偶联物及其医药用途 |
CN201910217709.XA Pending CN111196853A (zh) | 2015-04-17 | 2016-04-07 | 抗c-Met抗体和抗c-Met抗体-细胞毒性药物偶联物及其医药用途 |
CN201680001857.2A Active CN106687480B (zh) | 2015-04-17 | 2016-04-07 | 抗c-Met抗体和抗c-Met抗体-细胞毒性药物偶联物及其医药用途 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910217709.XA Pending CN111196853A (zh) | 2015-04-17 | 2016-04-07 | 抗c-Met抗体和抗c-Met抗体-细胞毒性药物偶联物及其医药用途 |
CN201680001857.2A Active CN106687480B (zh) | 2015-04-17 | 2016-04-07 | 抗c-Met抗体和抗c-Met抗体-细胞毒性药物偶联物及其医药用途 |
Country Status (11)
Country | Link |
---|---|
US (1) | US10543284B2 (zh) |
EP (1) | EP3284751A4 (zh) |
JP (1) | JP2018516539A (zh) |
KR (1) | KR20170138451A (zh) |
CN (3) | CN106188293A (zh) |
AU (1) | AU2016248357A1 (zh) |
BR (1) | BR112017021245A2 (zh) |
CA (1) | CA2982777A1 (zh) |
MX (1) | MX2017012965A (zh) |
RU (1) | RU2017135257A (zh) |
TW (1) | TWI731856B (zh) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018177369A1 (zh) | 2017-03-30 | 2018-10-04 | 江苏恒瑞医药股份有限公司 | 抗体药物偶联物的制备方法 |
WO2018223958A1 (zh) * | 2017-06-06 | 2018-12-13 | 江苏恒瑞医药股份有限公司 | 一种含c-Met抗体药物偶联物的药物组合物及其用途 |
WO2019034176A1 (zh) * | 2017-08-18 | 2019-02-21 | 四川百利药业有限责任公司 | 一种喜树碱-抗体偶联物 |
CN110090306A (zh) * | 2018-01-31 | 2019-08-06 | 江苏恒瑞医药股份有限公司 | 双醛连接臂的配体-药物偶联物、其制备方法及其应用 |
WO2019242505A1 (zh) | 2018-06-17 | 2019-12-26 | 上海健信生物医药科技有限公司 | 靶向cldn18.2的抗体、双特异性抗体、adc和car及其应用 |
CN111093701A (zh) * | 2017-06-15 | 2020-05-01 | 财团法人生物技术开发中心 | 含有抗globo h抗体的抗体药物偶联物及其用途 |
CN111328333A (zh) * | 2019-09-29 | 2020-06-23 | 烟台迈百瑞国际生物医药有限公司 | 一种酸法制备抗体药物偶联物中间体的方法及其应用 |
CN112543771A (zh) * | 2018-09-30 | 2021-03-23 | 江苏恒瑞医药股份有限公司 | 抗b7h3抗体-依喜替康类似物偶联物及其医药用途 |
CN112683857A (zh) * | 2021-01-06 | 2021-04-20 | 上海药明生物医药有限公司 | 一种通过评估分析物的溶剂效应对亲和力实验的影响来指导spr检测前处理的方法 |
CN113227143A (zh) * | 2018-12-07 | 2021-08-06 | 首尔大学校产学协力团 | 抗c-Met激动剂抗体及其应用 |
WO2021190602A1 (zh) * | 2020-03-25 | 2021-09-30 | 江苏恒瑞医药股份有限公司 | 一种抗体药物偶联物的制备方法 |
WO2022078279A1 (zh) * | 2020-10-12 | 2022-04-21 | 昆山新蕴达生物科技有限公司 | 抗体-药物偶联物及其应用 |
WO2022205316A1 (en) * | 2021-04-01 | 2022-10-06 | Shanghai Allygen Biologics Co., Ltd. | Targeting conjugates comprising effector molecules and uses thereof |
CN115297889A (zh) * | 2020-09-01 | 2022-11-04 | 荣昌生物制药(烟台)股份有限公司 | 抗c-Met抗体药物偶联物及其应用 |
CN115975030A (zh) * | 2021-09-30 | 2023-04-18 | 杭州邦顺制药有限公司 | 抗cd39抗体-药物偶联物及其用途 |
WO2024109914A1 (zh) * | 2022-11-24 | 2024-05-30 | 江苏恒瑞医药股份有限公司 | 一种包含特异性结合hgfr和egfr的双特异性抗体的药物组合物 |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2708461C2 (ru) * | 2015-02-15 | 2019-12-09 | Цзянсу Хэнжуй Медсин Ко., Лтд. | Конъюгат лиганда с цитотоксическим лекарственным средством, способ его получения и применение |
MX2018010128A (es) * | 2016-02-26 | 2019-01-21 | Jiangsu Hengrui Medicine Co | Toxina nueva y metodo de preparacion de un intermediario de la misma. |
WO2017201204A1 (en) * | 2016-05-17 | 2017-11-23 | Abbvie Biotherapeutics Inc. | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE |
TWI782930B (zh) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗met抗體,結合met之雙特異性抗原結合分子及其使用方法 |
TW201825515A (zh) * | 2017-01-04 | 2018-07-16 | 美商伊繆諾金公司 | Met抗體以及其免疫結合物及用途 |
KR102221755B1 (ko) * | 2018-05-02 | 2021-03-02 | (주)에임드바이오 | c-Met에 특이적으로 결합하는 항체 및 그의 용도 |
AU2020349462A1 (en) | 2019-09-16 | 2022-03-03 | Regeneron Pharmaceuticals, Inc. | Radiolabeled MET binding proteins for immuno-PET imaging |
CN112521507B (zh) * | 2020-08-10 | 2021-06-08 | 北京鼎成肽源生物技术有限公司 | 抗人c-Met人鼠嵌合单克隆抗体及其应用 |
CN112924665B (zh) * | 2021-02-19 | 2023-10-03 | 山东莱博生物科技有限公司 | 一种抗体辣根过氧化物酶标记物及其制备与应用 |
EP4297798A1 (en) * | 2021-02-25 | 2024-01-03 | Allygen Group | Targeting conjugates comprising effector molecules and uses thereof |
EP4372001A1 (en) * | 2021-07-14 | 2024-05-22 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Antigen-binding molecule specifically binding to hgfr and egfr, and pharmaceutical use thereof |
CN118159567A (zh) * | 2021-11-05 | 2024-06-07 | 正大天晴药业集团股份有限公司 | 抗c-Met抗体及其应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004010957A2 (en) * | 2002-07-31 | 2004-02-05 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
BR122018071808B8 (pt) * | 2003-11-06 | 2020-06-30 | Seattle Genetics Inc | conjugado |
MX2007001470A (es) * | 2004-08-05 | 2007-03-26 | Genentech Inc | Antagonistas anti-cmet humanizados. |
US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
TW201116297A (en) * | 2009-10-02 | 2011-05-16 | Sanofi Aventis | Antibodies that specifically bind to the EphA2 receptor |
KR20130037153A (ko) * | 2011-10-05 | 2013-04-15 | 삼성전자주식회사 | 항 c-Met 항체 및 그의 용도 |
AR090549A1 (es) * | 2012-03-30 | 2014-11-19 | Genentech Inc | Anticuerpos anti-lgr5 e inmunoconjugados |
WO2014178791A1 (en) * | 2013-04-30 | 2014-11-06 | Agency For Science, Technology And Research | Mab 2 anti-met antibody |
-
2015
- 2015-06-04 CN CN201510300885.1A patent/CN106188293A/zh active Pending
-
2016
- 2016-04-07 JP JP2017553320A patent/JP2018516539A/ja active Pending
- 2016-04-07 CA CA2982777A patent/CA2982777A1/en not_active Abandoned
- 2016-04-07 MX MX2017012965A patent/MX2017012965A/es unknown
- 2016-04-07 CN CN201910217709.XA patent/CN111196853A/zh active Pending
- 2016-04-07 EP EP16779555.8A patent/EP3284751A4/en not_active Withdrawn
- 2016-04-07 US US15/565,928 patent/US10543284B2/en active Active
- 2016-04-07 KR KR1020177031260A patent/KR20170138451A/ko unknown
- 2016-04-07 BR BR112017021245-5A patent/BR112017021245A2/zh not_active Application Discontinuation
- 2016-04-07 RU RU2017135257A patent/RU2017135257A/ru not_active Application Discontinuation
- 2016-04-07 AU AU2016248357A patent/AU2016248357A1/en not_active Abandoned
- 2016-04-07 CN CN201680001857.2A patent/CN106687480B/zh active Active
- 2016-04-15 TW TW105111792A patent/TWI731856B/zh active
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110177569A (zh) * | 2017-03-30 | 2019-08-27 | 江苏恒瑞医药股份有限公司 | 抗体药物偶联物的制备方法 |
WO2018177369A1 (zh) | 2017-03-30 | 2018-10-04 | 江苏恒瑞医药股份有限公司 | 抗体药物偶联物的制备方法 |
WO2018223958A1 (zh) * | 2017-06-06 | 2018-12-13 | 江苏恒瑞医药股份有限公司 | 一种含c-Met抗体药物偶联物的药物组合物及其用途 |
CN110382008A (zh) * | 2017-06-06 | 2019-10-25 | 江苏恒瑞医药股份有限公司 | 一种含c-Met抗体药物偶联物的药物组合物及其用途 |
CN111093701A (zh) * | 2017-06-15 | 2020-05-01 | 财团法人生物技术开发中心 | 含有抗globo h抗体的抗体药物偶联物及其用途 |
WO2019034176A1 (zh) * | 2017-08-18 | 2019-02-21 | 四川百利药业有限责任公司 | 一种喜树碱-抗体偶联物 |
CN110090306B (zh) * | 2018-01-31 | 2023-04-07 | 江苏恒瑞医药股份有限公司 | 双醛连接臂的配体-药物偶联物、其制备方法及其应用 |
CN110090306A (zh) * | 2018-01-31 | 2019-08-06 | 江苏恒瑞医药股份有限公司 | 双醛连接臂的配体-药物偶联物、其制备方法及其应用 |
WO2019242505A1 (zh) | 2018-06-17 | 2019-12-26 | 上海健信生物医药科技有限公司 | 靶向cldn18.2的抗体、双特异性抗体、adc和car及其应用 |
US11912763B2 (en) | 2018-06-17 | 2024-02-27 | L & L Biopharma Co., Ltd. | Antibody targeting CLDN18.2, bispecific antibody, ADC, and CAR, and applications thereof |
CN112543771B (zh) * | 2018-09-30 | 2023-04-11 | 江苏豪森药业集团有限公司 | 抗b7h3抗体-依喜替康类似物偶联物及其医药用途 |
CN112543771A (zh) * | 2018-09-30 | 2021-03-23 | 江苏恒瑞医药股份有限公司 | 抗b7h3抗体-依喜替康类似物偶联物及其医药用途 |
CN113227143A (zh) * | 2018-12-07 | 2021-08-06 | 首尔大学校产学协力团 | 抗c-Met激动剂抗体及其应用 |
CN111328333B (zh) * | 2019-09-29 | 2023-10-03 | 烟台迈百瑞国际生物医药股份有限公司 | 一种酸法制备抗体药物偶联物中间体的方法及其应用 |
CN111328333A (zh) * | 2019-09-29 | 2020-06-23 | 烟台迈百瑞国际生物医药有限公司 | 一种酸法制备抗体药物偶联物中间体的方法及其应用 |
WO2021190602A1 (zh) * | 2020-03-25 | 2021-09-30 | 江苏恒瑞医药股份有限公司 | 一种抗体药物偶联物的制备方法 |
CN115297889A (zh) * | 2020-09-01 | 2022-11-04 | 荣昌生物制药(烟台)股份有限公司 | 抗c-Met抗体药物偶联物及其应用 |
WO2022078279A1 (zh) * | 2020-10-12 | 2022-04-21 | 昆山新蕴达生物科技有限公司 | 抗体-药物偶联物及其应用 |
CN112683857B (zh) * | 2021-01-06 | 2022-10-14 | 上海药明生物医药有限公司 | 一种通过评估分析物的溶剂效应对亲和力实验的影响来指导spr检测前处理的方法 |
CN112683857A (zh) * | 2021-01-06 | 2021-04-20 | 上海药明生物医药有限公司 | 一种通过评估分析物的溶剂效应对亲和力实验的影响来指导spr检测前处理的方法 |
WO2022205316A1 (en) * | 2021-04-01 | 2022-10-06 | Shanghai Allygen Biologics Co., Ltd. | Targeting conjugates comprising effector molecules and uses thereof |
CN115975030B (zh) * | 2021-09-30 | 2023-09-26 | 杭州邦顺制药有限公司 | 抗cd39抗体-药物偶联物及其用途 |
CN115975030A (zh) * | 2021-09-30 | 2023-04-18 | 杭州邦顺制药有限公司 | 抗cd39抗体-药物偶联物及其用途 |
WO2024109914A1 (zh) * | 2022-11-24 | 2024-05-30 | 江苏恒瑞医药股份有限公司 | 一种包含特异性结合hgfr和egfr的双特异性抗体的药物组合物 |
Also Published As
Publication number | Publication date |
---|---|
US10543284B2 (en) | 2020-01-28 |
EP3284751A1 (en) | 2018-02-21 |
CN111196853A (zh) | 2020-05-26 |
MX2017012965A (es) | 2018-06-06 |
KR20170138451A (ko) | 2017-12-15 |
RU2017135257A3 (zh) | 2019-09-24 |
EP3284751A4 (en) | 2018-12-05 |
CN106687480A (zh) | 2017-05-17 |
CA2982777A1 (en) | 2016-10-20 |
AU2016248357A1 (en) | 2017-10-26 |
JP2018516539A (ja) | 2018-06-28 |
TWI731856B (zh) | 2021-07-01 |
BR112017021245A2 (zh) | 2018-06-26 |
CN106687480B (zh) | 2019-04-19 |
US20180110875A1 (en) | 2018-04-26 |
RU2017135257A (ru) | 2019-05-17 |
TW201638108A (zh) | 2016-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106687480B (zh) | 抗c-Met抗体和抗c-Met抗体-细胞毒性药物偶联物及其医药用途 | |
JP7064629B2 (ja) | 抗cdh6抗体及び抗cdh6抗体-薬物コンジュゲート | |
CA2990572C (en) | Method for selectively manufacturing antibody-drug conjugate | |
WO2016165580A1 (zh) | 抗c-Met抗体和抗c-Met抗体-细胞毒性药物偶联物及其医药用途 | |
JP2019069983A (ja) | 新規抗体コンジュゲートおよびその使用 | |
US20160106861A1 (en) | Axl antibody-drug conjugate and its use for the treatment of cancer | |
CN111110862A (zh) | 抗cldn18.2抗体的药物偶联体及其制备方法和用途 | |
CN115698079A (zh) | 抗cd79b抗体药物偶联物、其制备方法及其医药用途 | |
EP3545974A1 (en) | Medical use of anti-c met antibody-cytotoxic drug conjugate | |
JP2020527332A (ja) | 抗−il1rap抗体および抗体薬物コンジュゲート | |
EP4374879A1 (en) | Drug conjugate of eribulin derivative | |
WO2023046202A1 (zh) | 一种抗体及其药物偶联物和用途 | |
WO2024082055A1 (en) | Antibody-drug conjugates targeting napi2b and methods of use | |
CN118317795A (zh) | 用在治疗化疗耐药性癌症的方法中的抗体-药物偶联物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20161207 |